

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: July 20, 2004, 10:09:00 ; Search time 21 Seconds
(without alignments)
2510.141 Million cell updates/sec

Title: US-10-033-245-24
Perfect score: 2668
Sequence: 1 MRLNGTFLTLFLCLAF.....IQTDSPVWILSEIFLKAD 548

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 283366 seqs, 96191526 residues
Total number of hits satisfying chosen parameters: 283366

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR_78:*
1: pir1:*
2: pir2:*
3: pir3:*
4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1558	54.3	360	2 T47170	hypothetical prote
2	129	4.5	638	2 E84799	similar to axi 1 p
3	108	3.8	578	2 E64609	DNA polymerase III
4	108	3.8	586	2 B83790	hypothetical prote
5	107.5	3.7	970	2 S01352	type III site-spec
6	107.5	3.7	1288	2 T09908	hypothetical prote
7	106.5	3.7	1273	2 C96767	unknown protein P2
8	106	3.7	1054	2 D70425	conserved hypotet
9	105.5	3.7	1165	2 A70423	valine-tRNA ligase
10	105.5	3.7	6486	2 T31076	tyrocidine synthet
11	105	3.7	2324	1 A29924	acetyl-CoA carboxy
12	104.5	3.6	3770	2 A40889	delta-(L-alpha-ami
13	104	3.6	1039	2 A12284	translational initia
14	104	3.6	1642	2 T08880	NMDA receptor-bind
15	104	3.6	1818	1 E73852	hypothetical prote
16	103	3.6	2339	2 S41121	acetyl-CoA carboxy
17	102.5	3.6	575	2 G95093	hypothetical prote
18	102.5	3.6	584	2 D97961	hypothetical prote
19	102.5	3.6	3498	2 T32330	hypothetical prote
20	102	3.6	428	2 S09134	gene ND4L intron 1
21	102	3.6	671	2 C83934	methyI-accepting c
22	102	3.6	829	2 F83905	adenylate cyclase
23	102	3.6	838	2 A38172	starch synthase ho
24	102	3.6	1071	2 T04926	probable myosin he
25	102	3.6	1611	2 A84743	DNA topoisomerase
26	101.5	3.5	916	2 E22864	signal-transducing
27	101	3.5	547	2 S70538	type I site-specif
28	101	3.5	1025	2 T09459	hypothetical prote
29	99.5	3.5	1105	2 F71079	

30	99.5	3.5	4540	2 T30838	cytoplasmic dynein
31	99	3.5	1557	2 T29132	hypothetical prote
32	99	3.5	1870	2 C47521	gag-pol-like fusio
33	99	3.5	4056	2 H96599	protein P14U16.10
34	98.5	3.4	451	1 J80240	lIM kinase (EC 2.7
35	98.5	3.4	617	2 J05814	lIM motif-containi
36	98.5	3.4	638	2 J05813	lIM motif-containi
37	98.5	3.4	783	2 AG3402	polyporphosphate kina
38	98.5	3.4	1006	2 S20126	exoribonuclease RA
39	98.5	3.4	1091	2 C95133	exonuclease RexB [
40	98.5	3.4	1091	2 C98001	second chain of ma
41	98	3.4	1025	2 T30322	type I site-specif
42	98	3.4	1025	2 T44802	type I site-specif
43	97.5	3.4	1487	2 S62048	probable membrane
44	97.5	3.4	1839	1 RRMPEM	genome polypotein
45	97	3.4	697	2 H84791	hypothetical prote

ALIGNMENTS

RESULT 1
T47170
hypothetical protein DKFZp762F216.1 - human (fragment)
C/Species: Homo sapiens (man)
C/Date: 20-Apr-2000 #sequence_revision 20-Apr-2000 #text_change 20-Apr-2000
C/Accession: T47170
R/Blocher, H.; Boecher, M.; Brandt, P.; Mewes, H.W.; Well, B.; Wiemann, S.
submitted to the Protein Sequence Database, March 2000
A/Reference number: Z24376
A/Accession: T47170
A/Status: preliminary
A/Molecule type: mRNA
A/Residues: 1-360 <AAA>
A/Cross-references: EMBL:AL162067
A/Experimental source: adult melanoma (Memo cell line); clone DKFZp762F216
A/Genetics:
A/Note: DKFZp762F216.1

Query Match 54.3%; Score 1558; DB 2; Length 360;
Best Local Similarity 92.6%; Pred. No. 2.4e-112;
Matches 302; Conservative 1; Mismatches 15; Indels 8; Gaps 2;

Qy	176	EDSVIVVLI	AEQTSQVSAVTENIKALFTEIHSGLEVISPSHFYDPSRLRESFGDP	235
Db	1	EDSVIVVLI	AEQTSQVSAVTENIKALFTEIHSGLEVISPSHFYDPSRLRESFGDP	60
Qy	236	KERVVRMTK	QNLDYCFIMMTAQSNGIYYVQLLEDIVAKPNYLSMKNFALQOPESEDMIL	295
Db	61	KERVVRMTK	QNLDYCFIMMTAQSNGIYYVQLLEDIVAKPNYLSMKNFALQOPESEDMIL	120
Qy	296	EFSGQGF	IGKMFSLDLSLVEFTIMFYRDKPIDMLDLHIMVAVCNPEADAKHCDROKA	355
Db	121	EFSGQGF	IGKMFSLDLSLVEFTIMFYRDKPIDMLDLHIMVAVCNPEADAKHCDROKA	179
Qy	356	NLRIRFP	SLFOHVGTHSSLAGKIQLKDKDPFGQALRKHVNPAVSTSLKTYQHFTL	415
Db	180	NLRIRFP	SLFOHVGTHSSLAGKIQLKDKDPFGQALRKHVNPAVSTSLKTYQHFTL	239
Qy	416	EKAVLRD	FPMAFPAAAGDFIRFRFQPLRLERFFFSNGNIHEDDYLFNTSVVLPFDN	475
Db	240	EKAVLRD	FPMAFPAAAGDFIRFRFQPLRLERFFFSNGNIHEDDYLFNTSVVLPFDN	296
Qy	476	PQSDKEAL	QEGRTATLTPYRSPDGYL 501	
Db	297	STLSQTR	RCRRAPPPSGTL 318	

RESULT 2
E84799
similar to axi 1 protein from Nicotiana tabacum [imported] - Arabidopsis thaliana
C/Species: Arabidopsis thaliana (mouse-ear cress)
C/Date: 02-Feb-2001 #sequence_revision 02-Feb-2001 #text_change 02-Feb-2001

C:Accession: E84799
R:Lin, X.; Kaul, S.; Rounsley, S.D.; Shea, T.P.; Benito, M.I.; Town, C.D.; Fujii, C.Y.;
M.; Koo, H.; Moffat, K.S.; Cronin, L.A.; Shen, M.; Vanaken, S.E.; Umayam, L.; Tallon, L.;
Nunes, D.; Nierman, W.C.; White, O.; Eilen, J.A.; Salzberg, S.L.; Fraser, C.M.; Venter, J.
Nature 402, 761-766, 1999
A:Title: Sequence and analysis of chromosome 2 of the plant *Arabidopsis thaliana*.
A:Reference number: A84420; MUID:20083487; PMID:10617197
A:Accession: E84799
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-638 <STO>
A:Cross-references: GB:AB002093; NID:g4895186; PIDN:AA032773.1; GSPDB:GN00139
C:Genetics:
A:Gene: At2g37980
A:Map position: 2

Query Match 4.5%; Score 129; DB 2; Length 638;
Best Local Similarity 20.9%; Pred. No. 0.082;
Matches 111; Conservative 76; Mismatches 187; Indels 156; Gaps 27;

103 NGSHRVHLPTVPHLP---HLAKESLQPAVVGQRTGV-----SVV 145
79 GSHVHHDH---HYHHPTIRYFLRLRL--PFLPDVGSTAVVGQGMWLCGRNVGRRI 134
146 MGIPSVREVSYSYLDTHLS--LISELSPQEKSDVIYVLLAETDSQYTSVATEYIKALF 203
135 LGLMIFFVVSJFLKVSLSMGRVVDHARRDLNELVNRALHEDVSMQORATENV--- 190
204 PTEHSGLEVISPSPHFY--PDPSRLRSFGDPKERVWRTRKONLDYCFLLMVAOS--- 258
131 -----VIEKL-PPEIWKQRESGNVYQACSRPQRSLRKRKTN---GYLVHANGSLN 239
259 ---KGIYVVOLEDDIVAKPNYLSTMKNPALQOPSEDMILR-----FSQLGFIGMKFSL 310
240 QMRGTIC-----DWVAAAKIMNATLVLPILDHESFTWIDPSTFKQIFDPRHFMVILKQDV 293
311 DLSLIVEITLMYR-----DKPIWLDHILMVVNCPEKDAKDCQKAKLRIRFRPS 364
294 D---IYEYLPRTYAMRPLKAPVSW-----SKASYRSSEMLPLKKNHVT 336
365 LFOHVG---HSSLAGTIQKLDK-----DFGKQALKKEHNPPEAVSTSLK 408
337 KETHDSRLANNGLPSPQRLKCRANYQALGYSKEIEBFGKLVNRLKNNSEPTAL--- 393
409 TYQHFTLEKAYLRDFFWAFTP-----AAGDFIRFRFQPLRLERFFRSGNIEHPEDKL 463
394 ---HLYREKMDL-----AFTGCSHNLTAGB-----AEELRIMRY-----NVKMKKEKE 433
464 FNTSVLEVLPFDNPQSDKA---LQSGRTATLRYPSDPGYLQISFYKG----- 509
434 IDSRERRIQGGCGPMSPREAIFLK-----AMGYPSSTVYIVAGETVIGNSMDAFREBYR 488
510 -----VAEGEVDPAFGP-----LEALRLSIQTSPPVWVILSEIFLKKA 547
489 NVFAHSYLAETEELER-FKPYGNRLAALDYVALESDFVYTYDDNMKA 537

RESULT 3
B64609
DNA polymerase III gamma and tau subunits - Helicobacter pylori (strain 26695)
C:Species: Helicobacter pylori
C:Date: 09-Aug-1997 #sequence_revision 09-Aug-1997 #text_change 08-Oct-1999
C:Accession: E64609
R:Tomb, J.F.; White, O.; Kellavag, A.R.; Clayton, R.A.; Sutton, G.G.; Fleischmann, R.D.;
Peterson, S.; Loftus, B.; Richardson, D.; Dodson, R.; Khairat, H.G.; Glodek, A.; McKen-
son, J.D.; Kelley, J.M.; Cotton, M.D.; Weidman, J.M.; Fujii, C.; Bowman, C.; Watthey, L.
Nature 388, 539-547, 1997
A:Authors: Wallin, E.; Hayes, W.S.; Borodovsky, M.; Karpk, P.D.; Smith, H.O.; Fraser, C.
A:Title: The complete genome sequence of the gastric pathogen *Helicobacter pylori*.
A:Reference number: A64520; MUID:97394467; PMID:9252185
A:Accession: B64609
A:Status: preliminary; nucleic acid sequence not shown; translation not shown
A:Molecule type: DNA

A:Residues: 1-578 <TOM>
A:Cross-references: GB:AB000584; GB:AB000511; NID:g2313834; PIDN:AA07767.1; PID:g2313841

Query Match 3.8%; Score 108; DB 2; Length 578;
Best Local Similarity 19.0%; Pred. No. 2.9;
Matches 115; Conservative 87; Mismatches 177; Indels 226; Gaps 31;

42 EFLALRDR-LHAAL---QESLRSKELNVLDEIKRAVSRQALRDQDGNRTWRL----- 93
2 QVLAALKRPPKFSFELVQESV--AKTSLALDNRNLNNAVYFSGLRSGKTSRRIFARA 59
94 ---TEDRLKP-----WNGSHRVHLPTVPHLP---HLAKESLQPAVVGQRT 140
60 LMCEGPKAVPCDTCICQCSALNNHDIIMD-----GASNR 97
141 GVSVMGI-----PSVR-----EVHSYLDTHLSLISELSPQEKSDVIYVLLAE 186
98 GIDVVRNLIEGTRKYPSPGRYKFIIDEVHNFTEARVALKTL---EPPSHVKPLAT 154
187 TDSQYTSVTEYIKALFPEIHSGLLEVISPSPHF---YPD---FSRLRSFGDPKERV 239
155 TDALKPLAT-----ILSRTHFRFRKIPENSIVSHLKTIL--EKEQV 194
240 RWRP-----KONLDYC-----FLMVAOSKGI---YVVOQL 266
195 SETSALAEKLAHSGQSLRDTITLLBOALINCDNAITESKYAEMLGALDSVLEDFQSL 254
267 --EDDIYAKPNYLSTMKNPALQOPSEDMILR-----EFSQGLFIGMKFSL--DLSL 314
255 INQDEARLKERY-ALLENVETESVLEEMWFLKAKLSPDYSILLERFKIIMSSLSL 313
315 IVE-----FILMFPRDK-----PIDWLDHILMVVNC---NPKDAKHCDQKAKLRIR 360
314 LKEGANSFVYLLIKMFKEALKFALDDALILELQPPNQPISYNAPOKESKNIIEKR 373
361 FKPSLFOHV-GTHSSLAGTIQKLDKDFGKQALKKEHNPPEAVSTSLKTQHFTLEKAY 419
374 EKIQIETISGT-----KREKLE-----KKEAETPQTMLSAKORIFHNL----- 415
420 LREDFWAFPTPAAGDFIRFRFQPLRLERFFRSGNIEHPEDKLNTSVLEVLPDN--- 475
416 -----FKQVQLVYER-----NYELGAVFEKNIRIFIDPSQTKT 449
476 -----PQSKKALQSGRTATLRYPSDPGYLQISFYKGVAGCVDPAPGPLEALRLS 528
450 LTWESLATDKQKELRE-----RFK-----IVKSIYDGVFGKESIKIA 488
529 IQTDS 533
489 LKNHS 493

RESULT 4
B83790
hypothetical protein BH1122 (imported) - Bacillus halodurans (strain C-125)
C:Species: Bacillus halodurans
C:Date: 01-Dec-2000 #sequence_revision 01-Dec-2000 #text_change 15-Jun-2001
C:Accession: B83790
R:Takami, H.; Nakasone, K.; Takaki, Y.; Maeno, G.; Saeaki, R.; Masui, N.; Fujii, F.; Hiran
Nucleic Acids Res. 28, 4317-4331, 2000
A:Title: Complete genome sequence of the alkaliphilic bacterium *Bacillus halodurans* and
A:Reference number: A83650; MUID:20512582; PMID:11058132
A:Accession: B83790
A:Status: preliminary
A:Molecule type: DNA
A:Residues: 1-586 <STO>
A:Cross-references: GB:AB001511; GB:BA000004; NID:g10173727; PIDN:BA04841.1; GSPDB:GN001
A:Experimental source: strain C-125
C:Genetics:
A:Gene: BH1122

Query Match 3.8%; Score 108; DB 2; Length 586;
Best Local Similarity 20.7%; Pred. No. 3;

	Matches	105;	Conservative	72;	Mismatches	147;	Indels	184;	Gaps	27;
QY	50	LIHAABQBS--LKRSGKEMLN-VLDEIKRAVSERQALRDGDGNRTWGRLTEDPRLKPMNGSH	106							
Db	193	VHASTIETFWLKKQKQESWLMIIDKQGRFVA-----TSDPQ-----H	228							
QY	107	RHYVHLPRVFHHHLPHLLAKESSLQPAVAVGGQ--RTGVASVYMGIPSVR--REYHSVLT	160							
Db	229	ESVLYSPDFDQYLPY-----QPTMQTGENDDKDALFVSMPLPNTHEWTLKQVTPY--	278							
QY	161	DTLSLSLSELSPOEABEDSVIVLLAETDSQTSVAATENIKALPPTBHSGLLEIVSPSPH	220							
Db	279	-----SELTEGSRKMAALIVITIGALIMIVALLVTVSLTKKFTTPPIYE-LKQVLSK---	327							
QY	221	FYPDF-----SRLESFGDPKERVWRTRKONTDYCEFLMAYASQGIYYVQLEDDIVA-	272							
Db	328	-YPPQDLSGELPSDVRNRFEGFLFEGYKGLIRNNE-----LYRSLHRYQKRGREARIKAL	381							
QY	273	---KENTL-STMKNFALQSPSEDMILE-----FSQLGFTGKMFSLDSLIVERFLM	321							
Db	382	QANINPFLYNTLIDOL-----NMMALIEKDRTWSHMLEMIGQMLR-IGLS-NGESILP	432							
QY	322	FYRDKPIDMLDHLIMVAVCNPEKDAKHCDCQKXANLRIRFPSPLEFQHVGTHSSLAGKQK	381							
Db	433	L-EKEVAYLKYTL-----KIQK	448							
QY	382	LKDQDFGKQALRKEHVNPAAEVSTSLKTY--QHFTLEKAVLREDFFMAFTPAAGDPIFR	439							
Db	449	LK-----MGERLTYYDVDPVWLKYRLPKLTLQ-PLVENCEFHFOGGRGGEVYIR	498							
QY	440	F-----FQPL-----RLERFFRSQNIHPEDKL	463							
Db	499	AMEDQNHIVMTIQDNIGIFQFQVTTKRSKLDMGQYGIKRVMERLDDVDFRYASVAVTGDQ	558							
QY	464	FNISVEVLPFPDNPQ--SDKEALQEGRTAT	470							
Db	559	GGIIVKQI---IPKVLNKRRLDGRSIT	583							

```

RESULT 5
S01352
type III site-specific deoxyribonuclease (EC 3.1.21.5) EcoPI chain res - phase P1
N/Alternate names: type III restriction enzyme EcoPI chain res
C/Species: phase P1
C/Date: 30-Sep-1989 #sequence_revision 30-Sep-1989 #text_change 08-Oct-1999
C/Accession: S01352
R/Humbelin, M.; Sur, B.; Rao, D.N.; Hornby, D.P.; Eberle, H.; Pripfel, T.; Kenel, S.; F
J. Mol. Biol. 200, 23-29, 1988
A/Title: Type III DNA restriction and modification systems EcoPI and EcoPI5. Nucleotide
A/Reference number: S01351; MUID:88245189; PMID:2837577
A/Accession: S01352
A/Molecule type: DNA
A/Residues: 1-970 <HUB>
A/Cross-references: EMBL:X06287; NID:g15138; PIDN:CAA29615.1; PID:g15140
C/Keywords: hydrolase

Query Match          3.7%; Score 107.5; DB 2; Length 970;
Best Local Similarity 19.1%; Pred. No. 6.9;
Matches 105; Conservative 76; Mismatches 161; Indels 207; Gaps 26;

QY 54 EESIKRSKEINLVDELIKRAVSEKQALRDGDGNKRWGLTDEPRLKPMGSHRHVLAHP 113
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 477 EINEIHLHKEILLSDNDRPRRFLPSKWTLRG-----WDN-----P 511

QY 114 TVFHHLPHLLAKESLQCPAVVGGCGRTGVSVMGIPSVREHVSYL----- 159
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 512 NVF-QICKLRSSGSTSKLQEVGRG-----LRLPVNEYMCYKVRKNFTLKKYV 558

QY 160 -----TDLTHSISELSPEKEDSVIVVLAETDSQTSVAVTENIKALPTEIHSGLL--- 212
      | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db 559 DFTKEDFPDLSLVKVENNESSFKERV-----PSKFTGLKEQIRAQYF-ELSSRALMNE 609

QY 213 -----EVISPSPHFYPD--FSRLRBSF-----GDPKERVRRRTQKNDLYC 250

```

```

Db      610 LFNDELLIDNDNDFKSDAYSRLKSKYPPAAPPYGVKPGKIKKATDGGKRRTRKGRVKSSEBK 665
Qy      251 FLMMVAQS2KGIYVOLED2EDD2IVAKPNYLS2TMKNFALQOPSEDMLEFSOLG2--IGKMP 307
        670 ELMELLNQA2V-----IEYKINS2ENF2LSIFKSPMLEE2-----RFTKSV2HTRIDIX2 719
Qy      308 KSLDLSLIVEFI-----LMFYRDKPIDMLDHI--LMWKCVP2EXDARH--CD 351
        720 IHNDMA2MSISYSDDDDFAKJNTMSYR2-----FLDNL2SGTIFVK-----HDTLHKV2CD 768
Qy      352 -R2OKANL-----RIRKPSL2FOHVG2HS-----LAGI2Q2LK----- 388
        770 IKOTINITEYLNIQTIRIKISGFSKYLLNNSFNKFSLGYNLSIGSIHP2TFNADGKPLD 828
Qy      384 ---DKPFGKALRKEHVNPRAEVS2LSLTQ2HPTLEKAYLRE----- 422
        830 EYLS2SLD2---VL2DN2SKAPLD2TYLFEEFYVDS2ELERENITDRBISQVWFSKIPKNSIK 886
Qy      423 -----DFA2FPAPAGD2FI2RFR2-----PGL2ELERFFPRSGNI2HEPDKL2 464
        887 IPVAGGYTSPFAFAYVKTAE2GDY2NI2FIETKNVDSK2SLRE--EKKKIEHAQ2-ALF 941
Qy      465 N---TSVEV 470
        942 NQISQSVK 950
Db

```

RESULT 6

T09908
hypothetical protein T22A6.280 - Arabidopsis thaliana
C:/Species: Arabidopsis thaliana (mouse-ear cross)
C:/Date: 16-Jul-1999 #sequence_revision 16-Jul-1999 #ext_change 15-Oct-1999
C:/Accession: T09908
R:/Byern, M.; Zimmermann, W.; Grenetisen, A.; Wambutt, R.; Bancroft, I.; Mewes, H.W.; Maye
submitted to the Protein Sequence Database, June 1999
A:/Reference number: Z16896
A:/Accession: T09908
A:/Molecule type: DNA
A:/Residues: 1-1288 <BEV>
A:/Cross-references: EMBL:AL078637; GSPDB:GN00062; ATSP:T22A6.280
A:/Experimental source: cultivar Columbia; BAC clone T22A6
C/Genetics:
A:/Gene: ATSP:T22A6.280
A:/Map position: 4
A:/Introns: 18/2; 31/3; 68/2; 89/3; 120/2; 170/3; 272/3; 313/2; 378/3; 408/2; 453/2; 507/3;
1151/3; 1182/3; 1221/2

Query Match 3.7%; Score 107.5; DB 2; Length 1288;
Best Local Similarity 20.1%; Pred. No. 10;
Matches 113; Conservative 88; Mismatches 168; Indels 193; Gaps 31;

Dd 51 HAAGESLK---RSKEINLVLEIK--RAVERQALRDGDGNGRTWGLTEDPRLK-PMN 103
 ::::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Dd 76 HSKGQALQTFFVKSGDAVVVILLRDPRAIRIEFLKSGSHRWLRQHNGNFRVEIPMN 135
 ::||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Qy 104 GSHRRVHLPLPYFHHLLPHLLAKESSLOPAVRVGQGRTGV-SVMYGIISVAREVHSYL--- 159
 |::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Dd 136 DLHAH-----HRIPRTLERRAHKIWDKRGKRPQSARBEQIIDYDNAVELHAELARG 187
 -----|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Qy 160 -----TDTLSLISE-----LSPOEKEDSVIIVLIAE 186
 ::||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Dd 188 ISLDIELQNSVPEKESEBPHMTDISRKKHVDQKMLQKYTEPIINNSGSVKSALAE 247
 ::||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Qy 187 TDSQTSAVTENIKALPFTEIHSGILEVISBPSPHPFPDSRLRE--SFGDKPKERVWRTK 244
 ||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Dd 248 LSKR--SVGQENLVSOQSFHNANVEITIIISRSSK-----GMIREIAYAGPGR--TWQVQ 297
 ::||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Qy 245 QNLDDCFPLMYTAQSQKGIYYVQLDED----YAKPNVLSTMKFALOOPSDMMILFEFSQL 300
 ::||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Dd 298 Q-----PSIGSSQS-----HQBSGCIFILIYLNLTHTQIFPTL-----EKFDIMLKRG 342
 ::||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Qy 301 GFPGKMF-----KSLD-----LSLIVEFILMFYDRDKPIDWLIDHI 335

```
Db 343 GVGVGIOFVWISGSGVWNNNGANFVNVVLKASADSTSGLDVDEKVL-----KMLLD-- 392
QY 336 LMKVYCNPEKDAKHCROKQANLRIRFKPSLFQHVGHSSLACKIQKDKFGK----- 389
Db 393 ---EISERKEKMR-----SLMHRF-----NIATELT-----EKCROGGGCGIGIMV 432
QY 390 ---QALR-----KEVNPPEAVSTSLKTYQHFTLEKAVLREDFFWAFPPAAGDFIRRF 440
Db 433 WMRFWATRHLLWNKNVNVPREISEALERTFNL-MEKIYLQO-----PNKREIVRLTM 484
QY 441 F-----QPLTERFFF-----RSGNIHEDEKLFTNTSVLELPFDPNPSDKAL 483
Db 485 ALVGRGGQGVGRIFDELIVIORNNHCSGMMEWHQKLN-----NSSADVLI 535
QY 484 QEGRTATLRYPRSP---DGYLQ 502
Db 536 CE---ALLNVYRSDFRIDAYWQ 554
```

RESULT 7

```
C96767
unknown protein F2P9.17 [imported] - Arabidopsis thaliana
C/Species: Arabidopsis thaliana (mouse-ear cress)
C/Date: 02-Mar-2001 #sequence_revision 02-Mar-2001 #text_change 31-Mar-2001
C/Accession: C96767
R/Theologian, A.; Becker, J.R.; Palm, C.U.; Federspiel, N.A.; Kaul, S.; White, O.; Alonso,
Chin, C.W.; Chung, M.K.; Conn, L.; Conway, A.B.; Conway, A.R.; Creasy, T.H.; Dewar, K.;
anzen, N.F.; Hughes, B.R.; Hultzar, L.
Nature 408, 816-820, 2000
A/Author: Hunter, J.L.; Jenkins, J.; Johnson-Hopson, C.; Khan, S.; Khaykin, E.; Kim, C.
C.A.; Li, J.H.; Li, Y.; Lin, X.; Liu, S.X.; Liu, Z.A.; Luroe, J.S.; Maiti, R.; Marziani,
Rizzo, M.; Rooney, T.; Rowley, D.; Sakao, H.
A/Authors: Salzman, S.L.; Schwartz, J.R.; Shim, P.; Southwick, A.M.; Sun, H.; Tallon,
ker, M.; Wu, D.; Yu, G.; Fraser, C.M.; Venter, J.C.; Davis, R.W.
A/Title: Sequence and analysis of chromosome 1 of the plant Arabidopsis.
A/Reference number: A66141; MUID:21016719; PMID:11130712
A/Accession: C96767
A/Status: preliminary
A/Molecule type: DNA
A/Residues: 1-1273 <STO>
A/Cross-references: GB:AE005173; NID:g7109476; PIDN:AAF6740.1; GSPDB:GN00141
C/Genetics:
A/Gene: F2P9.17
A/Map position: 1
```

```
Query Match 3.7%; Score 106.5; DB 2; Length 1273;
Best Local Similarity 21.0%; Pred. No. 12;
Matches 120; Conservative 75; Mismatches 179; Indels 197; Gaps 34;
QY 113 PTVFPHLPHLAKES-SLOPAVRVGGRTGVVWGIPSVREHVSYLTDLHLSLSLS 171
Db 75 PTVFEPYPHQNSSESSNNNSVSDPASADAAAMEYGLKRE-----DTANLINCCK 128
QY 172 P-----QEKEDSVLVLAETDSQYTSAVTENIKAL-----FPTIEHSGLELVSPSPHFP 223
Db 129 PEKDSSEQJLDSVTL-----ENSGQSGEAKQNVKLIRINYWEKISGEL-----HEDG 176
QY 224 DF-----SRLRES-----FGDPKERVRMRTKONLDYCFLLMYAQSQKGIYVQLEDDIYAK 273
Db 177 NIVHDNQNRRARCMPCIDDEYHRSFPLEFVPHNFVAV-SVGLTLQVWCKEDDTQX 235
QY 274 PNYLSTMKFALQOQSEDMILFESQLGFTGKF-----KSLDSLIVETLMF 322
Db 236 -TYVVELAIPRIARVYEDYLSANF-PFGYQVFLPREWVYTSSTGASLSIFSSHLYD 293
QY 323 VR--DKPI-----DMLDHI-----LMVKCNPEKQAK 348
Db 294 EKVIOQTIDTRIKLASALAKQWFGVYITPESPNDWMLDGLAGFLTDMFKOFLANNEAR 353
QY 349 HCDROKAN-----LRIRFKPSLFQHVGHSS-SLAGKIQKDKDFGQALRKEH 396
Db 354 Y-RRIRKANCAVCKADDSGAMCLSSPSKCDLFGTHSIGMHGKIRWKSII--LQKIRSA 409
```

```
QY 397 VNPRAEV-STSLKTYQH-----TLEKAVLREDFFWAFPPAAG-DFIRFRFPQIRLE-- 447
Db 410 KDPNSISLSTKEPRQANKIGNIRPFLKE-FFORVVASYGCPVLIGLSYNKRKNV 468
QY 448 -----RFFPSGNIHEDEKLFTNTS 467
Db 469 EMALRECTALDARLSYIGATSDSESRDVAGMPGMSIKVYELDGNSDHPK----- 521
QY 468 VEVLFPDNPQSDKEALQF-----GRATATLRYPR-----SPDGYLQIGSFYKVAEGEVDPA 518
Db 522 ---LPM---AGBRWQTLLEPCHSKLAARQYQPKKGKPDG-----AEDNVD-A 563
QY 519 FGPLALRLSTQDQSPV-WVLSIFFLKAD 548
Db 564 IAPLEN-KTISI-ESPIAWI-----KAD 583
```

RESULT 8

```
D70425
conserved hypothetical protein aq_1442 - Aquifex aeolicus
C/Species: Aquifex aeolicus
C/Date: 08-May-1998 #sequence_revision 08-May-1998 #text_change 15-Sep-2003
C/Accession: D70425
R/Decker, G.; Warren, P.V.; Gaasterland, T.; Young, W.G.; Lenox, A.L.; Graham, D.E.; Ove
V.
Nature 392, 353-358, 1998
A/Title: The complete genome of the hyperthermophilic bacterium Aquifex aeolicus.
A/Reference number: A70300; MUID:98196666; PMID:9537320
A/Accession: D70425
A/Status: preliminary; nucleic acid sequence not shown; translation not shown
A/Molecule type: DNA
A/Residues: 1-1054 <AAQ>
A/Cross-references: GB:AE000740; NID:g2983826; PIDN:AA007394.1; PID:g2983839; GB:AE00065;
A/Experimental source: strain VPS
C/Genetics:
A/Gene: aq_1442
C/Superfamily: oxygen sensor diguanylate cyclase/c-di-GMP phosphodiesterase
```

```
Query Match 3.7%; Score 106; DB 2; Length 1054;
Best Local Similarity 19.6%; Pred. No. 10;
Matches 120; Conservative 86; Mismatches 183; Indels 224; Gaps 32;
QY 20 LSLSVYALSGQKGVYVQREFLADRLLAAEQESLKSKEINLVLDIKAVSERQ 79
Db 381 LKFVWVGKLS-EKGEVIVYLT-----CGEEEDYVKKVKISINPDEBGMKPTAK 428
QY 80 ALRDS-----DGNRTGRLTEDPRLKPM-----NGSHRHVHLPTVF 116
Db 429 ALREKVIYNRN-----TLENPDVEPRREEMLKRNFLSSCALPIQLBEGCTGVINL---Y 480
QY 117 HHLPHLAKES-----SLOPAVRVGGRTGVVWGIPSVREHVSYLTDLHLSLSLS 171
Db 481 ASEFYFREENKEILYELKEDVEFLRV-----RELBNYL-----ILSKAL 522
QY 172 PQEKDSVIVVLAETDSQ--YTSAVTENIKALPPTIEHSGLELVISPHFYDPFSLR 229
Db 523 EESRE---WVLIDREKIIIVYKGVBEI-SKYSAB-----ELIGTPRIFGSGYHPQ 571
QY 220 ESPGDPKERVRMRTKONLDYCFLLMYAQSQKGIYVQLEDDIYAKPNYISTMKNFALQPS 289
Db 572 SFY-----KRLMQT-----ILSGKPFHAFVAVKKNKYGELFYLD-QKIIPLRPR 614
QY 290 EDMMILFESQLGFTG---KMFKSLDSLIVETLMFPRDKPIDWLDHILMVKVCNPEKD 346
Db 615 GD-----LFFIGLCNDITKEVLT-----EEVEWITTHNVEGTLLN----- 650
QY 347 AKGCDROKANLRIRFKPSLFQHVGHSSLACKIQ-----KLKQXDRFQKALRKHVNP 400
Db 651 -----KVGQKVLSPILGLTSGTALILDMWGFSLRIKEFGEEAIKK----- 693
QY 401 AEVSTSLKTYQHFTLEKAVLREDFFWAFPPAAG-----FIRF 438
```

Db 694 -----LINKAVALRLEKFFRRGDII-----AKGDDEPLIFAPYLLKKDVLSTLEIKRQ 742
Qy 439 RFFQPLRLR-----RFFFRSGNIHEDP-----KLFNTSV-----EVLFPDNPQ 477
Db 743 KFSKRLTIDDKKIRLSFIVGVTVYDGRTPSELVYRAITVAKEAKRRGAGSVVLFDE-E 801
Qy 478 SDKEA--LOEGRTATLRIPRSPDGYLQIGSFYKVAEGEVDPAFGPLALRISTGSPV 535
Db 802 LDKEVERLIEGE-KLLR-----KAVEENLFTFHQPIYRLR-----DMKI 840
Qy 536 WVIILSEIFLKKAD 548
Db 841 FSLEALVRIKGD 853

RESULT 9

A70423
valine-tRNA ligase (EC 6.1.1.9) - Aquifex aeolicus

C:Species: Aquifex aeolicus

C>Date: 08-May-1998 #sequence_revision 08-May-1998 #text_change 03-Jun-2002

C:Accession: A70423

R:Decker, G.; Warren, P.V.; Gaasterland, T.; Young, W.G.; Lenox, A.L.; Graham, D.E.; O'V.

Nature 392, 353-358, 1998

A:Title: The complete genome of the hyperthermophilic bacterium Aquifex aeolicus.

A:Reference number: A70300; MUID:98196666; PMID:9537320

A:Accession: A70423

A:Status: preliminary; nucleic acid sequence not shown; translation not shown

A:Molecule type: DNA

A:Residues: 1-1165 <AQP>

A:Cross-references: GB:A5000739; NID:g2983813; PIDN:AAC07375.1; PID:g2983819; GB:A500065

A:Experimental source: strain VFS

C:Genetics:

A:Gene: valS

C:Superfamily: valine-tRNA ligase

C:Keywords: aminoacyl-tRNA synthetase; ligase; protein biosynthesis

Query Match 3.7%; Score 105.5; DB 2; Length 1165;

Best Local Similarity 19.1%; Pred. No. 13;

Matches 66; Conservative 58; Mismatches 103; Indels 119; Gaps 17;

Qy 174 EKEDSVIVLAEFDSQTSV-----TENIALPPT-----HSGLLAV 214
Db 719 EQRRLV-----DTWFSALMPGVFGWPESTDLKLYPTDLVTGPDIIFFWVARM 771
Qy 215 ISPSHPFVDF-----SRLRSFG-----DPKERVAKRKQULDYCFIMMY 255
Db 772 IMMGTHEKDIIPYDVVYHALVRDKYGRKMSKTIGNVIDPUDILERRGADALRFTLALT 831
Qy 256 AQSQGI-----YYOLE--DIIVAKPNVLTAKNFALQOPSEDM 292
Db 832 VQGRDILAEKFEFGYKHPAKIMVAAVYVLMNPEDFIARIPYAPLK-----PEKWM 885
Qy 293 MLEFSQIG-FIGKFKSLDSLIVEFILMFYRDKPIDMLDHI--LMVRY--CNPBKD 346
Db 886 IITKLMEFAEENKALENYQSOAHAIYERFWSMDYIEFTGERIYKAPEDNEBK 945
Qy 347 AK-----HCDQKANKLR--RKPSSLPHQV-----GTHSSLA----- 376
Db 946 AKVENERTTALYTLHYLEKA-LRLIHPMPPIYTEELNHLPNAGESISLAEPPOKNE 1004
Qy 377 -----GKIOLKDKDFGKQALRKE-HVNPAAVESTSLKTYOHT 414
Db 1005 RIYEDBKVERLKEIIISAIRIRSDLOIKSEKIKSKFTESERS 1050

RESULT 10

T31076

tyrocidine synthetase 3 - Brevibacillus brevis

C:Species: Brevibacillus brevis

C>Date: 02-Sep-2000 #sequence_revision 02-Sep-2000 #text_change 01-Dec-2000

C:Accession: T31076

R:Mootz, H.D.; Marahiel, M.A.

J. Bacteriol. 179, 6843-6850, 1997
A:Title: The tyrocidine biosynthesis operon of Bacillus brevis: Complete nucleotide sequ
A:Reference number: Z20969; MUID:98012987; PMID:9352938

A:Accession: T31076

A:Status: preliminary; translated from GB/EMBL/DBJ

A:Molecule type: DNA

A:Residues: 1-6486 <MOO>

A:Cross-references: EMBL:Af004835; NID:g2623770; PID:g2623773; PIDN:AAC45930.1

C:Genetics:

A:Gene: tyoC

C:Function:

A:Pathway: tyrocidine biosynthesis

C:Superfamily: acyl carrier protein homology; acetate-CoA ligase homology

C:Keywords: carrier protein; phosphopantetheine; phosphoprotein

F:510-950/Domain: acetate-CoA ligase homology <ACLI>

F:968-1036/Domain: acyl carrier protein homology <ACP1>

F:1546-1987/Domain: acetate-CoA ligase homology <ACP1>

F:2005-2073/Domain: acyl carrier protein homology <ACP2>

F:2583-3025/Domain: acetate-CoA ligase homology <ACLI3>

F:3043-3111/Domain: acyl carrier protein homology <ACP3>

F:3621-4060/Domain: acetate-CoA ligase homology <ACLI4>

F:4078-4146/Domain: acyl carrier protein homology <ACP4>

F:4656-5104/Domain: acetate-CoA ligase homology <ACLI5>

F:5122-5190/Domain: acyl carrier protein homology <ACP5>

F:5702-6147/Domain: acetate-CoA ligase homology <ACLI6>

F:6165-6233/Domain: acyl carrier protein homology <ACP6>

F:1000,2037,3075,4110,5154,6197/Binding site: phosphopantetheine (Ser) (covalent) #statuc

Query Match 3.7%; Score 105.5; DB 2; Length 6486;

Best Local Similarity 21.5%; Pred. No. 1.66+02;

Matches 113; Conservative 73; Mismatches 216; Indels 123; Gaps 27;

Qy 50 LHAAROSLKRKSLNVLDEIKRAVSEQALRDGDGRRTWG-----RLTED---PRLK 100
Db 4309 LYAGKQLSDLRIRQKDDPAWQTKLAQSDRQKQDPMTRTPAGIRPLNLPHPDIPRSVQ 4368
Qy 101 PWSGSHRHVHLPTVFHRLPHLLAKESSLQPAVVGQRTGVSVWGI PSVREVS YLT 160
Db 4369 SFDGD---TVALLGT-GHLLLEQLRLKLA-----ENGTTLFM-----VLL 4403
Qy 161 DTLHSLSLSLPQKESVIVLAEFDSQTSVAVTENIKALPFTTEHSGLEVISPSPH 220
Db 4404 AAYVVLISKYAGQE-----IVGTPIDAGSHADVRIYGMFVNTL--ALKNTAAGSL 4455
Qy 221 FYPDFSLRBSFGPKRVRMRKONLDYCFIMMYAQSGLIYVQLRBDIVAKENYSTLM 280
Db 4456 F-----KALEBVQKNA-LHAFEHODYFPEH-----VEKLQVRDLSRNPLF-DTM 4500
Qy 281 KNFALQPPSE---DMWLEFSQIGFIKMFKSLDL-----SLIVEF--ILMFYRDRPID 329
Db 4501 FSLGLASABGEVADLKVSPYPVNGHIAKFDLSIDANEKODGULVQSYCTKLPKAKETVD 4560
Qy 330 WLDH---ILWVKCNPEKAKHCDROKANKIRIRFKSLRQHVGTSSLAGKLOKDKD 386
Db 4561 RLAAHYVQLQOTIYAD-----DIELARISVLSKAEI-EHM-LHSFLATKTAAYPTDKT 4611
Qy 387 FGKQALRKHY-NRPAEVS-----TSLKTYOHT-----LEKAYLREBP----- 424
Db 4612 F--OKLFEBOVEKTPNEIAVLFGNEQLTYOELNANKANQALVARLRKRGKPESTYGLIVDR 4669
Qy 425 -----FWAFTPAAGDFIRFRFQPLRLRFFRSGNIHEDKLFNT-----SVEVL P 472
Db 4670 SLVYVIGMLAVLKAGGFVFPIDPDYFLERQAFW-----LDSSEAKLLTLIQKMSQVAF P 4724
Qy 473 FDNPDQSKALQSGRTYATLRYPRSPD--GYLQIGSFYKVAEGEV 515
Db 4725 YETFYLDTEYVDOETGNLEHVAQPENVAAYIITYSGTGRKGVV 4769

RESULT 11

A29924

acetyl-CoA carboxylase (EC 6.4.1.2), hepatic - chicken

C:Species: Gallus gallus (chicken)

Db 1779 LRNPOTDS 1787

RESULT 13

Translation initiation factor IF-2 [imported] - Nostoc sp. (strain PCC 7120)
C:Species: Nostoc sp. PCC 7120
A:Note: Nostoc sp. strain PCC 7120 is a synonym of Anabaena sp. strain PCC 7120
C:Date: 14-Dec-2001 #sequence_revision 14-Dec-2001 #text_change 09-Dec-2002
C:Accession: A12284
R:Kaneko, T.; Nakamura, Y.; Wolk, C.P.; Kuritz, T.; Sasa moto, S.; Matsumoto, A.; Iri guchi, S.; Tanabe, T.; Shimizu, S.; Sugimoto, M.; Takazawa, M.; Yamada, M.; Yasuda, M.; Tabata, S.
DNA Res. 8, 205-213, 2001
A:Title: Complete Genomic Sequence of the Filamentous Nitrogen-fixing Cyanobacterium Anabaena PCC 7120
A:Reference number: AB1807; MUID:21595285; PMID:11759840
A:Accession: A12284
A:Status: Preliminary
A:Molecule type: DNA
A:Residues: 1-1039 <KUR>
A:Cross-references: GB:BA000019; PIDN:BA875531.1; PID:G17132966; GSPDB:GN00179
C:Genetics:
A:Gene: infB
C:Superfamily: translation initiation factor IF-2; translation elongation factor Tu homolog

Query Match 3.6%; Score 104; DB 2; Length 1039;

Best Local Similarity 20.6%; Pred. No. 14; Mismatches 158; Indels 150; Gaps 26;

Matches 100; Conservative 78; Mismatches 158; Indels 150; Gaps 26;

62 KRLNVLDEIRKAVSERQALRDGDNRTWGRITLTPDLKPNVSHRVLHPTVFHLLPH 121

501 KELEI---EVTAEPEEA-----RKVTETIEV---GDLHLRRPVTITMGH 543

122 LLAKESSLOPVR---VCGRTGVSVVMGIPSVREHVSITLTLHSLSLSLSPOKEDS 178

544 VDHCKTLLDLSIRTKVAAGAG-----GITQIHGAYHVDIVH-----DGEQ 586

179 VIIVLLETDSQYSAVENTIKALPTEIHSGLEVISPSHPFVDFSLRESFGDPKER 238

587 QIVLDPFGHAFIARARARARV---TDI---AVLVVA-----DDG 622

239 VRMTKQNDYCFIMMYAQSQGIYYVQLEDDIVAKPNYLSITMKNFALQPSSEDMITLIFS 298

623 VRPQVEAIS-----HQAGV-----PIVVAINKID--KGA--QF--DKVQELT 663

299 QLGFTGKMFSLSLIYEFILMFYRDKPIWMLDHIIMVK-----VCNPKDAK----- 348

664 QYGLTSEBEGERTIMVPSAI-----RGENLDTLLEMILLVAEVBLSANPDNRNARGVIE 719

349 -HCDROKANLIRFPKSLFOHVG---THSLAGRIQKDKDPGKQMLRKEHVNPPAEVS 404

720 AHDPAKAVATLILQNTLHVGDILAGSAPGKRAVVD--DRG---KRDVINGPS--- 771

405 TSLKTYQHFTLEKAYLRDPFMAFTRPAAGPIRFRFQPLRLBERFFPSGNIIEHEDTLF 464

772 -----FAVEVGLSD-----VPAAGD-----EPEVF 792

465 NTSVEVLPFDNPODKALQ---EGR-TATLRPRSPGTY-QIGSPKGVAGEVDPAF 519

793 DNEKEARALADRADKORLSRLQGRVTLTTLASAQAGELKEINLILKGDVQGSVEATV 852

520 GPLEAL 525

853 GSKQI 858

RESULT 14

T08880
NMDA receptor-binding protein yotiao - human
C:Species: Homo sapiens (man)
C:Date: 11-Jun-1999 #sequence_revision 11-Jun-1999 #text_change 21-Jul-2000
C:Accession: T08880

R:Lin, J.W.; Wyszynski, M.; Madhavan, R.; Sealock, R.; Kim, J.U.; Sheng, M.
J. Neurosci. 18, 2017-2027, 1998
A:Title: Yotiao, a novel protein of neuromuscular junction and brain that interacts with
A:Reference number: Z16511; MUID:98151389; PMID:9482789
A:Accession: T08880
A:Status: Preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-1642 <LIN>
A:Cross-references: EMBL:AF026245; NID:g2623067; PIDN:AAB86384.1; PID:g2623068
C:Genetics:
A:Map position: 7q21-22
C:Keywords: brain; cerebral cortex; coiled coil; neuromuscular junction; skeletal muscle

Query Match 3.6%; Score 104; DB 2; Length 1642;

Best Local Similarity 20.2%; Pred. No. 28; Mismatches 104; Indels 184; Gaps 21;

Matches 87; Conservative 56; Mismatches 104; Indels 184; Gaps 21;

27 ALSGQKDVVDVYOREFLALRDLAAEQSLK-----RSKLNLVLDIKRAVSR-- 78

1154 ALCSIKELIFAOEIKELQ-KIHOLELQTMKTOETGDEGKPLHLIGLQKRVSECS 1212

79 ---QAL-----RODGNRTWGRITLTPDLKPNV-----GSHRVHL 111

1213 YFLQTLCSVIGERYTPALCKEVNAEDKENGDIYSENEDDELQRYEVODFOENMTL- 1271

112 LPVFFHLLPHLLAKESLSOPAVRVGQRTGVSVVMGIPSVRRE-----VHSYLTD--- 161

1272 LNKVTEYNKLVIVQTLRSKI--WGQOTDGMKLFEGENLPKERTLSLSHQMNLNEDI 1329

162 -----THSLISLSLSPOKEDS----- 176

1330 DVNHKSLSSLODEKTKLEQVQLESLISLSXQQLKEQYVNAEIHCLQKRLQAVSR 1389

177 -----DSVIVLLETDSQY---SAVENTIKALPTEIHSGLEVISPSHPFYP 223

1390 STVPSPSLPVDVSV---LTESDAPQRTMTPGSCVKKNL-----DTIE----- 1427

224 DFSRLRESFGDPKER--VRMTKQNDYCFIMMYAQSQGIYYVQLEDDIV----- 271

1428 -FS---GEFVKERTINVLKLEKQ-----YQGLSEEVAKVIVMSIAF 1467

272 -----AKPNYLSITMKNFALQPSSEDM---MILFSQGLGFTGKMFSLSLIYVE 317

1468 AQOTELSRISGKENTASSQAHAVCOEQHYNEMKLSQDQIGF--QTFEYDVVKER 1525

318 FILMFYRDKPI 328

1526 F-----KPL 1529

RESULT 15

S73852
Hypothetical protein MG218 homolog P10_orf1818 - Mycoplasma pneumoniae (strain ATCC 29342;
C:Species: Mycoplasma pneumoniae
A:Variety: ATCC 29342
C:Date: 10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change 21-Jul-2000
C:Accession: S73852

R:Himmelreich, R.; Hillbert, H.; Plagens, H.; Pirkel, E.; Li, B.C.; Hermann, R.
Nucleic Acids Res. 24, 4420-4449, 1996

A:Title: Complete sequence analysis of the genome of the bacterium Mycoplasma pneumoniae.
A:Reference number: S73327; MUID:97105885; PMID:8948653

A:Accession: S73852
A:Status: nucleic acid sequence not shown; translation not shown

A:Molecule type: DNA
A:Residues: 1-1818 <HIM>

A:Cross-references: EMBL:AF000051; GB:U00089; NID:g1674211; PIDN:AAB96174.1; PID:g1674223
A:Note: the nucleotide sequence was submitted to the EMBL Data Library, November 1996

C:Genetics:
A:Genetic code: SGC3

C:Superfamily: Mycoplasma genitalium hypothetical protein MG218

Query Match 3.6%; Score 104; DB 1; Length 1818;
Best Local Similarity 19.7%; Pred. No. 32;

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: July 20, 2004, 10:07:10 ; Search time 13 Seconds
(without alignments)
2194.957 Million cell updates/sec

Title: US-10-033-245-24

Perfect score: 2868
Sequence: 1 MRLNNGTFLTLFLCLCAFL.....IQTDSPVWVILSEIFLKAD 548

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 141681 seqs, 52070155 residues

Total number of hits satisfying chosen parameters: 141681

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Swissprot_42:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	136	4.7	740	1	BBAP_HUMAN
2	123	4.3	1553	1	OSP_DROME
3	119.5	4.2	1290	1	RA50_SCHPO
4	113.5	4.0	1755	1	PEPL_MOUSE
5	108	3.8	274	1	POSC_MOUSE
6	108	3.8	838	1	CYAA_PASMU
7	107.5	3.7	970	1	T3RE_BPPI
8	107	3.7	658	1	KPCI_LYPI
9	105.5	3.7	1165	1	SVV_AQUAE
10	105.5	3.7	6486	1	TYCC_BREPA
11	105	3.7	2324	1	COAC_CHICK
12	105	3.7	3911	1	AKA9_HUMAN
13	104.5	3.6	3770	1	ACVS_EMENI
14	104	3.6	1039	1	IF2_ANASP
15	104	3.6	1818	1	HMW2_MYCN
16	104	3.6	2280	1	YCF2_OENHO
17	103	3.6	1247	1	KPBA_DROME
18	102.5	3.6	575	1	EZRA_STRPN
19	102.5	3.6	575	1	EZRA_STR6
20	101.5	3.5	412	1	TOP1_HUMAN
21	101.5	3.5	916	1	TOP1_ARATH
22	101	3.5	406	1	OLFL_HUMAN
23	101	3.5	547	1	CITA_KLEPN
24	99.5	3.5	4540	1	DYHC_PAPRE
25	99	3.5	1839	1	POLR_EPV
26	98.5	3.4	1006	1	RAT1_YEAST
27	97.5	3.4	1487	1	MD53_YEAST
28	97	3.4	1698	1	CUL7_HUMAN
29	96.5	3.4	868	1	PD61_HUMAN
30	96	3.3	422	1	GAS7_RAT
31	96	3.3	865	1	STY_THEMA
32	96	3.3	2663	1	CEN2_HUMAN
33	95.5	3.3	638	1	LIR2_RAT

34	95.5	3.3	869	1	PD61_MOUSE
35	95.5	3.3	1232	1	Y908_METJA
36	95	3.3	543	1	SYFB_THEAC
37	95	3.3	562	1	EZRA_BACSU
38	95	3.3	914	1	ITTH_MESAU
39	95	3.3	2345	1	COA1_RAT
40	94.5	3.3	4910	1	MDN1_YEAST
41	94	3.3	487	1	5HT3_MOUSE
42	94	3.3	591	1	SYD_PSEEM
43	94	3.3	757	1	GSHI_PASMU
44	93.5	3.3	417	1	AGP_PRORE
45	93.5	3.3	448	1	T2EA_SCHPO

ALIGNMENTS

RESULT 1

ID	BBAP_HUMAN	STANDARD;	PRT;	740 AA.
AC	Q8TDB6;			
DT	10-OCT-2003 (Rel. 42, Created)			
DT	10-OCT-2003 (Rel. 42, Last sequence update)			
DT	10-OCT-2003 (Rel. 42, Last annotation update)			
DE	B-lymphoma- and BAL-associated protein (Rhysin 2) (Rhysin2).			
GN	BBAP.			
OS	Homo sapiens (Human).			
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC	Mammalia; Euteria; Primates; Carnivora; Homiidae; Homo.			
OX	NCBI_TaxID=9606;			
RN	[1]			
RP	SEQUENCE FROM N.A., IN VITRO UBIQUITIN LIGASE ACTIVITY, AND			
RP	INTERACTION WITH BAL AND DTX1.			
RX	MEDLINE=22679154; PubMed=12670957;			
RA	Takeyama K., Aguilar R.C.T., Gu L., He C., Freeman G.J., Kutec J.L.,			
RA	Aster J.C., Shipp M.A.;			
RT	"The BAL-binding protein BBAP and related Deltex family members			
RT	exhibit ubiquitin-protein isopeptide ligase activity.";			
RL	J. Biol. Chem. 278:21930-21937(2003).			
RN	[2]			
RP	SEQUENCE FROM N.A.			
RP	Roberts R.C., Kendrick-Jones J., Jensen O.N.;			
RT	"Rhysin is a novel protein identified by mass spectrometry found in a			
RT	myosin VI-containing complex isolated by immunoprecipitation.";			
RL	Submitted (FEB-2002) to the EMBL/GenBank/DBJ databases.			
RN	[3]			
RP	SEQUENCE FROM N.A.			
RP	TISSUE=Lymph;			
RC	MEDLINE=22388257; PubMed=12477932;			
RX	Klausner R.D., Collins F.S., Wagner L., Sherman C.M., Schuler G.D.,			
RA	Strausberg R.L., Collins F.S., Wagner L., Sherman C.M., Schuler G.D.,			
RA	Aleschul S.F., Zeeberg B., Buettow K.H., Schaefer C.F., Bhat N.K.,			
RA	Hopkins R.F., Jordan H., Moore T., Wax S.I., Wang J., Hsieh F.,			
RA	Dickchenko L., Marusha K., Farmer A.A., Rubin G.M., Hong L.,			
RA	Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,			
RA	Brownstein M.J., Uedin T.B., Toshiyuki S., Carninci P., Prange C.,			
RA	Raha S.S., Loguclano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,			
RA	Boak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,			
RA	Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Huij S.W.,			
RA	Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,			
RA	Foley J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,			
RA	Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,			
RA	Blakeley R.W., Touchman J.W., Green E.D., Dickson M.C.,			
RA	Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,			
RA	Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalhe D.E.,			
RA	Schneerch A., Schein J.B., Jones S.J.M., Marra M.A.;			
RT	"Generation and initial analysis of more than 15,000 full-length human			
RT	and mouse cDNA sequences.";			
RL	Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).			
CC	-I- FUNCTION: Functions as an ubiquitin ligase protein in vitro.			
CC	-I- SUBUNIT: Homodimer and heterodimer. Can heterodimerize with DTX1,			
CC	enhancing its ubiquitin ligase activity in vitro. Interacts with			
CC	BAL. Found in a complex with MYO6.			


```

RP SEQUENCE FROM N.A. (ISOFORM SHORT).
RC STRAIN=Berkley; TISSUE=Embryo;
RA Stipledon M., Brooks P., Hong L., Asgabayani A., Carlson J.W.,
RA George M., Chavez C., Dorsett V., Dresnek D., Farfan D., Friese B.,
RA George R.A., Gonzalez M., Guarin H., Krommiller B., Li P.W., Liao G.,
RA Miranda A., Mungall C.J., Nunoo U., Pacled J.M., Parasas V., Park S.,
RA Patel S., Phouanavong S., Wan K.H., Yu C., Lewis S.E., Rubin G.M.,
RA Celniker S.E.;
RL Submitted (JUN-2002) to the EMBL/GenBank/DBJ databases.
RN [5]
RP SEQUENCE OF 117-271 FROM N.A.
RX MEDLINE=63271469; PubMed=6410283;
RA Kretzen M.;
RT "Nucleotide polymorphism at the alcohol dehydrogenase locus of
RT Drosophila melanogaster.";
RL Nature 304:412-417(1983).
CC -! ALTERNATIVE PRODUCTS:
CC Event-Alternative Splicing; Named Isoforms=2;
CC Name=Long;
CC IsoId=Q27421-1; Sequence=Displayed;
CC Name=Short;
CC IsoId=Q27421-2; Sequence=VSP_004063, VSP_004064, VSP_004065;
CC -! SIMILARITY: Contains 2 PH domains.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to licenses@isb-sib.ch).
CC -----
DR EMBL; AE003410; AAF44880.1; -
DR EMBL; AE003410; AAF44881.1; -
DR EMBL; AE003644; AAF3402.3; -
DR EMBL; AY118512; AAM99881.1; -
DR EMBL; M17837; AAA70211.1; ALT_INIT.
DR EMBL; M19547; AAA70209.1; ALT_INIT.
DR EMBL; Z00030; CAA7329.1; ALT_INIT.
DR FlyBase; FBgn003016; osp.
DR InterPro; IPR001849; PH.
DR Pfam; PF00169; PH; 2.
DR SMART; SM00233; PH; 2.
DR PROSITE; PS00003; PH DOMAIN; 2.
DR Repeat; Alternative splicing.
FT DOMAIN 71 177 PH 1.
FT VARSPLIC 1 462 Missing (in isoform short).
FT VARSPLIC 1373 1373 /FTId=VSP_004063.
FT VARSPLIC 1374 1553 /FTId=VSP_004064.
FT VARSPLIC 1553 AA; 174107 MW; 861104687ECBIDE1 CRC64;
SQ SEQUENCE 1553 AA; 174107 MW; 861104687ECBIDE1 CRC64;
Query Match 4.3%; Score 123; DB 1; Length 1553;
Best Local Similarity 21.5%; Pred. No. 0.49;
Matches 109; Conservative 69; Mismatches 200; Indels 130; Gaps 23;
OY 40 GREFLALDRLLAAEQE--SLKSKELNVLVDIKRAVSRQALRDGNGRTWGLRTED 96
DB 931 ERQVALLKOKLAKSKRRSLKKGKQELKLSLQRTVERK-----EGTPSSSSSES 985
OY 97 PLKPMNGSHRHVLLPTVFPHLPHLT--AKK-----SILQPNRVGO-GRIGVSYVMG 147
DB 986 SSGSTPLN-----HLQRLHSLHLEVLGSKRYERLQSLTQLO-QIRAGQRTFRSVSPND 1038
OY 148 IPSVAREVHASYLDT-----LHSLISLSPQEKEDSVLVLLA 185
DB 1039 RKDGLRQLERLALERTCWVWSQMETLGLQDSCHKKCDLRQVREKLSALQQO-----T 1090
OY 186 ETDQSYSAVTENIKALFPTLHSGLELVISPSPH---FYDPFSRLRESFDPDKERVNR 242

```

```

DB 1091 ETDQSRQQLLEQRE---TLDAQALEKCAQSOEBOELLQORLESELGRQOERCR-R 1145
OY 243 TKONLDYCFLLMYVQSKGIVYVQLEDDIVAKPNYLSSTKKNPALQOPSEDMWILEFSQJGF 302
DB 1146 LKRLLE---LLERHGK-----QLE---CLREYVHTHANADQSPKRYQTEIEQURT 1194
OY 303 I-GKPFSLDISLIVERFLMEYRDKPDIMDLHLMVKNVCPKQDANKCDRQKANLR--- 358
DB 1195 LCEKGLSAMETS-----HKRLTMDLEQKHMEIERLEKREKETAALAEETQATLALD 1245
OY 359 -----IRFPSLFGVGHSSLAGKIQKDKDPGKQALRKENVPPREVS 404
DB 1246 AMRAHOSVQREVARFQGFQFRLQVQGEQKRGCAKKEKEDLELRN-----BTL 1296
OY 405 TSLKTYQFTLEKAYLIEDPFMAFTPAAGDPIRRFPQPLRLERFFPSGNIHREDXLF 464
DB 1297 AFSEKYSIKCYENNALEKLMANSKLK---HQQMOQLELRKQPRRA---H----- 1342
OY 465 NTSVEVLPEFDPNPGSKDEALQGRATATLR 492
DB 1343 -----LASDDPSNDVHFVQ-GLTSNAR 1363
RESULT 3
R50 SCHPO STANDARD; PRT; 1290 AA.
AC 09UTU8; 09J75;
DT 10-OCT-2003 (Rel. 42, Created)
DT 10-OCT-2003 (Rel. 42, Last sequence update)
DT 15-MAR-2004 (Rel. 43, Last annotation update)
DE RAD50 repair protein rad50.
GN RAD50 OR SPAC1556.01C OR SPAP49.01C.
OC Schizosaccharomyces pombe (Fission Yeast).
OC Eukaryota; Fungi; Ascomycota; Schizosaccharomycetes;
OC Schizosaccharomycetales; Schizosaccharomycetaceae;
OC Schizosaccharomycetes.
OX NCBI_TaxID=4896;
RN [1]
RP SEQUENCE FROM N.A., FUNCTION, AND INTERACTION WITH RAD21 COHESIN
RP COMPLEX.
RX MEDLINE=2158333; PubMed=11726502;
RA Hartsulker E., Vaessen E., Carr A.M., Kohl J.;
RT "Fission yeast Rad50 stimulates sister chromatid recombination and
RT links cohesion with repair.";
RL EMBO J. 20:6660-6671 (2001).
[2]
RP SEQUENCE FROM N.A.
RC STRAIN=972;
RX MEDLINE=21848401; PubMed=11859360;
RA Wood V., Gwilliam R., Rajandream M.A., Lyne M., Lyne R., Stewart A.,
RA Sgouros J., Peat N., Hayles J., Baker S., Basham D., Bowman S.,
RA Brooks K., Brown D., Brown S., Chillingworth T., Churcher C.M.,
RA Collins M., Connor R., Cronin A., Davis P., Feltham T., Fraser A.,
RA Gentles S., Goble A., Hamlin N., Harris D., Hidalgo J., Hodgson G.,
RA Holtroyd S., Hornsby T., Howarth S., Huckle E.J., Hunt S., Jagels K.,
RA James K., Jones L., Jones M., Leather S., McDonald S., McLean J.,
RA Mooney P., Moule S., Mungall K., Murphy L., Niblett D., Odell C.,
RA Oliver K., O'Neill S., Pearson D., Quail M.A., Rabinovich E.,
RA Rutherford K., Rutter S., Saunders D., Seeger K., Sharp S.,
RA Skellton T., Simmonds R., Squares R., Squares S., Stevens K.,
RA Taylor K., Taylor R.G., Tivey A., Walsh S.V., Warren T., Whitehead S.,
RA Woodward J., Voickert G., Aert R., Robben J., Grymopoulos B.,
RA Wellens J., Vanstelele B., Rieger M., Scheef M., Mueller-Auer S.,
RA Gabel C., Fuchs M., Fritz C., Holzer E., Moestl D., Hilbert H.,
RA Borzym K., Langer I., Beck A., Lehnach H., Reinhardt R., Pohl T.M.,
RA Eger P., Zimmermann W., Wedler H., Wambutt R., Purnelle B.,
RA Goffeau A., Cadieu B., Dreano S., Gloux S., Lelaire V., Mottier S.,
RA Gaibaudi F., Aves S.J., Xiang Z., Hunt C., Moore K., Hurst S.M.,
RA Lucas R., Rocher M., Galliard C., Tallada V.A., Garzon A., Rhode G.,
RA Daga R.R., Cruzado L., Jimenez J., Sanchez M., del Rey F., Benito J.,
RA Dominguez A., Revuelta J.U., Moreno S., Armstrong J., Forsburg S.L.,
RA Cernutti L., Lowe T., McCombie W.R., Paulsen I., Potashkin J.,
RA Shpakovski G.V., Uesery D., Barrell B.G., Nuree P.;

```

RT "The genome sequence of *Schizosaccharomyces pombe*.";
 RN Nature 415:871-880(2002).
 RP SUBUNITS, AND SUBCELLULAR LOCATION.
 RX MEDLINE=22825616; PubMed=12944482;
 RA Chawan C, Nakamura T.M., Sivakumar S., Russell P., Rhind N.;
 RT "The fission yeast Rad32 (Mre11)-Rad50-Nbs1 complex is required for
 the S-phase DNA damage checkpoint.";
 RL Mol. Cell. Biol. 23:6564-6573(2003).
 CC -1- FUNCTION: Involved in DNA double-strand break (DSB) repair.
 CC Involved in mating type switching and has a role in choosing the
 CC sister chromatid for recombinational repair. Also has a role in
 CC telomere length maintenance.
 CC -1- SUBUNIT: Interacts with the rad21 cohesin complex. Forms a
 CC multibunit endonuclease complex, MNM, together with nbs1 and
 CC rad32.
 CC -1- SUBCELLULAR LOCATION: Nuclear.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.ebi.ac.uk/ebis/sib.ch/announce/>
 CC or send an email to license@sib.ch).
 CC -----
 CC EMBL, AL132984; CAB61212.1; -;
 CC EMBL, AL360094; CAB96041.1; -;
 CC PIR, T50080; T50080.
 CC GenDB, Spombe; SPAC1556.01c; -;
 CC InterPro, IPR003439; ABC transporter.
 CC InterPro, IPR004584; Rad50.
 CC TIGRPFAMS; TIGR00606; rad50; 1.
 CC DNA repair; Hydrolyase; ATP-binding; Coiled coil; Nuclear protein;
 CC Telomere; Meiosis.
 CC NP BIND 34 41 ATP (POTENTIAL).
 CC DOMAIN 295 365 COILED COIL (POTENTIAL).
 CC DOMAIN 727 809 COILED COIL (POTENTIAL).
 CC DOMAIN 814 902 COILED COIL (POTENTIAL).
 CC SEQUENCE 1290 AA; 149562 MW; 47BD2211E619D694 CRC64;
 SQ
 Query Match 4.2%; Score 119.5; DB 1; Length 1290;
 Best Local Similarity 19.3%; Pred. No. 0.69; Indels 155; Gaps 22;
 Matches 100; Conservativity 84; Mismatches 180;
 QY 34 DVVDVYQREFFLARLRLHAAEQESLRSKELNLVLDEIKRAVSEKQA--LRDGDG-NRTW 90
 DB 512 EIVDSYHK-YSGVTRTKLVFEENKTKNSAILANQMTLKSSPVSWSYELKDDVYNEEL 570
 QY 91 GRLTEDPRLKPNWNGSHRVHLHPTVFHLLPHLLAKESSLQAPRVVVGQRTGVSVVMGLPS 150
 DB 571 DKLIVEDVRKK-----LOEKESLARSVRERLIRISLSVQS 608
 QY 151 VR-----REHVSYLDTLHSLISLSPOKE-----DSVIVV 182
 DB 609 INDLTENKKIKTKTKLSY-SGFASNTISIKALEBIEENRKLTHSLQGSTFYKALETI 667
 QY 183 LIAETDSQYTS-AVTENIKALPPTTEHSGILEVISPSPHFYDPFSLRESFGDPKRYVM 241
 DB 668 CVDQHAQCQCSRLDKEBEKLVCHCHSMIDVIRPKSAVYHHLTLTITF----- 718
 QY 242 RTKQNLDFCLMVAOSKGIYVVLQEDDIVAKPNYLSYTKNPFALQOQSEDMILFSPQLG 301
 DB 719 ---KNL-----SEAKPIF-----DEIELDKRLSETK-----TELS 746
 QY 302 FIGKNKFSIDL--SLIVFIMFYRDKRIDWLHLLHVVKVCNPEKQAKHCDROKANIR 358
 DB 747 DLQGLDQGLDIDKDEIQSELDTLVLRANLEKL--QLVKDLSNBEERLRTDRETEVLR 804
 QY 359 IRFKPSLFGHVGTHSLAGIKQIKDKDQFGKALKEHNPAPAVSTSLKTYQHFTLEKA 418
 DB 805 IELPSSIAHH--NDEIYMERKLEK---RGYLRKQ-----IERT 840

QY 419 YLRDFFWATPPAGDFIRFFPQPLRLERFFPSGNIHEHEDKLFTMS-----V 468
 DB 841 KLEET---SFKKKIDDAVLANNEQLKTLKLNPFVNEBLEKQIKNSSEPCDYLQKKLL 897
 QY 469 EV-----LFPDNP-OSDKAL-----QEGRTATL 491
 DB 898 EVSSKQSQAPFNLNLESEYEKLEADIQEMQKRTTEL 936
 RESULT 4
 ID PEPL_MOUSE STANDARD; PRT; 1755 AA.
 AC 09R269; 070231; 09CUT1; 09JL27;
 DT 16-OCT-2001 (Rel. 40, Created)
 DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Periplakin.
 GN PPL.
 OS Mus musculus (Mouse).
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 OC NCBI_TaxId=10090;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC TISSUE=Embryo;
 RA de Vries-Smits A.M.M., Waldmann V., Burgering B.M.T.;
 RL Submitted (FEB-1999) to the EMBL/Genbank/DBJ databases.
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=129/Sv;
 RA Ryoo Y.W., Li K., Aho S., Cho B.H., Klement J.F., Uitto J.;
 RT "Mouse periplakin: genomic cloning and gene targeting";
 RL Submitted (DEC-1998) to the EMBL/Genbank/DBJ databases.
 RN [3]
 RP SEQUENCE OF 1643-1755 FROM N.A.
 RC STRAIN=C57BL/6J; TISSUE=Head;
 RX MEDLINE=21085660; PubMed=11217851;
 RA Kawai J., Shinagawa A., Shibata K., Yoshino M., Itoh M., Ishii Y.,
 RA Arakawa T., Hara A., Fukunishi Y., Konno H., Akaishi J., Fukuda S.,
 RA Aizawa K., Izawa M., Nishi K., Kiyosawa H., Kondo S., Yamataka I.,
 RA Saito T., Okazaki Y., Gojobori T., Bono H., Kasukawa T., Saito R.,
 RA Kadota K., Matsuda H.A., Ashburner M., Batalov S., Casavant T.,
 RA Fleischmann W., Gaasterland T., Gissi C., King B., Kochiwa H.,
 RA Kuehl P., Lewis S., Matsuo Y., Nikaido I., Pesole G., Quackenbush J.,
 RA Schiml L.M., Staebli F., Suzuki R., Tomita M., Wagner L., Washio T.,
 RA Sakai K., Okido T., Furuno M., Aono H., Baldarelli R., Barsh G.,
 RA Brownstein M.J., Bult C., Fletcher C., Fujita M., Gariboldi M.,
 RA Guenichich S., Hill D., Hofmann M., Hume D.A., Kamliya M., Lee N.H.,
 RA Lyons P., Marchionni L., Mashima J., Marzarelli I., Sakamoto N.,
 RA Nordone P., Ring B., Ringwald M., Rodriguez I., Sakamoto N.,
 RA Saeki H., Sato K., Schoenbach C., Seta T., Shibata K., Storch K.-F.,
 RA Suzuki H., Toyooka K., Wang K.H., Weitz C., Whitlaker C., Wilming L.,
 RA Wyshahzaki Y., Yoshida K., Hasegawa Y., Kawaji H., Kohlsaki S.,
 RA Hayashizaki Y.;
 RT "Functional annotation of a full-length mouse cDNA collection.";
 RL Nature 409:685-690(2001).
 RN [4]
 RP SEQUENCE OF 1647-1755 FROM N.A.
 RC STRAIN=C57BL/6J;
 RX MEDLINE=98190524; PubMed=9521878;
 RA Aho S., McLean W.H.T., Li K., Uitto J.;
 RT "cDNA cloning, mRNA expression, and chromosomal mapping of human and
 RT mouse periplakin genes.";
 RL Genomics 48:242-247(1998).
 CC -1- FUNCTION: Component of the cornified envelope of desmosomes and intermediate
 CC filaments (by similarity).
 CC May link the cornified envelope to desmosomes and intermediate
 CC filaments (by similarity).
 CC -1- SUBUNIT: MAY FORM A HOMODIMER OR A HETERODIMER WITH EVPL (BY
 CC SIMILARITY).
 CC -1- SUBCELLULAR LOCATION: ASSOCIATED WITH DESMOSOMES AND INTERMEDIATE
 CC FILAMENTS (BY SIMILARITY).
 CC -1- SIMILARITY: Contains 2 plectin repeats.

```

CC -1 SIMILARITY: Contains 3 spectrin repeats.
CC -1 SIMILARITY: Belongs to the plaklin or cytolinker family.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on items
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see http://www.ldb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC -----
DR EMBL; AF126834; AAD20642.1; -
DR EMBL; AF116523; AAF29436.1; JOINED.
DR EMBL; AF116519; AAF29436.1; JOINED.
DR EMBL; AF116520; AAF29436.1; JOINED.
DR EMBL; AF116521; AAF29436.1; JOINED.
DR EMBL; AF116522; AAF29436.1; JOINED.
DR EMBL; AK014700; BAB29510.1; -.
DR EMBL; AF013715; AAC40068.1; -.
DR MGD; MGI:1194898; Ppl
DR InterPro; IPR001101; Plectin_repeat.
DR InterPro; IPR002017; Spectrin.
DR Pfam; PF00681; Plectin; 1.
DR Pfam; PF00435; spectrin; 5.
DR SMART; SMO0250; PLEC; 3.
KW Keratinization; Repeat; Coiled coil; Cytoskeleton; Structural protein.
FT DOMAIN 16 125 COILED COIL (POTENTIAL).
FT REPEAT 182 387 COILED COIL (POTENTIAL).
FT REPEAT 214 315 SPECTRIN 1.
FT REPEAT 321 483 SPECTRIN 2.
FT REPEAT 503 610 SPECTRIN 3.
FT DOMAIN 611 819 COILED COIL (POTENTIAL).
FT DOMAIN 883 1644 COILED COIL (POTENTIAL).
FT REPEAT 1650 1684 PLECTIN 1.
FT REPEAT 1699 1734 PLECTIN 2.
FT REPEAT 166 166 E -> Q (IN REF. 2).
FT REPEAT 592 592 N -> T (IN REF. 2).
FT REPEAT 648 648 R -> S (IN REF. 2).
FT REPEAT 671 672 GK -> EQ (IN REF. 2).
FT CONFLICT 689 721 OECPDLEKQAEVHKMNPNNLSQOVERRAQ ->
FT CONFLICT 689 721 PRAIPFGAAGRGAAQAPTRQOPQAGTE (IN REF.
FT CONFLICT 983 983 T -> A (IN REF. 2).
FT CONFLICT 1325 1325 G -> R (IN REF. 2).
FT CONFLICT 1344 1345 QR -> G (IN REF. 2).
SQ SEQUENCE 1755 AA; 204003 MW; 3FEA343086E4CB8F CRC64;

Query March 4.0%; Score 113.5; DB 1; Length 1755;
Best Local Similarity 18.4%; Pred. No. 3;
Matches 107; Conservative 94; Mismatches 229; Indels 151; Gaps 20;

QY 42 EFLALDRILHAAEBSLRSKELNLVLDIEIRAVSERQALDGDGNFTWGLTEDPRLK- 100
Db 1007 EVQLRLRELELARQKGARREHVLILQGRVALAALAEKSRGVEKYTEHEVVLQNDPQLEA 1066
QY 101 -----PWNGSHRHVLLPTVFHHLPHLLAKESSIQPAVRVQGRTGVSVMGT-- 148
Db 1067 EYRLROEHSRGREGTLREKQE-----EELSFLQAKTLRLREKERAHAEGKITVKEVLAKYEKD 1121
QY 149 PSYRREHVSYLTDLHLISLSLSPOKEKDSYIVVLIAETDSQYSATENIKALPPIEIH 208
Db 1122 AAVREHVDN-ITROYEDEBAARSGQRKTELLKRIWALEE-----ENAKVVQOEKVR 1173
QY 209 SGLLEVISPSPHFPDPSRLTRESFGDPERVRMRMTKONLDYCFILMYAOSKG----- 260
Db 1174 -----EIVRPDPKASVYANLRLLELVGQRKRGABEDQKASQSELEALRNRPQVEYKEV 1229
QY 261 ----IYV-----QLEDIVAKENYLSYTKNPFALQPSDDMMILFESQLGFIGKM 306
Db 1230 TKEVIKYKTTDDETEQELORLEELIMDKTRLIERC-DLEIYQKQEIQALKQTK----- 1281
QY 307 FKSLDSLIVFIILFVRDKRIIDLHLHLLMVKVCNPEKAKHCDRQKANKRIKFSKSLF 366

```

```

Db 1282 PQVOTREVVQELIQFOED-----PQKKEVESLRQISEBOK 1313
Qy 367 QHVGTHSSLACKTOKLKDQFPGKALAKREH-----NP--AEVS-----404
Db 1319 KQVLDLEGRASQOEKIRKREBELAQOKRERVROBQVQVEBPLRLVFTAFNIDSAL 1378
Qy 405 -----TSKTYOHFTLE-----KAVLRBDFPAFTPAADPTIRFRFPQRLRPFPR 452
Db 1379 QVIDKLHVELRLRHRRAELEROLEBERER-----QARRAELEVORLQOR 1425
Qy 453 SGNIEHEP---DKLFNTSVSEVLPFPDNPQSDKEALQEGRTALTREYPSPDGYLGISFYK 508
Db 1426 LAALQEBEAKTGKGVNTQTKVVLQDDQQRHHLHLAQLQEBEHRHQ-----1473
Qy 509 GVAEGVDPAFGPLPALRLSITQDSPVWVILSE-IFLKKAD 548
Db 1474 -LLEGLEPELRKLALAE---KAEIKERKVPSESVQVEKGD 1510

RESULT 5
POSC_MOUSE STANDARD; PRT; 274 AA.
ID POSC_MOUSE
AC Q922Y8;
DT 16-OCT-2001 (Rel. 40, Created)
DT 16-OCT-2001 (Rel. 40, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Proline synthetase co-transcribed bacterial homolog protein.
GN PROSC.
OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
CX NCBI_TaxID=10090;
RN [1]
RP SEQUENCE FROM N.A.
RA MEDLINE=99426086; PubMed=10496079;
RA Ikegawa S., Isomura M., Koshizuka Y., Nakamura Y.;
RT "Cloning and characterization of human and mouse PROSC (proline
RL synthetase co-transcribed) genes."
RT J. Hum. Genet. 44:337-342(1999).
CC -1 SIMILARITY: Belongs to the UPF0001 family.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
CC EMBL; AB018567; BAA36843.1; -.
DR HSSP; P38197; 1B54.
DR MGD; MGI:1891207; Prosc.
DR InterPro; IPR001608; UPF0001.
DR Pfam; PF01168; Ala_race_mase_N_1.
DR TIGRFAMs; TIGR00044; TTGR00044; 1.
DR PROSITE; PS01211; UPF0001; FALSE_NEG.
SO SEQUENCE 274 AA; 30048 MW; 358C67207DB11113 CRC64;

Query March 3.8%; Score 108; DB 1; Length 274;
Best Local Similarity 21.6%; Pred. No. 0.6; Mismatches 80; Indels 90; Gaps 12;
Matches 59; Conservative 44;

Qy 41 REFLALDRLLAAEQESLKRKSELNVLDEIKRAVSEKALRDGGRNTRWGR-----92
Db 33 RDLPAIQRLVA-----VSKTKPADVITYAV-----GHGRTGENTVQELLE 75
Qy 93 -----LTDPRLLKPMNGSHRHVLAHLPYFPHLPHLLAKSSILQPAVRVGQGTGVSIV 145
Db 76 KASNPKLISSCPEIK-----WHFIGHV-----QKQNNKL 105
Qy 146 MGIP--SVREHVSY-LTDTLHSLISELSPOEKDSYIVVLAFTDSOY-----TSAYT 196
Db 106 MANDVNSLMELETVDVSKLADKVNSSWQKGPTEPLKAVWQVINTSDESKHGLIPSETTAVV 165

```

QY 197 ENIKALPTEIHSGLLEV-----ISPSHFYDPFSRLR-----ESFGDKERVMKT 243
 DB 166 EHIKASCSLEFVGLMTIGTSFGHDLSSQGN--PDFORLLTLTRELCERKGIQVFEQVELSM 223
 QY 244 KQNLVYCFLMVYVQSGIYVVOLEDDIVAKPNY 276
 DB 224 GMSMDF---QHAIEVGSITVNRIGSTIFGERDY 252

RESULT 6
 CYAA_PASMTU
 ID CYAA_PASMTU STANDARD; PRT; 838 AA.
 AC 005766;
 DT 01-JUN-1994 (Rel. 29, Created)
 DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DT 28-FEB-2003 (Rel. 41, Last annotation update)
 DE Adenylate cyclase (EC 4.6.1.1) (ATP pyrophosphate-lyase) (Adenyl
 cyclase).
 GN CYA OR PM1811.
 OS Pasteurella multocida.
 OC Bacteria; Proteobacteria; Gammaproteobacteria; Pasteurellales;
 OC Pasteurellaceae; Pasteurella.
 OX NCBI_TaxID=747;
 RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=CNPI / NTCC 10322;
 RX MEDLINE=92011391; PubMed=1917858;
 RA Mock M., Crasner M., Duflot E., Dumay V., Danchin A.;
 RT "Structural and functional relationships between Pasteurella
 multocida and enterobacterial adenylate cyclases.";
 RL J. Bacteriol. 173:6265-6269(1991).
 RN [2]
 RP SEQUENCE FROM N.A.
 RC STRAIN=Pm70;
 RX MEDLINE=21145866; PubMed=11248100;
 RA May B.J., Zhang Q., Li L.L., Paustian M.L., Whitlam T.S., Kapur V.;
 RT "Complete genomic sequence of Pasteurella multocida Pm70.";
 RL Proc. Natl. Acad. Sci. U.S.A. 98:3460-3465(2001).
 RN [3]
 RP REVIEW.
 RX MEDLINE=93119764; PubMed=8418825;
 RA Danchin A.;
 RT "Phylogeny of adenylate cyclases.";
 RL Adv. Second Messenger Phosphoprotein Res. 27:109-162(1993).
 CC -1- CATALYTIC ACTIVITY: ATP = 3',5'-cyclic AMP + diphosphate.
 CC -1- SUBCELLULAR LOCATION: Cytoplasmic.
 CC -1- SIMILARITY: Belongs to the adenylate cyclase class-1 family.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).
 CC -----
 CC EMBL; M68901; AAA25532.1; -.
 DR EMBL; AB06218; AAK03895.1; -.
 DR PIR; A38172; A38172.
 DR InterPro; IPR000274; Adenylate cyclase_1.
 DR Pfam; PF01295; Adenylate cyclase_1.
 DR PROSITE; PS01092; ADENYLATE CYCLASE_1; 1.
 DR PROSITE; PS01093; ADENYLATE CYCLASE_1; 2; 1.
 DR Lysase; CAMP biosynthesis; Complete proteome.
 KW DOMAIN 1 541 CATALYTIC (POTENTIAL).
 FT DOMAIN 547 838 REGULATORY (POTENTIAL).
 FT CONFLICT 469 469 D -> A (IN REF. 1).
 FT CONFLICT 659 660 TA -> PH (IN REF. 1).
 SQ SEQUENCE 838 AA; 96798 MW; 08D64CA7B0A30E62 CRC64;

Query Match 3.8%; Score 108; DB 1; Length 838;
 Best Local Similarity 21.4%; Pred. No. 2.8;

Matches 95; Conservative 59; Mismatches 161; Indels 128; Gaps 19;
 QY 47 RDRLHAAEQESLAKSK-----ELNLVIDEIKRAVSEQALRDGNGRTWRLT 94
 DB 125 RDDLSTKEKALQKRTLLKMAKQFNIEINFYIMDQKRFRCFRYA----- 170
 QY 95 EDRPLKPNNGSHRVVHLPTVFNHLPHTLLAK-----ESSLOPAVRVQ- 137
 DB 171 -EPLTAENCGSAQYMLLDDEFYRSAIRLAGKPLMLHLLIEQENYESVEVRLVPTQIC 229
 QY 138 -----GRGVSVVMGIPSVRREVSALTDTLSLISELSPOKEDSVIVLLAET-DS 189
 DB 230 LDDWVDFEGGLG-----QLSANEYFGASIMQLYGIDAPYK--SVIKILLETYS 277
 QY 190 QYTSAVTENIKALPTEIHSGLLEVISPPHFYDPFSRLRESFDPKERVAKTKON-- 246
 DB 278 EYPN--TYLIARQKEELITGKL--NPSHHFDYLAMLQPA-----TRYLTKHMLK 325
 QY 247 -LDVCFLMVYVQSGIYVVOLEDDIVAKPNYLSMTKPNALQPSQEDW-----MILEPSQ- 299
 DB 326 RLGFV-----RISVYIKATEGMCWODPNATNWRLOQLKLQEDWSDALIEBLNQR 378
 QY 300 LGFTGKMFSLDLIVEFIIMFYRDKPIDWLDDHILVVKVCNPEKDAKCDROKAMLR 359
 DB 379 ANWKIKQYKKAHNDLI-KETMLSTRN-----LVAFARKKVNSSIMPDISTVLT 426
 QY 360 RPKDSLQHVGTSSLSLACKIQKDKQFGKQALRKEHVPAPAEVSTSLKTYQHFTLEAY 419
 DB 427 RKLVTAFQ-----ELPKITLL-----NPOISINTLSKMLLFEVVKSK 465
 QY 420 LRDEPFMAF--TPAAGPIRRRF 440
 DB 466 TFKDGVVYVNOTFSVAGFVQKRY 488

RESULT 7
 T3RE_BPPI
 ID T3RE_BPPI STANDARD; PRT; 970 AA.
 AC P08764;
 DT 01-NOV-1988 (Rel. 09, Created)
 DT 01-NOV-1988 (Rel. 09, Last sequence update)
 DT 10-OCT-2003 (Rel. 42, Last annotation update)
 DE Type III restriction-modification system EcoPI enzyme res
 DE (EC 3.1.21.5).
 GN RES.
 OS Bacteriophage P1.
 OC Viruses; dsDNA viruses, no RNA stage; Caudovirales; Myoviridae;
 OC P1-like viruses.
 OX NCBI_TaxID=10678;
 RN [1]
 RP SEQUENCE FROM N.A.
 RX MEDLINE=88245189; PubMed=2837577;
 RA Huebner M., Suri B., Rao D.N., Hornby D.P., Eberle H., Pripi T.,
 RA Kiesel S., Bickle T.A.;
 RT "Type III DNA restriction and modification systems EcoPI and EcoPI5.
 RT Nucleotide sequence of the EcoPI operon, the EcoPI5 mod gene and some
 RT EcoPI mod mutants.";
 RL J. Mol. Biol. 200:23-29(1988).
 CC -1- FUNCTION: THIS PROTEIN CUTS THE DNA SOME 25 BASE-PAIRS TO THE
 CC 3'-END OF THE RECOGNITION SITE. IT IS ONLY REQUIRED FOR
 CC RESTRICTION BUT NEEDS THE PRESENCE OF THE MODIFICATION ENZYME.
 CC -1- CATALYTIC ACTIVITY: Endonucleolytic cleavage of DNA to give
 CC specific double-stranded fragments with terminal 5'-phosphates.
 CC -1- SUBUNIT: CONTAINS TWO DIFFERENT SUBUNITS: RES AND MOD.
 CC -1- SIMILARITY: WITH OTHER TYPE III RES PROTEINS.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>

or send an email to license@sib.ch.

CC EMBL; X06287; CAA29615.1; -
 DR PIR; S01352; S01352.
 DR REBASE; 968; ECOLI.
 DR InterPro; IPR006935; ResIII.
 DR Pfam; PF04851; ResIII; 1.
 DR Restriction System; Hydrolyase; Nuclease; Endonuclease; Helicase.
 SQ SEQUENCE 970 AA; 111458 MW; B599110154D723AA CRC64;

Query Match 3.7%; Score 107.5; DB 1; Length 970;

Best Local Similarity 19.1%; Pred. No. 3.8; Matches 105; Conservative 76; Mismatches 161; Indels 207; Gaps 28;

```

QY 54 EDSIKRSKELNVLDEIKRAVSEKQALRDGDNRTWGRLTEDPRLKPNNGSHRHVILP 113
DB 477 EINEIHLHKEILLSDNRRRFRFSKWTIREG-----WDN-----P 511
QY 114 TVFHHLPMLAKESLQPAVRVGGRTGVSVVMGIPSVREVHLSYL----- 159
DB 512 NVF-QICKLRSSGTSSTSKIQEYGRG-----RLPVNEXMCHVKDQNFILTKYV 558
QY 160 ----TDTLSLISELSPOKEDSVYVLAETDQYTSAVTENIKALPTEIHSGL- 212
DB 559 DFEKDFVDSLVKVENESSFKERV-----PSKFTQELKEQIRAOYP-BLSSPALMNE 609
QY 213 ----EVISPPHPYPD--FSRLRESF-----GDPKERVWRRTKONLBYC 250
DB 610 LFNDEIINDNDFKQSDAYSRLKSKYPAAPFPGIKAKATDKRTKRVGKFSBLK 669
QY 251 FLMMYAGSKGIYVQLEDIVAKPNYISTMKNFALQDSEDMILFESQLGF--IGMF 307
DB 670 ELMELINQKAV-----IEYKINSENEFLSIFKSFMLEETE-----RFTKSGVHTRIDKIY 719
QY 308 KSLDLSLIVERI-----LMFYRKPIDMLDHI--LMVYVCNPEADAG--CD 351
DB 720 IHNDAWMSKSIIVSDDDDFAKINTMSYRE--FLDNLISQITFYK--HDTLHKVPCD 769
QY 352 -ROKANL-----RIRKPSLFQVGHSS-----LAGKIQLK----- 383
DB 770 IKDITNIEYINIQIRIKISGFSKYLANNFKNLSGLNLSGSIHFTKTNADGKLD 829
QY 384 --DKDFGKQALRKHVNPAVSTSLTKYQHTLEKAYLR----- 422
DB 830 EVLSSDLG--VLQNSKAPLDIYLFEBVFYDSELRNINIDRIQSVVFSKIPKNSIK 866
QY 423 -----DFFWAFTPAAGDFIRRF-----PQPLLERFFFSGNIHPEDETLF 464
DB 887 IPVAGGYTSPDFAVVVTAGSDYINFLIETKNVDSKDSLRL- -EKKKIEHAQ-ALF 941
QY 465 N---TSVEV 470
DB 942 NQISQSVAV 950

```

RESULT 8
 KPCL LYTPI STANDARD; PRT; 658 AA.

AC Q25378;
 DT 15-JUL-1999 (Rel. 38, Created)
 DT 15-JUL-1999 (Rel. 38, Last sequence update)
 DT 15-JUL-1999 (Rel. 38, Last annotation update)
 DE Protein kinase C (EC 2.7.1.-).
 GN PKC1.
 OS Lytechinus pictus (Painted sea urchin).
 CC Eukaryota; Metazoa; Echinodermata; Eleutherozoa; Echinozoa;
 CC Echinoidae; Euechinoidae; Echinacea; Temnopleuroidea; Toxopneustidae;
 CC Lytechinidae.
 NCBI_TaxID=7653;
 RX [1]
 RN SEQUENCE FROM N.A.
 RP TISSUE=Ovary;
 RA Rakow T.L., Shen S.S.;

RT "Molecular cloning and characterization of protein kinase C from the
 RT sea urchin *Lytechinus pictus*." EMBL/GenBank/DBJ databases.
 RL Submitted (OCT-1993) to the EMBL/GenBank/DBJ databases.
 CC -1- FUNCTION: This is a calcium-activated, phospholipid-dependent,
 CC serine- and threonine-specific enzyme (By similarity).
 CC -1- FUNCTION: PKC is activated by diacylglycerol which in turn
 CC phosphorylates a range of cellular proteins. PKC also serves as
 CC the receptor for phorbol esters, a class of tumor promoters (By
 CC similarity).
 CC -1- SIMILARITY: Contains 2 zinc-dependent phorbol-ester and DAG
 CC binding domains.
 CC -1- SIMILARITY: Contains 1 C2 domain.
 CC -1- SIMILARITY: Belongs to the Ser/Thr family of protein kinases. PKC
 CC subfamily.

 This SWISS-PROT entry is copyright. It is produced through a collaboration
 between the Swiss Institute of Bioinformatics and the EMBL outstation -
 the European Bioinformatics Institute. There are no restrictions on its
 use by non-profit institutions as long as its content is in no way
 modified and this statement is not removed. Usage by and for commercial
 entities requires a license agreement (See <http://www.sib.ch/announce/>
 or send an email to license@sib.ch).

```

CC EMBL; U02967; AAA03447.1; -.
DR HSSP; P05697; ITBN.
DR InterPro; IPR000008; C2.
DR InterPro; IPR008973; C2 CALB.
DR InterPro; IPR002219; DAG_PE-BIND.
DR InterPro; IPR000961; PKINASE-C.
DR InterPro; IPR000719; Prot_KINASE.
DR InterPro; IPR008271; Ser_Thr_Pkin_AS.
DR InterPro; IPR002290; Ser_Thr_Pkinase.
DR InterPro; IPR001245; Tyr_Pkinase.
DR pfam; PF00168; C2; 1.
DR pfam; PF00130; DAG_PE-BIND; 2.
DR pfam; PF00069; pkinase; 1.
DR pfam; PF00433; pkinase_C; 1.
DR PRINTS; PR00360; C2DOMAIN.
DR PRINTS; PR00008; DAGPEDOMAIN.
DR PRINTS; PR00109; TYRKINASE.
DR PRODOM; PD000001; Prot_Kinase; 1.
DR SMART; SM00109; C1; 2.
DR SMART; SM00239; C2; 1.
DR SMART; SM00133; S_TK_X; 1.
DR SMART; SM00220; S_TKC; 1.
DR PROSITE; PS00499; C2_DOMAIN_1; 1.
DR PROSITE; PS50004; C2_DOMAIN_2; 1.
DR PROSITE; PS00479; DAG_PE_BIND_DOM_1; 2.
DR PROSITE; PS50081; DAG_PE_BIND_DOM_2; 2.
DR PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
KW ATP-binding; Transferase; Serine/threonine-protein kinase;
KW Phorbol-ester binding; Zinc; Repeat.
FT DOMAIN 28 77 PHORBOL-ESTER AND DAG BINDING 1.
FT DOMAIN 93 142 PHORBOL-ESTER AND DAG BINDING 2.
FT DOMAIN 164 251 C2 DOMAIN.
FT DOMAIN 325 583 PROTEIN KINASE.
FT NP_BIND 331 339 ATP (BY SIMILARITY).
FT BINDING 354 354 ATP (BY SIMILARITY).
FT ACT_SITE 449 449 BY SIMILARITY.
SQ SEQUENCE 658 AA; 74871 MW; 74B5A274A9C635A2 CRC64;

```

Query Match 3.7%; Score 107; DB 1; Length 658;

Best Local Similarity 19.6%; Pred. No. 2.4; Matches 108; Conservative 76; Mismatches 138; Indels 226; Gaps 31;

```

QY 63 ELNVLDEIKRAVSEKQALRDGDNRTWGRLTEDPRLKPNNGSHRHVILPVTFFHILPIL 122
DB 188 KKLKIPDQ-KRRTKKRTIKGSLNPTWGB-SFDNLIEDDRRR-----L 231
QY 123 LAKESLQPAVR--VGQRTGVSVVM-GIPSVREVHLSYLTDTLSLISELSPOKED 177

```

```

Db 232 LVEVDMDRATNDMDGALSGISLMDKAV-----DMWYLLG-----QEEGE 275
Qy 178 SVTVVLAETDSQYTSAAVTENIKAL-FPTEIH-----SGLEVISPSHPYDPSR 227
Db 276 YYNVAIALETSS--IDELTSNIKKLPMPFQEHVKPQNSNSG-MGVVRAS-----DFNF 327
Qy 228 L-----RESFGDKKVRKRTKNDLYCFLMTAOSKG--IYYVL-----EDD1-- 270
Db 328 LSVLKGSGFGK-----VMLAEKKGDELVAIKLKVDVLIQDDVBC 369
Qy 271 -----VAKPNVLSMTKNFALQOPEBDMWIEF-----SOLGPFGK-----MF 307
Db 370 TMTKRAVLGLPEKPAFLTLNHS-CQYMDRLFPWMEFVNGGLMQIQKVGKFRPHAVF 428
Qy 308 KSLDSLIVEFLI--MFYRDKPIDMLDLHWVCNPEKDAKCDROKANLRIRPKRS 364
Db 429 YAAEIAVGVFLYHSGQVIRDLKLD-----NVLVDAB----- 460
Qy 365 LFGVGHSHSLAGKIQKLDKDPFGKQALRKENV-----PRAVSTSLKTYQHFT 414
Db 461 -----GHIKIADFG--MCKEHNEDGDTTRTFPGCTPDYIAPEIYAYQ--- 499
Qy 415 LEKAVLRDEDFMAF-----TPAAGDFIRFRFPQPLERFFRSGNIIEHPEDKL 463
Db 500 ---PYGKAVDMWAFVGLYKMLAGQPPRYGE-----DEDEL 532
Qy 464 FNTSVLEVLPFDNPQSKDALOEGRTATLRP-----RSPDGYLQI--GSFYKV- 511
Db 533 FQSIWEHVSPYKSMRSBSVTWCCKGFLTGHPGKRLGSGPTGQDIREHQFRRIDMEKLA 592
Qy 512 EGEVDAFCP 521
Db 593 NREIQPPFVP 602

RESULT 9
SYV_AQUAE
ID SYV_AQUAE STANDARD; PRT; 1165 AA.
AC 067411;
DT 30-MAY-2000 (Rel. 39, Created)
DT 30-MAY-2000 (Rel. 39, Last sequence update)
DT 16-OCT-2001 (Rel. 40, Last annotation update)
DE Valyl-tRNA synthetase (EC 6.1.1.9) (Valine--tRNA ligase) (ValRS).
GN VALS OR AQ_1413.
OS Aquifex aeolicus.
OC Bacteria; Aquificae; Aquificales; Aquificaceae; Aquifex.
OX NCBI_TaxID=63363;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=VF5;
RA MEDLINE=98196666; PubMed=9537320;
RA Deckert G., Warren P.V., Gaasterland T., Young W.G., Lenox A.L.,
RA Graham D.E., Overbeek R., Sneed M.A., Keller M., Anjey M., Huber R.,
RA Feldman R.A., Short J.M., Olson G.J., Swanson R.V.;
RA "The complete genome of the hyperthermophilic bacterium Aquifex
aeolicus."
RL Nature 392:353-358 (1998).
CC -1- CATALYTIC ACTIVITY: ATP + L-valine + tRNA(Val) = AMP + diphosphate
CC + L-valyl-tRNA(Val).
CC -1- SUBUNIT: Monomer (By similarity).
CC -1- SUBCELLULAR LOCATION: Cytoplasmic.
CC -1- SIMILARITY: Belongs to class-I aminoacyl-tRNA synthetase family.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sb.ch/announce/
CC or send an email to license@isb-sb.ch).
CC -----
CC EMBL: AE000739; AAC07375.1; -.
CC PIR: A70423; A70423.

```

```

DR HSBP; P96142; 16XK.
DR InterPro; IPR002300; tRNA-synt-1a.
DR InterPro; IPR001412; tRNA-synt-1.
DR InterPro; IPR002303; tRNA-synt val.
DR InterPro; IPR009008; ValRS_1Iers_edit.
DR Pfam; PF00133; tRNA-synt 1; 1.
DR PRINTS; PR00986; TRNASYNTHAL.
DR TIGRFAMs; TIGR00422; VALS; 1.
DR PROSITE; PS00178; AA_tRNA_LIGASE_I; 1.
KW Aminoacyl-tRNA synthetase; Protein biosynthesis; Ligase; ATP-binding;
KW Complete proteome.
FT SITE 43 53 "HIGH" REGION.
FT SITE 800 804 "KMSK" REGION.
FT BINDING 803 803 ATP (BY SIMILARITY).
SQ SEQUENCE 1165 AA; 137150 MW; E612D4F28BEFA237 CRC64;

Query Match 3.7%; Score 105.5; DB 1; Length 1165;
Best local similarity 19.1%; Pred. No. 7;
Matches 66; Conservative 58; Mismatches 103; Indels 119; Gaps 17;

Qy 174 EKEDSVTVVLAETDSQYTSAAV-----TENIKALFTE-----HSGLELV 214
Db 719 EGERDVL-----DTWSSSALMPFGVGFGEWPESTEDIKNLVPTDLVTGFDIIFFWARM 771
Qy 215 ISPSPHFYPPD-----SRLESFG-----DPKERVWRKTKNDLYCFLIMY 255
Db 772 IMGTGTFMKDIPFYDVYVHALVRDKYGRKMSKTGNVIDPDIERYGADLRFTLALT 831
Qy 256 AOSKGI-----YVYQLE--DDIVAKPNVLSMTKNFALQOPEBDM 292
Db 832 VQGRDILAEKEFGYGFHFNKINMARVYLMNPEDFIRIPYMAPLK-----PEDKW 885
Qy 293 MLEPSQLG-FIGKMFKSLDSLIVEFLIMFYRDKPIDMLDHI--LWVKV--CNPEKD 346
Db 886 IITKLNTEAEENVNKALENVQYQAHAHYEFWSDYCDWYIEFTKERYKKCAPEDNEBEK 945
Qy 347 AK-----HCDROKANLRI--RFKPSLFOHV-----GTHSSLA----- 376
Db 946 AKVENERTTALTYLHYLEKA-LRIHPFMYIYTEELHKLPMNAEGESISLAIEFPQKNED 1004
Qy 377 -----GKIQKLDKDPFGKQALRKE-HVNPRAVSTSLKTYQHFT 414
Db 1005 EIVEDKQKVRLEKEIISATRAIRSDQIKSEKIKXSFKTESFES 1050

RESULT 10
TYCC_BREPA
ID TYCC_BREPA STANDARD; PRT; 6486 AA.
AC 030409;
DT 15-JUL-1999 (Rel. 38, Created)
DT 15-JUL-1999 (Rel. 38, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Tyrocidine synthetase III (includes: ATP-dependent asparagine
DE adenylylase (AsnA) (Asparagine activase); ATP-dependent glutamine
DE adenylylase (GlnA) (Glutamine activase); ATP-dependent tyrosine
DE adenylylase (TyrA) (Tyrosine activase); ATP-dependent valine adenylylase
DE (ValA) (Valine activase); ATP-dependent ornithine adenylylase (OrnA)
DE (Ornithine activase); ATP-dependent leucine adenylylase (LeuA) (Leucine
DE activase)).
GN TYCC.
OS Brevibacillus parabrevis.
OC Bacteria; Firmicutes; Bacillales; Paenibacillaceae; Brevibacillus.
OX NCBI_TaxID=54914;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=ATCC 8185 / IAM 1031 / IFO 3331 / NCDO 717 / NCIB 8598;
RX MEDLINE=98012987; PubMed=9352938;
RA Mootz H.D., Marahiel M.A.;
RA "The tyrocidine biosynthesis operon of Bacillus brevis: complete
RT nucleotide sequence and biochemical characterization of functional
RT internal adenylation domains."
RL J. Bacteriol. 179:6843-6850 (1997).
CC -1- FUNCTION: INCORPORATES SIX AMINO ACIDS (FOR TYROCIDINE A, ASN,

```



```

CC      GLN, TYR, VAL, ORN, AND LEU) IN THEIR L-CONFIGURATION INTO THE
CC      PEPTIDE PRODUCT.
CC      -1- COPACITOR: Contains 6 covalently bound phosphopantetheines (By
CC      similarity).
CC      -1- PATHWAY: Cyclic peptide antibiotic tyrocidine biosynthesis.
CC      -1- SUBUNIT: LARGE MULTENZYMIC COMPLEX OF TYCA, TYCB AND TYCC.
CC      -1- DOMAIN: CONSISTS OF SIX MODULES, AND HARBORS A PUTATIVE
CC      THIOESTERASE DOMAIN AT ITS C-TERMINAL END. EACH MODULE
CC      INCORPORATES ONE AMINO ACID INTO THE PEPTIDE PRODUCT AND CAN BE
CC      FURTHER SUBDIVIDED INTO DOMAINS RESPONSIBLE FOR SUBSTRATE
CC      ADENYLATION, THIOYLATION, CONDENSATION (NOT FOR THE INITIATION
CC      MODULE), AND EPIMERIZATION (OPTIONAL), AND N METHYLATION
CC      (OPTIONAL).
CC      -1- MISCELLANEOUS: TYROCIDINE IS A MIXTURE OF FOUR CYCLIC
CC      DECAPEPTIDES, TYROCIDINE A (D-PHE-PRO-PHE-D-PHE-ASN-GLN-TYR-VAL-
CC      ORN-LEU), B, C, AND D, IN WHICH PHE, AT POSITIONS 3, 4, AND TYR
CC      RESIDUES ARE GRADUALLY REPLACED BY TRP, DEPENDING ON THE RELATIVE
CC      CONCENTRATIONS OF THESE AMINO ACIDS IN THE GROWTH MEDIUM.
CC      -1- SIMILARITY: Belongs to the AMP-dependent AMP-binding enzyme
CC      family.
CC      -1- SIMILARITY: Contains 6 acyl carrier domains.
CC      -----
CC      This SWISS-PROT entry is copyright. It is produced through a collaboration
CC      between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC      the European Bioinformatics Institute. There are no restrictions on its
CC      use by non-profit institutions as long as its content is in no way
CC      modified and this statement is not removed. Usage by and for commercial
CC      entities requires a license agreement (See http://www.isb.ch/announce/
CC      or send an email to license@isb-sib.ch).
CC      -----
CC      EMBL; AF004835; AAC45930.1; -.
CC      PDB; 1DNY; 17-MAY-00.
CC      DR InterPro; IPR000873; AMP-bind.
CC      DR InterPro; IPR001242; Condensatn.
CC      DR InterPro; IPR006163; Pp bind.
CC      DR InterPro; IPR006162; Pantine S.
CC      DR InterPro; IPR000379; Ser_ester.
CC      DR InterPro; IPR001031; Thioesterase.
CC      DR Pfam; PF00501; AMP-binding; 6.
CC      DR Pfam; PF00668; Condensation; 6.
CC      DR Pfam; PF00550; Pp-binding; 6.
CC      DR Pfam; PF00975; Thioesterase; 1.
CC      DR PRINTS; PR00154; AMPBINDING.
CC      DR PROSITE; PS00012; PHOSPHOPANTETHEINE; 6.
CC      DR PROSITE; PS00455; AMP BINDING; 6.
CC      DR PROSITE; PS00075; ACP DOMAIN; 6.
CC      KW Ligase; Antibiotic biosynthesis; Phosphopantetheine;
CC      KW Multifunctional enzyme; Repeat; 3D-structure.
CC      FT REPEAT 466 1038 DOMAIN 1 (ASPARAGINE-ACTIVATING).
CC      FT REPEAT 1521 2070 DOMAIN 2 (GLUTAMINE-ACTIVATING).
CC      FT REPEAT 2536 3113 DOMAIN 3 (TYROSINE-ACTIVATING).
CC      FT REPEAT 3590 4149 DOMAIN 4 (VALINE-ACTIVATING).
CC      FT REPEAT 4606 5203 DOMAIN 5 (ORNITHINE-ACTIVATING).
CC      FT REPEAT 5658 6245 DOMAIN 6 (LEUCINE-ACTIVATING).
CC      FT DOMAIN 970 1037 ACYL CARRIER (ACP) 1.
CC      FT DOMAIN 2007 2074 ACYL CARRIER (ACP) 2.
CC      FT DOMAIN 3045 3112 ACYL CARRIER (ACP) 3.
CC      FT DOMAIN 4080 4147 ACYL CARRIER (ACP) 4.
CC      FT DOMAIN 5124 5191 ACYL CARRIER (ACP) 5.
CC      FT DOMAIN 6167 6234 ACYL CARRIER (ACP) 6.
CC      FT BINDING 1000 1000 PHOSPHOPANTETHEINE (BY SIMILARITY).
CC      FT BINDING 2037 2037 PHOSPHOPANTETHEINE (BY SIMILARITY).
CC      FT BINDING 3075 3075 PHOSPHOPANTETHEINE (BY SIMILARITY).
CC      FT BINDING 4110 4110 PHOSPHOPANTETHEINE (BY SIMILARITY).
CC      FT BINDING 5154 5154 PHOSPHOPANTETHEINE (BY SIMILARITY).
CC      FT BINDING 6197 6197 PHOSPHOPANTETHEINE (BY SIMILARITY).
CC      FT SEQUENCE 6486 AA; 724011 MW; 4934900AF0DF786 CRC64;
CC      Query Match 3.7%; Score 105.5; DB 1; Length 6486;
CC      Best Local Similarity 21.5%; Pred. No. 77;
CC      Matches 113; Conservative 73; Mismatches 216; Indels 123; Gaps 27;

```

Dh	4309	LYAGKQJSDLRIRQYKDPAWMQTKLAQSDRQCKQEDFWTRFFAGEIPLILNI.PHDYRRPSVQ	4368
Qy	101	PMNGSHRHVTLHPVFEHHLPHLLAKESLQPAVAVGGRGVSVMGI.PSVREYHSYLT	160
Dh	4369	SFDD-----TYALGT-GHHLLQELRKLAA-----ETGTLTFM-----VLT	4403
Qy	161	DLTSLILSELSPQKEDSVLVLLAEHQDSQYTSAVTENIKALPTEILHSGLEVI.SPSPH	220
Dh	4404	AAHVYLLSKTAGQBE-----IVGPTPIAGSHADVERIVGMFVNTL--ALKNTAAGSL	4455
Qy	221	FYPDFSLRBSFGPKRVERWRTKQNDYCFELMAYAGSKGIYYVVLBDDIVAKENYLS.TM	280
Dh	4456	F-----RAFLBYVKQNA-LHAEHQDYPEHL-----VEKQVARDLSRNLF--DTM	4500
Qy	281	KNFALQGPSE---DMWILEFSQLGFGKMFSLD-----SLIVER--ILMFYRDKPID	329
Dh	4501	FSLLGAESAEGEVAIDLKVPSPYAVNGHIAKEPLSLIDAMEKODGLLVQPSYCTKLPAKEV.D	4560
Qy	330	WLDH---ILMVKCNPEKAKHCDROKANILRFRKSLPLQHVQTHSSLAGKLOKLDKD	386
Dh	4561	RLAAHYVOLLQTTTADP-----DIELARISVLSKAEI-EHM-LHSFPLAKTAYPTD.KT	4611
Qy	387	FGKQALRKHY-NPPAIVS---TSLKTYQHFT-----LEKAYVREDF-----	424
Dh	4612	F--OKLFEBOYEKTPNEIAYLFGNEQLTYQELNKKANQALVLRKRGVKEPSTYGLVDR	4665
Qy	425	-----FMAFTPAAGDFIRRFQOPRLERFFFRSGNIHEPDKLFNT-----SVEVL.P	472
Dh	4670	SLVYVIGMLAVLKAGGFVPIPDYPLERQAFM-----LEDSEAKLLITLOKNNQVAF.P	4724
Qy	473	FDNQSQSKREALQEGRTATLRKPRPD--GYLQIGSFYKVAEGEV	515
Dh	4725	YEFYLDPTETVDOETGNLEHVAQPENVAAYIITYSGTTGKRGVV	4769
RESULT 11			
ID	COAC_CHICK	STANDARD;	PRT; 2324 AA.
AC	P11029;		
DT	01-JUL-1989	(Rel. 11, Created)	
DT	01-JUL-1989	(Rel. 11, Last sequence update)	
DT	28-FEB-2003	(Rel. 41, Last annotation update)	
DE	Acetyl-CoA carboxylase (EC 6.4.1.2) (ACC) [includes: Biotin		
DE	carboxylase (EC 6.3.4.14)].		
GN	ACAC.		
OS	Gallus gallus (Chicken).		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
OC	Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;		
OC	Gallus.		
OX	NCBI_TaxID=9031;		
RN	[1]		
RP	SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.		
RC	TISSUE=Liver;		
RX	MEDLINE=86139305; PubMed=2893793;		
RA	Takai T., Yokoyama C., Wada K., Tanabe T.;		
RT	"Primary structure of chicken liver acetyl-CoA carboxylase deduced		
RT	from cDNA sequence."		
RL	J. Biol. Chem. 263:2651-2657(1988).		
RN	[2]		
RP	SEQUENCE OF 493-820 FROM N.A.		
RC	TISSUE=Liver;		
RX	MEDLINE=87106011; PubMed=2879745;		
RA	Takai T., Wada K., Tanabe T.;		
RT	"Primary structure of the biotin-binding site of chicken liver		
RT	acetyl-CoA carboxylase."		
RL	FEBS Lett. 212:98-102(1987).		
CC	-1- FUNCTION: Catalyzes the rate-limiting reaction in the biosynthesis		
CC	of long-chain fatty acids. This protein carries three functions:		
CC	biotin carboxyl carrier protein, biotin carboxylase, and		
CC	carboxyltransferase.		
CC	-1- CATALYTIC ACTIVITY: ATP + acetyl-CoA + HCO(3) (-) = ADP + phosphate		
CC	+ malonyl-CoA.		

QY	331	LDHIIIMWKC--NPEADAKHCDBQXANLRLRFRRPSPFJHGVGTHSSLAGKIQKLDKDPG	388
Db	501	PRGHVIARIRISENPDECFRRSSGTGVELNRSKNXWGVSV--AAAGGLHFPADSGF	558
QY	389	K----QALRKEHVPNPPEAVSTSLKTYOHFTLEKAYLEBDFPFAFTPAAGDIFRRFPQPL	444
Db	559	HCFMGENREERAIISNMVVALTELISIRGDFRTVEYLK-----LLETSEFOQN	606
QY	445	R-----LIERFRRSGNLEHPE-----DKLENTSV-----EVLFPENP	476
Db	607	RIDRGWLDRLIAEKVQALRPDTMLGVCGALHVADVSPRNSVSNFLSLERGOVLPAAHTL	666
QY	477	QS--DKKALQCGRTATRYRPR--SPDGYLQI-----GSPYKGV	510
Db	667	LNTYDVELIYGRKCYKLVKTRQGSNSYSVYVINNSSCVEDVHRLSDGGLLSYDSSYTTY	726
QY	511	AEGVD 516	
Db	727	MKEVD 732	
RESULT 12			
AKA9	HUMAN	STANDARD;	PRT; 3911 AA.
ID	AKA9_HUMAN		
AC	Q99996; Q14869; Q43355; Q94895; Q9UQH3; Q9UQ04; Q9Y6B8; Q9Y6Y2;		
DT	16-OCT-2001	(Rel. 40, Created)	
DT	16-OCT-2001	(Rel. 40, Last sequence update)	
DT	15-MAR-2004	(Rel. 43, Last annotation update)	
DE	A-kinase anchor protein 9 (Protein Kinase A anchoring protein 9)		
DE	(PKRA) (A-kinase anchor protein 450 kDa) (AKAP 450) (A-kinase anchor		
DE	protein 350 kDa) (AKAP 350) (hGAKAP 350) (AKAP 120 like protein)		
DE	(Hyperion protein) (Yociao protein) (Centrosome- and Golgi-localized		
DE	PKA-associated protein) (CG-NAP).		
GN	AKAP9 OR AKAP450 OR AKAP350 OR KIAA0803.		
OS	Homo sapiens (Human).		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrate; Euteleostomi;		
OC	Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.		
OX	NCBI_TaxID:9606;		
RN	[1]		
RN	SEQUENCE FROM N.A. (ISOFORM 4).		
RC	TISSUE=Brain;		
RX	MEDLINE=98151389; PubMed=9482789;		
RA	Lin J.W., Wyszynski M., Madhavan R., Sealock R., Kim J.U., Sheng M.;		
RT	"Yociao, a novel protein of neuromuscular junction and brain that		
RT	interacts with specific splice variants of NMDA receptor subunit		
RT	NR1.";		
RL	J. Neurosci. 18:2017-2027(1998).		
RN	[2]		
RN	SEQUENCE FROM N.A. (ISOFORM 2), AND VARIANT GLN-1347 INS.		
RX	MEDLINE=99219864; PubMed=10202149;		
RA	Wiczak O., Skalhogg B.S., Keryer G., Bornens M., Tasken K.,		
RA	Jahnsen T., Oerstavik S.;		
RT	"Cloning and characterization of a cDNA encoding an A-kinase anchoring		
RT	protein located in the centrosome, AKAP450.";		
RL	EMBO J. 18:1858-1868(1999).		
RN	[3]		
RN	SEQUENCE FROM N.A. (ISOFORM 3).		
RP	TISSUE=Brain;		
RX	MEDLINE=99287934; PubMed=1035086;		
RA	Takahashi M., Shibata H., Shimakawa M., Miyamoto M., Mukai H., Ono Y.;		
RT	"Characterization of a novel giant scaffolding protein, CG-NAP, that		
RT	anchors multiple signaling enzymes to centrosome and the Golgi		
RT	apparatus.";		
RL	J. Biol. Chem. 274:17267-17274(1999).		
RN	[4]		
RP	SEQUENCE FROM N.A. (ISOFORM 1).		
RP	Kemmerer W.A., Deiss S., Schwarz U.;		
RL	"Cloning of Hyperion.";		
RP	Submitted (AUG-1998) to the EMBL/GenBank/DBJ databases.		
RP	[5]		
RP	SEQUENCE OF 323-3911 FROM N.A. (ISOFORM 2).		
RC	TISSUE=Gastric parietal cell;		

RX MEDLINE=9915654; PubMed=9915845;
 RA Schmidt P.H., Dransfield D.T., Gaudin J.O., Hawley R.G.,
 RA Trotter K.W., Milgram S.L., Gaudin J.R.;
 RT "AKAP350, a multiply spliced protein kinase A-anchoring protein
 RT associated with centrosomes.";
 RL J. Biol. Chem. 274:3055-3066 (1999).
 RN (6)
 RP SEQUENCE OF 1802-3876 FROM N.A. (ISOFORM 5).
 RC TISSUE=Lymphoblast;
 RA Hinds K., Sutterer C., Becker M., Hawkins M.;
 RL Submitted (JAN-1998) to the EMBL/GenBank/DBJ databases.
 RN (7)
 RP SEQUENCE OF 2157-3911 FROM N.A. (ISOFORM 6).
 RC TISSUE=Lung;
 RA Milgram S.L., Gaudin J.R., Schmidt P.H.;
 RT "AKAP350: A multiply spliced family of proteins with centrosomal
 RT association.";
 RL Submitted (SEP-1998) to the EMBL/GenBank/DBJ databases.
 RN (8)
 RP SEQUENCE OF 2212-3911 FROM N.A. (ISOFORM 2/3).
 RC TISSUE=Brain;
 RA MEDLINE=99087487; PubMed=9872452;
 RA Nagase T., Ichikawa K.-I., Suyama M., Kikuno R., Miyajima N.,
 RA Tanaka A., Kotani H., Nomura N., Ohara O.;
 RT "Prediction of the coding sequences of unidentified human genes. XI.
 RT The complete sequences of 100 new cDNA clones from brain which code
 RT for large proteins in vitro.";
 RL DNA Res. 5:277-286 (1998).
 RN (9)
 RP SEQUENCE OF 17-1800 FROM N.A.
 RA Wu X., Graves T., Bradshaw H.;
 RL Submitted (SEP-1998) to the EMBL/GenBank/DBJ databases.
 CC -1- FUNCTION: Binds to type II regulatory subunits of protein kinase
 CC A. Scaffold protein that assembles several protein kinases and
 CC phosphatases on centrosome and Golgi apparatus where physiological
 CC events can be regulated by phosphorylation state of protein
 CC substrates. Isoform 4/Yotiao is associated with the N-methyl-D-
 CC aspartate receptor and is specifically found in the neuromuscular
 CC junction (NMJ) as well as in neuronal synapses explaining that its
 CC role may be to organize postsynaptic specializations.
 CC -1- SUBUNIT: Interacts with the regulatory region of protein kinase N
 CC (PKN), protein phosphatase 2A (PP2A), protein phosphatase 1 (Pp1)
 CC and the immature non-phosphorylated form of PKC epsilon.
 CC -1- SUBCELLULAR LOCATION: Centrosomal in many cell types and
 CC cytoplasmic in parietal cells.
 CC -1- ALTERNATIVE PRODUCTS:
 CC Event-Alternative splicing; Named isoforms=6;
 CC Name=1;
 CC IsoId=Q99996-1; Sequence=Displayed;
 CC Name=2;
 CC IsoId=Q99996-2; Sequence=VSP_004102, VSP_004107;
 CC Name=3; Synonyms=CG-NAP; Sequence=VSP_004105, VSP_004107;
 CC Name=4; Synonyms=Yotiao; Sequence=VSP_004103, VSP_004104;
 CC Name=5;
 CC IsoId=Q99996-4; Sequence=VSP_004103, VSP_004104;
 CC Name=6; Synonyms=AKAP350;
 CC IsoId=Q99996-5; Sequence=VSP_004108;
 CC TISSUE SPECIFICITY: Widely expressed. Isoform 4/Yotiao is highly
 CC expressed in skeletal muscle and in pancreas.
 CC -1- DOMAIN: R1-binding site, predicted to form an amphipathic helix,
 CC could participate in protein-protein interactions with a
 CC complementary surface on the R-subunit dimer.
 CC -1- CAUTION: Ref.6 sequence differs from that shown due to two
 CC frameshifts in positions 3782 and 3811.
 CC -1- CAUTION: Ref.9 sequence differs from that shown due to four
 CC frameshifts in positions 29, 1653, 1699 and 1735.
 CC -----
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL collaboration
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way

CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See [http://www.ebi.ac.uk/announcements/](http://www.ebi.ac.uk/announcements)
 CC or send an email to license@ebi.ac.uk).
 CC -----
 DR EMBL; AJ131693; CAB40713.1; -
 DR EMBL; AB019691; BAA78718.1; -
 DR EMBL; AJ010770; CAA09361.1; -
 DR EMBL; AF026245; AAB86384.1; -
 DR EMBL; AF083037; AAD22767.1; -
 DR EMBL; AC004013; AAB96867.1; -
 DR EMBL; AF091711; AAD39719.1; -
 DR EMBL; AB018346; BAA34523.1; -
 DR EMBL; AC000066; AAC60380.1; ALT_FRAME.
 DR Genew; HGNC:379; AKAP9.
 DR MIM; 604001; -
 DR GO; GO:0005813; C:centrosome; TAS.
 DR GO; GO:0005856; C:cytoskeleton; TAS.
 DR GO; GO:0004973; F:N-methyl-D-aspartate receptor-associated pr. .; TAS.
 DR GO; GO:000515; F:protein binding; TAS.
 DR GO; GO:0007165; P:signal transduction; TAS.
 DR GO; GO:0007268; P:synaptic transmission; TAS.
 DR GO; GO:0006810; P:transport; TAS.
 KM Coiled coil; Alternative splicing; Polymorphism.
 FT DOMAIN 2554 2567
 FT DOMAIN 164 914
 FT DOMAIN 944 1022
 FT DOMAIN 1100 1185
 FT DOMAIN 1253 1280
 FT DOMAIN 1336 1392
 FT DOMAIN 1434 1459
 FT DOMAIN 1585 1659
 FT DOMAIN 1857 2455
 FT DOMAIN 2544 2561
 FT DOMAIN 2603 2776
 FT DOMAIN 3065 3092
 FT DOMAIN 3124 3470
 FT DOMAIN 3587 3689
 FT DOMAIN 3726 3730
 FT DOMAIN 203 292
 FT DOMAIN 321 1010
 FT DOMAIN 1846 2772
 FT VASAPLIC 17 28
 FT VASAPLIC 1637 1642
 FT VASAPLIC 1643 3911
 FT VASAPLIC 2175 2182
 FT VASAPLIC 2175 2183
 FT VASAPLIC 2895 2907
 FT VASAPLIC 2895 2948
 FT VASAPLIC 3901 3911
 FT VARIANT 1347 1347
 FT CONFLICT 76 76
 FT CONFLICT 475 475
 FT CONFLICT 554 554
 FT CONFLICT 638 638
 FT CONFLICT 663 663
 FT CONFLICT 913 913
 FT CONFLICT 956 956
 FT CONFLICT 980 982
 FT CONFLICT 997 997
 FT CONFLICT 1001 1001
 FT CONFLICT 1020 1020
 FT CONFLICT 1028 1028
 E -> Q (IN REF. 3).
 M -> I (IN REF. 3).
 E -> G (IN REF. 3).
 R -> S (IN REF. 3).
 N -> S (IN REF. 3).
 H -> N (IN REF. 3).
 K -> N (IN REF. 3).
 OKH -> PKP (IN REF. 1 AND 2).
 Q -> P (IN REF. 1 AND 2).
 N -> D (IN REF. 3).
 V -> E (IN REF. 3).
 /FTId=VAR_010926.
 E -> Q (IN REF. 3).
 M -> I (IN REF. 3).
 E -> G (IN REF. 3).
 R -> S (IN REF. 3).
 N -> S (IN REF. 3).
 H -> N (IN REF. 3).
 K -> N (IN REF. 3).
 OKH -> PKP (IN REF. 1 AND 2).
 Q -> P (IN REF. 1 AND 2).
 N -> D (IN REF. 3).
 V -> E (IN REF. 3).
 /FTId=VSP_004102.
 QLOEHI -> LATARD (in isoform 4).
 /FTId=VSP_004103.
 Missing (in isoform 4).
 /FTId=VSP_004104.
 Missing (in isoform 3).
 /FTId=VSP_004105.
 SADRFOKVE -> Q (in isoform 6).
 /FTId=VSP_004106.
 VEGPYNMCFSTIC -> GSSIPELASHDAYOTREICSS
 (in isoform 2, isoform 3 and isoform 6).
 /FTId=VSP_004107.
 Missing (in isoform 5).
 /FTId=VSP_004108.
 STTOPHAGMER -> ALSITTSQMGHSARPTAPLPFETLSH
 SIG (in isoform 6).
 /FTId=VSP_004109.
 K -> KO.
 /FTId=VAR_010926.
 E -> Q (IN REF. 3).
 M -> I (IN REF. 3).
 E -> G (IN REF. 3).
 R -> S (IN REF. 3).
 N -> S (IN REF. 3).
 H -> N (IN REF. 3).
 K -> N (IN REF. 3).
 OKH -> PKP (IN REF. 1 AND 2).
 Q -> P (IN REF. 1 AND 2).
 N -> D (IN REF. 3).
 V -> E (IN REF. 3).

```

FT CONFLICT 1626 1626 R -> P (IN REF. 1 AND 2).
FT CONFLICT 1703 1703 N -> T (IN REF. 3).
FT CONFLICT 1707 1707 V -> G (IN REF. 3).
FT CONFLICT 1802 1803 MISSING (IN REF. 5).
FT CONFLICT 1843 1843 A -> P (IN REF. 3).

Query Match
Best Local Similarity 19.6%; Score 105; DB 1; Length 3911;
Matches 106; Conservative 78; Mismatches 145; Indels 212; Gaps 28;

QY 27 ALSGKGDVVDVYQREFLARDLAAEQESLK-----RSKEINLVDEIKRAVSR-- 78
DB 1154 ALCSLKEELIPAEQEKIKELQ-KIHOLELQTKTQETGEGKPHLLIKLOKAVSEBS 1212
QY 79 ---QAL-----RDGDNRTWGRLTEDPRLKPNV-----GSHRHVLA 111
DB 1213 YFLQLTCSVLGEVYTPALKEVNAEDKENSVDYISNEDPELDYRYEVDFOEMHTL- 1271
QY 112 LPTVHHHLPHLLAKESSLOPAVRVGQRTGVVWGIPSVRE-----VHSYLTD--- 161
DB 1272 LNKVTEEVNKLVLQTRLSKI--WGQQTDMKMLFGEENLPKEETEPFSLHSQMTNLEDI 1329
QY 162 -----TLHSLISELSPOEKE----- 176
DB 1330 DVNHSKSLSLQDLEKTKLEBOYQELIESLISLQOOLKETEOYTAHICLOKRLQAVSE 1389
QY 177 -----DSYIVVLIAETDSQYT---SAVTENIKALPTEIHSGLLEVISPPHFYP 223
DB 1390 STVPSPSLPVDVYV---ITESDAQRTMYPPSCVKKNI-----DGTIE----- 1427
QY 224 DSSRLRESGDPKREK--VAMRTKQNDYCFLLMVAOSKIYYVQLEDDIV----- 271
DB 1428 -FS--GEGVVEETNIYVLEKQ-----YQOOLEEYAKVIVSMGIAF 1467
QY 272 -----AKPVYISTMKNFALOQPSQEDW---MILEFSOLGFGFKSLDLSLVE 317
DB 1466 AAGTELSTRISGKENTASSKQAAVQOQCHFNEMKLSQDQIGF--QTFEVVDVKFEE 1525
QY 318 FLIMEYRDPIDWL-DHILWVKVCPNE---KDAKHC-----DRQKANLIRFKP 363
DB 1526 F-----KPLSEKGEHGEKILLNSDHPDIPESKDCVLTISEMFWKDTFI---VQO 1575
QY 364 SLFQVGHGTHSLAGKIQKLDKDFGQKALRKHNVPRAVVSLSKTYQHT--LEKAYLR 421
DB 1576 SIHDEIVSSMDASRQMLMEBQL--EDMRQELVROYO-----HQOATELLRQAHNR 1626
QY 422 E 422
DB 1627 Q 1627

RESULT 13
ACVS EMENI STANDARD; PRT; 3770 AA.
ID ACVS EMENI
P27742:
DT 01-AUG-1992 (rel. 23, Created)
DT 01-AUG-1992 (rel. 23, Last sequence update)
DT 28-FEB-2003 (rel. 41, Last annotation update)
DB N-(5-amino-5-carboxypentanoyl)-L-cysteiny1-D-valine synthase
DE (EC 6.3.2.26) (Delta-(L-alpha-aminoadipyl)-L-cysteiny1-D-valine
synthetase) (ACV synthetase) (ACVS).
GN ACVA.
OS Emericella nidulans (Aspergillus nidulans).
OC Eukaryota; Fungi; Ascomycota; Pezizomycotina; Eurotiomycetes;
OC Eurotiaceae; Trichocomaceae; Emericella.
OX NCBI_TaxID=162425;
RN [1]
RP SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.
RC STRAIN=6191;
RC MEDLINE=91286299; PubMed=2061333;
RA Maccabe A.P., van Liemt H., Pallisa H., Unkles S.E., Rlach M.B.R.,
RA Pfeiffer E., von Doehren H., Kinghorn J.R.;
RT "Delta-(L-alpha-aminoadipyl)-L-cysteiny1-D-valine synthetase from

```

```

RT Aspergillus nidulans. Molecular characterization of the acv gene
RT encoding the first enzyme of the penicillin biosynthetic pathway."
RL J. Biol. Chem. 266:12646-12654(1991).
CC -1- FUNCTION: Each of the constituent amino acids of the tripeptide
CC acv are activated as aminoacyl-adenylates with peptide bonds
CC formed through the participation of amino acid thioester
CC intermediates.
CC -1- CATALYTIC ACTIVITY: L-2-aminohexanedioate + L-cysteine + L-valine
CC + 3 ATP = N-(L-5-amino-5-carboxypentanoyl)-L-cysteiny1-D-valine +
CC 3 AMP + 3 diphosphate.
CC -1- COFACTOR: Contains 3 covalently bound phosphopantetheines
CC (potential).
CC -1- PATHWAY: Biosynthesis of penicillin and cephalosporin; first step.
CC -1- PRT: The N-terminus is blocked.
CC -1- SIMILARITY: Belongs to the ATP-dependent AMP-binding enzyme
CC family.
CC -1- SIMILARITY: Contains 3 acyl carrier domains.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@sib-sib.ch).
CC -----
CC EMBL; X54853; CAA38631.1; -.
CC DR PIR; A40889; A40889.
CC DR HSSP; P14687; 1AMU.
CC DR InterPro; IPR000873; AMP-bind.
CC DR InterPro; IPR001242; AMP-bind.
CC DR InterPro; IPR006163; PP-bind.
CC DR InterPro; IPR006162; Pantine_S.
CC DR InterPro; IPR000379; Ser_serine.
CC DR InterPro; IPR001031; Thioesterase.
CC DR Pfam; PF00501; AMP-binding; 3.
CC DR Pfam; PF00668; Condensation; 3.
CC DR Pfam; PF00550; PP-binding; 3.
CC DR Pfam; PF00975; Thioesterase; 1.
CC DR Pfam; PF00154; AMPBINDING.
CC DR PRINTS; PS00012; PHOSPHOPANTETHEINE; 3.
CC DR PROSITE; PS00455; AMP BINDING; 3.
CC DR PROSITE; PS00075; ACP_DOMAIN; 3.
CC KW Ligase; Antibiotic biosynthesis; Multifunctional enzyme;
CC Repeat; Phosphopantetheine.
CC FT REPEAT 321 910
CC FT REPEAT 1413 1993 DOMAIN 1 (ADIPATE-ACTIVATING).
CC FT REPEAT 2494 3078 DOMAIN 2 (CYSTEINE-ACTIVATING).
CC FT DOMAIN 850 919 DOMAIN 3 (VALINE-ACTIVATING).
CC FT DOMAIN 1929 2002 ACYL CARRIER (ACP) 1.
CC FT DOMAIN 3020 3087 ACYL CARRIER (ACP) 2.
CC FT BINDING 882 882 ACYL CARRIER (ACP) 3.
CC FT BINDING 1965 1965 PHOSPHOPANTETHEINE (BY SIMILARITY).
CC FT BINDING 3050 3050 PHOSPHOPANTETHEINE (BY SIMILARITY).
CC FT ACT SITE 3623 3623 PHOSPHOPANTETHEINE (BY SIMILARITY).
CC SQ SEQUENCE 3770 AA; 422448 MW; CB66B6D232A58CB0 CRC64;

Query Match
Best Local Similarity 19.7%; Score 104.5; DB 1; Length 3770;
Matches 108; Conservative 79; Mismatches 195; Indels 167; Gaps 24;

QY 39 YQREF--LALRDLLHAAEQESLKRSKEINLVDEIKRAVSRQALDGDGNNRTWGRLTE 95
DB 1352 YARELFDEIVSIELQVWRDTLLQVAKGLDPPVSLSLSSAQVA----- 1396
QY 96 DPLKPNNGSHRVHLHPTVFNHLPHLLAKESSLOPAVRVGQRTGVVWGIPSVR-RE 154
DB 1397 --QLDAMKARD--AEPPDTTLHA--MFEKAAQKP-----DKAAVVEQSGSLTRQ 1441
QY 155 VHSYLTDTLHSLISELSPOEKEKSDSVIVLIAETDSQYTSAVTENIKALPTEIHSGLLE 214
DB 1442 LNEANRRAHQDKSDISP--KPSNITLVVDKSEHMTAT-----ILAWKTK--GGAIVP 1491

```

QY 215 ISPSFHYPD-----FSRLSEFGDP---KERVWRTKONLDY 249
DB 1492 IDPR---YPDRIIRYILEDTSALAVISDACYLRSIQELIAGSIVRLRSDISTQIDGMSV 1548
QY 250 CFLLMWYASQKGIYYVQLEDDIVAKN-----YLSMKRPAALQOSEDMILIEF 297
DB 1549 SNPAPSSSTSTLAVIITYTSGTTGKKGVVHHGVNLQISLSKTFGLRD--TDDEVILSF 1607
QY 298 SOLGFIQGMFKSLDLISLIVEFLIMFRDPRDPIIDMLDILMWVCNPEADAKHCRKANL 357
DB 1608 SNYVF-----DHPYEQMTDALINGQTLVMDANKRSDKER---1642
QY 358 RIRFPRPSLFQVHGTN--SSLAGIKQKDKDFGKQALRKEHVNPAPVSTSLKTYQHFTL 415
DB 1643 -----LYQYIEYTRVTVYLSG-----TPSVISWYEFSSR 1669
QY 416 EKAYLR--EDFFWMTAPAGDPIRFRFQPLRLERFFRSGNIIEHPDKLPTSTEVLPF 473
DB 1670 FKDLHRRVDCVGEAASQPFQDIR-DTFOGLINIGY-----GPTISITTHKRLXP 1720
QY 474 DNPQSDKEALQEGRTAT-----LRYRSPDGYLQIGSFYKVAEGEVD--PARGPLEA 524
DB 1721 PERRDKSIGQIGSTISYVLANADMKRVPICANGVELYIGG--EGVARGYHNRPEVTARF 1778
QY 525 LRLSTQTD 533
DB 1779 LRPFTQDTS 1787

RESULT 14

ID IF2 ANASP STANDARD; PRT; 1039 AA.

AC 08YQJ1;

DT 15-MAR-2004 (Rel. 43, Created)

DT 15-MAR-2004 (Rel. 43, Last sequence update)

DE Translation initiation factor IF-2.

GN INFB OR ALR3832.

OS Anabaena sp. (strain PCC 7120).

OC Bacteria; Cyanobacteria; Nostocales; Nostocaceae; Nostoc.

NCBI_TaxID=103690;

RA (1)

RP SEQUENCE FROM N.A.

RX MEDLINE=21595285; PubMed=11759840;

RA Kaneko T., Nakamura Y., Molk C.P., Kuritz T., Sasamoto S.,

RA Watanabe A., Iriuch M., Ishikawa A., Kawashima K., Kimura T.,

RA Kishida Y., Kohara M., Matsumoto M., Matsuno A., Muraki A.,

RA Nakazaki N., Shimo S., Sugimoto M., Takazawa M., Yamada M.,

RA Yaoda M., Tabata S.;

RT "Complete genomic sequence of the filamentous nitrogen-fixing

RT cyanobacterium Anabaena sp. strain PCC 7120.";

RL DNA Ref. 8:205-213(2001).

CC -I- FUNCTION: One of the essential components for the initiation of

CC protein synthesis. Protects formylmethionyl-tRNA from spontaneous

CC hydrolysis and promotes its binding to the 30S ribosomal subunits.

CC Also involved in the hydrolysis of GTP during the formation of the

CC 70S ribosomal complex (By similarity).

CC -I- SUBCELLULAR LOCATION: Cytoplasmic.

CC -I- SIMILARITY: Belongs to the IF-2 family.

CC -----

CC This SWISS-PROT entry is copyright. It is produced through a collaboration

CC between the Swiss Institute of Bioinformatics and the EMBL outstation -

CC the European Bioinformatics Institute. There are no restrictions on its

CC use by non-profit institutions as long as its content is in no way

CC modified and this statement is not removed. Usage by and for commercial

CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>

CC or send an email to license@isb-sib.ch).

CC -----

CC EMBL; AP003594; BAB75531.1; -

DR PIR; A12284; A12284.

DR HAMAP; MF_00100; -; 1.

DR InterPro; IPR004161; EFTU_D2.

DR InterPro; IPR000795; EF_GTPbind.

DR InterPro; IPR00178; IF2.
DR InterPro; IPR006847; IF2_N.
DR InterPro; IPR005225; Small_GTP.
DR InterPro; IPR009000; Translat_factor.
DR Pfam; PF00009; GTP_EFTU_D2; 2.
DR Pfam; PF03144; GTP_EFTU_D2; 2.
DR Pfam; PF04760; IF2_N; 2.
DR PRINTS; PR00315; ELONGATIONFACT.
DR ProDom; PD186100; IF2; 1.
DR TIGRFAMs; TIGR00487; IF-2; 1.
DR TIGRFAMs; TIGR00231; small_GTP; 1.
DR PROSITE; PS01176; IF2; 1.
KW Initiation factor; Protein biosynthesis; GTP-binding;
KW Complete proteome.
FT DOMAIN 536 688 G-DOMAIN.
FT NP_BIND 542 549 GTP (BY SIMILARITY).
FT NP_BIND 592 596 GTP (BY SIMILARITY).
FT NP_BIND 646 649 GTP (BY SIMILARITY).
SQ SEQUENCE 1039 AA; 111595 MW; 91E0B2H1038071C0 CRC64;

Query Match 3.6%; Score 104; DB 1; Length 1039;

Best Local Similarity 20.6%; Pred. No. 7.7; Mismatches 158; Indels 150; Gaps 26;

Matches 100; Conservative 76; Mismatches 158; Indels 150; Gaps 26;

QY 62 KEINLVDEIKRAVSEKQALRDGDNRTWGRLEDPRLKPNWNGSHRVHLPTVFNHLP 121

DB 501 KELEI---EVEIAPPEA-----RKVTMEIV---GDLEHLRRPVPVTIMGH 543

QY 122 LIAKESLQPAVR---VGGRITGVSVMGIPSVAREVHSITLDTLSLSLSQEKEDS 178

DB 544 VDHGKTYLLDSIRKTKVAAGEAG-----GITQHIGAYHVDIVH-----DKEQ 586

QY 179 YIVVLIAETDSQYSAVTENIKALFTEIHSGLLEVISPSPHFYDPDSRLRESFGDKER 238

DB 587 QIVLDPFGHAFNAPARGARV---TDI--AVLVVA-----DDG 622

QY 239 VRWRTKONLDYCFLLMWYASQKGIYYVQLEDDIVAKPYYLSTMKNPALQOSEDMILIEFS 298

DB 623 VRPQTEAIS-----HAQAGV-----PIVAINKID--KEGA--QP--DRVKQELT 663

QY 299 QLGFIQGMFKSLDSLIVEFLIMFRDPRDPIIDMLDILMWK-----VCNEKQAK----- 348

DB 664 QYGLTSEWGETTMTVPSAI---KSENIDTLLEMTLLVAEVELSANDPRNARGTVIE 719

QY 349 -HCRORANLRIRKPSLPQHVQ---THSSLAGIKQKDKDFGKQALRKEHVNPAPVSV 404

DB 720 AHDKAKGAVATLLQNGTLHVGDIILAGSAFGKVRAMVD--DRG---KRVDIAGPS--- 771

QY 405 TSLKTYQHFTLEKAYLRDEFFWMTAPAGDPIRFRFQPLRLERFFRSGNIIEHPDKLP 464

DB 772 -----FAVEVLGLSD-----VPAAGD-----EPEVF 792

QY 465 NTSVEVLPFDPNPSQDEKALQ---EGR-TATLRIRSPDGYL-QIGSFYKVAEGEVDPAF 519

DB 793 DNEKEARALASDRADKQRLSLRLLQGRVLTITLTSQAQGEIKELNLTIKGDVQGSVEAIV 852

QY 520 GPUEAL 525

DB 853 GSLKQI 858

RESULT 15

ID HMW2 MYCPN STANDARD; PRT; 1818 AA.

AC P75471;

DT 01-NOV-1997 (Rel. 35, Created)

DT 01-NOV-1997 (Rel. 35, Last sequence update)

DT 16-OCT-2001 (Rel. 40, Last annotation update)

DE Cytochrome high molecular weight protein 2 (Cytochrome accessory

DE protein 2).

GN HMW2 OR MEN310 OR MP526.

OS Mycoplasma pneumoniae.

OC Bacteria; Firmicutes; Mollicutes; Mycoplasmataceae; Mycoplasma.

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using bw model

Run on: July 20, 2004, 10:06:45 ; Search time 55 Seconds
(without alignments)
2815.201 Million cell updates/sec

Title: US-10-033-245-24

Perfect score: 2868
Sequence: 1 MRLLNGFTLLFLCLCAFL.....IQTPSPVWVLLSEIFLKAD 548

Scoring table: BIOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database : A_Geneseq_29Jan04:*

1: geneseqp1980s:*\n2: geneseqp1990s:*\n3: geneseqp2000s:*\n4: geneseqp2001s:*\n5: geneseqp2002s:*\n6: geneseqp2003as:*\n7: geneseqp2003bs:*\n8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	* Query Match	Length	ID	Description
1	2868	100.0	548	3	AAV96737 PRO1927,
2	2868	100.0	548	3	AB24028 Human PRO
3	2868	100.0	548	5	ABG92711 Human sec
4	2868	100.0	548	5	ABG91363 Novel hum
5	2868	100.0	548	5	ABG31403 Human PRO
6	2868	100.0	548	6	ABU72379 Novel hum
7	2868	100.0	548	6	ABU80869 Human sec
8	2868	100.0	548	6	ABG73316 Human PRO
9	2868	100.0	548	6	ABU60815 Human sec
10	2868	100.0	548	6	ABU81238 Human PRO
11	2868	100.0	548	6	ABU62959 Human PRO
12	2868	100.0	548	7	ABO01896 Novel hum
13	2868	100.0	548	7	AAE38828 Human PRO
14	2865	99.9	548	2	AAW63559 Human bet
15	2701	94.2	563	4	AAAB94456 Human pro
16	1684	58.7	535	2	AAW63558 Human bet
17	1684	58.7	535	2	AAE05189 Human bet
18	1672	58.3	535	3	AAE05189 Human bet
19	1672	58.3	535	3	AAE05189 Human bet
20	1669	58.2	535	2	AAW63557 Bovine de
21	1098	38.3	578	4	ABB71754 Drosophila
22	1090	38.0	244	2	AAV73869 Human pro
23	1052	36.7	243	2	AAV73868 Human pro
24	605	21.1	464	5	ABB82145 Chicken a
25	598.5	20.9	508	4	ABB68205 Drosophila

26	564	19.7	478	3	AAV57603
27	562	19.6	478	3	AAAB42226
28	136	4.7	740	5	AAO17680
29	127	4.4	603	4	AAAO0777
30	123	4.3	900	4	ABB63162
31	123	4.3	1247	4	ABBS5934
32	113.5	4.0	287	4	AAAB8454
33	109.5	3.8	1005	6	ABO14664
34	109	3.8	436	7	ADC97190
35	108	3.8	933	5	ABP28348
36	108	3.8	578	6	ABU30855
37	108	3.8	2324	2	AAAO5707
38	107.5	3.7	1288	3	AAAG32186
39	107	3.7	406	4	AAAB65902
40	106	3.7	202	4	AAAB65881
41	106	3.7	320	4	AAAB65886
42	106	3.7	406	4	AAAB65903
43	105	3.7	406	4	AAAB65829
44	105	3.7	406	4	AAAB65901
45	105	3.7	3899	6	ABR32048

ALIGNMENTS

RESULT 1	AAV96737	standard; protein; 548 AA.
ID	AAV96737	
XX	AAV96737;	
AC		
XX		
DT	26-SEP-2000	(first entry)
XX		
DE	PRO1927, an N-acetylglucosaminyl transferase.	
XX		
KW	PRO1927, N-acetylglucosaminyl transferase; secreted protein;	
KM	transmembrane protein; recombinant production; gene therapy.	
XX		
OS	Homo sapiens.	
XX		
XX		
FH	Key	Location/Qualifiers
FT	Peptide	1..23
FT		/label= signal_peptide
FT	Modified-site	5..9
FT		/note= "N-glycosylation site"
FT	Modified-site	6..12
FT		/note= "N-myristoylation site"
FT	Modified-site	87..91
FT		/note= "N-glycosylation site"
FT	Modified-site	103..107
FT		/note= "N-glycosylation site"
FT	Modified-site	136..142
FT		/note= "N-myristoylation site"
FT	Modified-site	370..376
FT		/note= "N-myristoylation site"
FT	Modified-site	465..469
FT		/note= "N-glycosylation site"
FT	Modified-site	509..515
FT		/note= "N-myristoylation site"
XX		
PN	WO200036102-A2.	
XX		
PD	22-JUN-2000.	
XX		
XX		
PF	01-DEC-1999;	99WO-US028634.
XX		
PR	16-DEC-1998;	98US-0112851P.
PR	16-DEC-1998;	98US-0113145P.
PR	22-DEC-1998;	98US-0113511P.
PR	12-JAN-1999;	99US-0115568P.
PR	12-JAN-1999;	99US-0115565P.
PR	12-JAN-1999;	99US-0115733P.
PR	09-FEB-1999;	99US-0119341P.


```

QY 121 HLLAKESSLQPAVAVGQRTGVSVVMGIPSVRRVHSLTDTLHSLISELSPQEKEDSVI 180
DB 121 HLLAKESSLQPAVAVGQRTGVSVVMGIPSVRRVHSLTDTLHSLISELSPQEKEDSVI 180
QY 181 VVLAETDSQYTSAVTENIKALPFTETHSGLLEVISPSPHFYPPFSRLRESFGDPKERV 240
DB 181 VVLAETDSQYTSAVTENIKALPFTETHSGLLEVISPSPHFYPPFSRLRESFGDPKERV 240
QY 241 WRTKQNDYCLMNYAOSKGIYYVQLEDDIVAKPNYLSITMKNFALQOSEDMILLESQ 300
DB 241 WRTKQNDYCLMNYAOSKGIYYVQLEDDIVAKPNYLSITMKNFALQOSEDMILLESQ 300
QY 301 GFIGMFPSLILSLIVEFTLMFYRDKPIDWLMDHLMWKVCNPEKDAKCDROKANLIR 360
DB 301 GFIGMFPSLILSLIVEFTLMFYRDKPIDWLMDHLMWKVCNPEKDAKCDROKANLIR 360
QY 361 FKPSLFGVGHSSLAGKIQKLKDKDFGKALRKEHVNPPEAVSTSLKTYQHFTLEKAYL 420
DB 361 FKPSLFGVGHSSLAGKIQKLKDKDFGKALRKEHVNPPEAVSTSLKTYQHFTLEKAYL 420
QY 421 REDEFMAATPAAGPIRFRFPQPLRFRFPRSGNIHPEDEKLTFTSVTELPFNPOS DK 480
DB 421 REDEFMAATPAAGPIRFRFPQPLRFRFPRSGNIHPEDEKLTFTSVTELPFNPOS DK 480
QY 481 EALQEGRTATLRVPRSPPGYLOISFYKVAEGEVDPAFGLLEALRLSIOQDSPVWVILS 540
DB 481 EALQEGRTATLRVPRSPPGYLOISFYKVAEGEVDPAFGLLEALRLSIOQDSPVWVILS 540
QY 541 EIPFLKAD 548
DB 541 EIPFLKAD 548

```

RESULT 3
 A3G92711
 ID A3G92711 standard; protein, 548 AA.

AC A3G92711;
 DT 18-NOV-2002 (first entry)
 DE Human secreted protein PRO1927.
 XX

KM Human: secreted and transmembrane protein; PRO1800; PRO539; PRO982;
 KM PRO1434; PRO1863; PRO1917; PRO1868; PRO3434; PRO1927;
 KM inflammatory disorder; immune related disease; rheumatoid arthritis;
 KM systemic lupus erythematosus; systemic sclerosis; thyroiditis;
 KM autoimmune haemolytic anaemia; diabetes mellitus; infectious hepatitis;
 KM psoriasis; allergic disease of the lung; graft-versus host disease;
 KM tumour; gene therapy.

XX Homo sapiens.
 OS
 XX
 PN US2002098506-A1.
 XX
 PD 25-JUL-2002.
 XX
 PF 27-DEC-2001; 2001US-00033301.
 XX
 PR 04-AUG-1998; 98US-0095325P.
 PR 16-DEC-1998; 98US-0112851P.
 PR 16-DEC-1998; 98US-0113145P.
 PR 22-DEC-1998; 98US-0113511P.
 PR 12-JAN-1999; 99US-0115558P.
 PR 12-JAN-1999; 99US-0115558P.
 PR 12-JAN-1999; 99US-0115733P.
 PR 09-FEB-1999; 99US-0119341P.
 PR 10-FEB-1999; 99US-0119537P.
 PR 12-FEB-1999; 99US-0119965P.
 PR 02-JUN-1999; 99US-0162506P.
 PR 29-OCT-1999; 99US-0162506P.
 PR 01-DEC-1999; 99US-0162506P.

```

PR 02-DEC-1999; 99US-0028551.  

PR 09-DEC-1999; 99US-0170262P.  

PR 11-FEB-2000; 2000US-0003365.  

PR 22-FEB-2000; 2000US-0004414.  

PR 02-MAR-2000; 2000US-0005841.  

PR 03-MAR-2000; 2000US-0187202P.  

PR 30-MAR-2000; 2000US-0008439.  

PR 30-MAY-2000; 2000US-014941.  

PR 02-JUN-2000; 2000US-015268.  

PR 01-DEC-2000; 2000US-05032678.  

PR 25-MAY-2001; 2001US-0086034.  

XX  

PA (GETH ) GENENTECH INC.  

XX  

PI Bostein D, Deansyrs L, Ferrara N, Fong S, Gao W, Goddard A;  

PI Gunney AL, Pan J, Roy MA, Stewart TA, Tumas D, Watanabe CK;  

PI Wood WJ;  

XX  

DR WPI; 2002-690475/74.  

DR N-PSDB; ABS68394.  

XX  

PT Novel secreted and transmembrane polypeptides and polynucleotides useful  

PT for diagnosis and treatment of inflammatory disorders and immune-related  

PT diseases, and identifying modulators.  

XX  

PS Claim 12; Fig 18; 125pp; English.  

XX  

CC The invention relates to an isolated polypeptide having at least 80%  

CC amino acid sequence identity to secreted and transmembrane polypeptides  

CC PRO1800, PRO539, PRO1434, PRO1863, PRO1917, PRO1868, PRO3434 or  

CC PRO1927 and their encoding nucleic acids. Also included are vectors, host  

CC cells and antibodies against PRO polypeptides. PRO proteins are useful  

CC for identifying modulators of the polypeptide. PRO1868 useful for the  

CC diagnosis and treatment of inflammatory and immune related diseases  

CC including systemic lupus erythematosus, rheumatoid arthritis, systemic  

CC sclerosis, autoimmune haemolytic anaemia, thyroiditis, diabetes mellitus,  

CC infectious hepatitis, psoriasis, allergic diseases of the lung and graft-  

CC versus host disease and tumours. Pro nucleic acids are useful for  

CC constructing hybridisation probes for mapping the gene that encodes that  

CC PRO and for the genetic analysis of individuals with genetic disorders,  

CC and for generating transgenic animals which are useful in the development  

CC and screening of therapeutically useful reagents. PRO nucleic acids are  

CC also useful for gene therapy, chromosome identification, and tissue  

CC typing. PRO proteins are useful as molecular weight markers for protein  

CC electrophoresis purposes. The anti-PRO antibodies are useful in  

CC diagnostic assays for PRO, e.g. detecting its expression in specific  

CC cells, tissues or serum and for affinity purification of PRO. The present  

CC sequence represents a PRO protein  

XX  

SQ Sequence 548 AA;

```

Query Match 100.0%; Score 2868; DB 5; Length 548;
 Best Local Similarity 100.0%; Pred. No. 1,1e-270;
 Matches 548; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 1 MRLANGFTLLTLCFCAPLSLWYALSGQKGVVNVYREFLALDRHAAEQSLK 60
DB 1 MRLANGFTLLTLCFCAPLSLWYALSGQKGVVNVYREFLALDRHAAEQSLK 60
QY 61 SKELNVLVDEIKRAVSRQALRDGDGNRTWGRLTEDBRLKPMNGSHRVHLPTVFHPLP 120
DB 61 SKELNVLVDEIKRAVSRQALRDGDGNRTWGRLTEDBRLKPMNGSHRVHLPTVFHPLP 120
QY 121 HLLAKESSLQPAVAVGQRTGVSVVMGIPSVRRVHSLTDTLHSLISELSPQEKEDSVI 180
DB 121 HLLAKESSLQPAVAVGQRTGVSVVMGIPSVRRVHSLTDTLHSLISELSPQEKEDSVI 180
QY 181 VVLAETDSQYTSAVTENIKALPFTETHSGLLEVISPSPHFYPPFSRLRESFGDPKERV 240
DB 181 VVLAETDSQYTSAVTENIKALPFTETHSGLLEVISPSPHFYPPFSRLRESFGDPKERV 240
QY 241 WRTKQNDYCLMNYAOSKGIYYVQLEDDIVAKPNYLSITMKNFALQOSEDMILLESQ 300
DB 241 WRTKQNDYCLMNYAOSKGIYYVQLEDDIVAKPNYLSITMKNFALQOSEDMILLESQ 300

```

Db 241 WTKQNDLYCFLMTAQSNGIYYQLVEDDIYAKPNYLSMTKQFALQPSSEDMILFESQL 300
Qy 301 GFIGKMFSLDLSLIVEFLIMFYRDKPIDWLDHILMWVCNPEKDAKHCDROKANLRIR 360
Db 301 GFIGKMFSLDLSLIVEFLIMFYRDKPIDWLDHILMWVCNPEKDAKHCDROKANLRIR 360
Qy 361 FKPSLFQHVGHSSLAGKIQLKDKDFGQALRKEHVNPAPAVSTSLKTYQHFTLEKAYL 420
Db 361 FKPSLFQHVGHSSLAGKIQLKDKDFGQALRKEHVNPAPAVSTSLKTYQHFTLEKAYL 420
Qy 421 REDFFMAFTPAAGDFIRFRFQPLRLERFFRSNGNIHEPDKLFNTSVLEVLPFNDPQSDK 480
Db 421 REDFFMAFTPAAGDFIRFRFQPLRLERFFRSNGNIHEPDKLFNTSVLEVLPFNDPQSDK 480
Qy 481 EALQGRATLRYRSPSPDGYLQISFYKGVAGGEVDPAFGLEALRLSIQDPSVWVILS 540
Db 481 EALQGRATLRYRSPSPDGYLQISFYKGVAGGEVDPAFGLEALRLSIQDPSVWVILS 540
Qy 541 EIFLKKAD 548
Db 541 EIFLKKAD 548

RESULT 4
ABG91363
ID ABG91363 standard; protein; 548 AA.

AC ABG91363;

DT 29-NOV-2002 (first entry)

DE Novel human secreted protein #9.

XX Human, secreted protein; transmembrane protein; gene mapping; transgenic;
XX immunogenic.

XX Homo sapiens.

PN US2002098505-A1.

PD 25-JUL-2002.

PF 28-DEC-2001; 2001US-00033246.

XX 04-AUG-1998; 98US-0095325P.
PR 16-DEC-1998; 98US-0112851P.
PR 16-DEC-1998; 98US-0113145P.
PR 22-DEC-1998; 98US-0113151P.
PR 12-JAN-1999; 99US-0115558P.
PR 12-JAN-1999; 99US-0115565P.
PR 12-JAN-1999; 99US-0115733P.
PR 09-FEB-1999; 99US-0119341P.
PR 10-FEB-1999; 99US-0119537P.
PR 12-FEB-1999; 99US-0119655P.
PR 02-JUN-1999; 99US-012252.
PR 29-OCT-1999; 99US-0162506P.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 09-DEC-1999; 99US-0170262P.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 02-MAR-2000; 2000WO-US005841.
PR 03-MAR-2000; 2000US-0187202P.
PR 30-MAR-2000; 2000WO-US008439.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 01-DEC-2000; 2000WO-US032679.
PR 25-MAY-2001; 2001US-00866034.

XX (GETH) GENENTECH INC.

PA Borstein D, Desnoyers L, Ferrara N, Fong S, Gao W, Goddard A;
PI Gurney AL, Pan J, Roy MA, Stewart TA, Tumas D, Watanabe CK;

PI Wood WI;
XX WPI; 2002-665999/71.
DR N-PDB; ABS67462.
XX
PT New human secreted and transmembrane (PRO) polypeptides, useful for
PT treating conditions requiring PRO polypeptides, for screening PRO
PT antagonists and agonists useful as drug candidates.
PS Claim 12; Fig 18; 125pp; English.

XX The invention relates to new human secreted and transmembrane proteins
XX (PRO) and nucleic acids of the invention. The polypeptides can be
XX administered therapeutically, especially by expressing encoding
XX polynucleotides, e.g. in therapeutic compositions. They can be used to
XX screen for PRO polypeptide antagonists and agonists useful to identify
XX drug candidates. They can also be used to produce antibodies, useful to
XX detect PRO polypeptides (e.g. diagnostically), purify PRO polypeptides or
XX therapeutically (e.g. as antagonists or to target and/or deliver
XX cytotoxic agents). The polynucleotides are useful therapeutically e.g. to
XX produce antisense sequences to inhibit polypeptide production. They can
XX be used to produce probes and primers useful to detect or isolate
XX sequences encoding PRO polypeptides or similar sequences e.g. variants or
XX to generate transgenic animals. ABG91355-ABG91363 represent human PRO
XX amino acid sequences of the invention

SQ Sequence 548 AA;

Query Match 100.0%; Score 2868; DB 5; Length 548;

Best Local Similarity 100.0%; Pred. No. 1,1e-270; Mismatches 548; Conservative 0; Indels 0; Gaps 0;

Qy 1 MLNRNGFTLTLTCLCAFLSLSWYALSGQGVVDVYQREFLALDRRLAAQESLKR 60
Db 1 MLNRNGFTLTLTCLCAFLSLSWYALSGQGVVDVYQREFLALDRRLAAQESLKR 60
Qy 61 SKEINLVIDEIKRAVSEKQALRDGDKRTWGRLEDPRLKRWNGSHRVHLPTVFNHLP 120
Db 61 SKEINLVIDEIKRAVSEKQALRDGDKRTWGRLEDPRLKRWNGSHRVHLPTVFNHLP 120
Qy 121 HLAKESLQPAVAVGQRTGVSVVMGIPSVRREVSHVLTDTLSLSLSELSPOKEDSVI 180
Db 121 HLAKESLQPAVAVGQRTGVSVVMGIPSVRREVSHVLTDTLSLSLSELSPOKEDSVI 180
Qy 181 VVLAETDSQYTSAVTENIKALPTEIHSGLEVIISPSPHFYPDFSRRLRSFGDPKERV 240
Db 181 VVLAETDSQYTSAVTENIKALPTEIHSGLEVIISPSPHFYPDFSRRLRSFGDPKERV 240
Qy 241 WTKQNDLYCFLMTAQSNGIYYQLVEDDIYAKPNYLSMTKQFALQPSSEDMILFESQL 300
Db 241 WTKQNDLYCFLMTAQSNGIYYQLVEDDIYAKPNYLSMTKQFALQPSSEDMILFESQL 300
Qy 301 GFIGKMFSLDLSLIVEFLIMFYRDKPIDWLDHILMWVCNPEKDAKHCDROKANLRIR 360
Db 301 GFIGKMFSLDLSLIVEFLIMFYRDKPIDWLDHILMWVCNPEKDAKHCDROKANLRIR 360
Qy 361 FKPSLFQHVGHSSLAGKIQLKDKDFGQALRKEHVNPAPAVSTSLKTYQHFTLEKAYL 420
Db 361 FKPSLFQHVGHSSLAGKIQLKDKDFGQALRKEHVNPAPAVSTSLKTYQHFTLEKAYL 420
Qy 421 REDFFMAFTPAAGDFIRFRFQPLRLERFFRSNGNIHEPDKLFNTSVLEVLPFNDPQSDK 480
Db 421 REDFFMAFTPAAGDFIRFRFQPLRLERFFRSNGNIHEPDKLFNTSVLEVLPFNDPQSDK 480
Qy 481 EALQGRATLRYRSPSPDGYLQISFYKGVAGGEVDPAFGLEALRLSIQDPSVWVILS 540
Db 481 EALQGRATLRYRSPSPDGYLQISFYKGVAGGEVDPAFGLEALRLSIQDPSVWVILS 540
Qy 541 EIFLKKAD 548
Db 541 EIFLKKAD 548

ID	ABG31403	standard; protein; 548 AA.
XX	ABG31403;	
XX	29-NOV-2002	(first entry)
XX	Human PRO1927	polypeptide.
XX	Human;	secreted and transmembrane polypeptide; PRO polypeptide;
KW	T-lymphocyte proliferation;	inflammatory disease; rheumatoid arthritis;
KW	inflammatory bowel disease;	Sjogren's syndrome; thyroiditis;
KW	autoimmune hemolytic anaemia;	diabetes mellitus; multiple sclerosis;
KW	hepatitis;	contact dermatitis; allergic disease; psoriasis; vitiligo;
KW	immune related disease;	kidney disease; antiinflammatory; antithyroid;
KW	antirheumatic;	antiarthritic; immunosuppressive; antineoplastic;
KW	antidiabetic;	neuroprotective; hepatotrophic; antiinflammatory;
KW	dermatological;	antiallergic; antipsoriatic; PRO1927.
XX		
OS	Homo sapiens.	
XX		
FX	Key	Location/Qualifiers
FX	Peptide	1..23
FT	Modified-site	/label= Signal_peptide
FT	Modified-site	5..9
FT	Modified-site	/note= "N-glycosylation site"
FT	Modified-site	6..12
FT	Modified-site	/note= "N-myristoylation site"
FT	Protein	24..548
FT	Modified-site	/label= Mature_PRO1927
FT	Modified-site	87..91
FT	Modified-site	/note= "N-glycosylation site"
FT	Modified-site	103..107
FT	Modified-site	/note= "N-glycosylation site"
FT	Modified-site	136..142
FT	Modified-site	/note= "N-myristoylation site"
FT	Modified-site	370..376
FT	Modified-site	/note= "N-myristoylation site"
FT	Modified-site	465..469
FT	Modified-site	/note= "N-glycosylation site"
FT	Modified-site	509..515
FT	Modified-site	/note= "N-myristoylation site"
XX		
PN	US2002098507-A1.	
XX		
PD	25-JUL-2002.	
XX		
PF	27-DEC-2001;	2001US-00033326.
XX		
PR	04-AUG-1998;	98US-00953325P.
PR	16-DEC-1998;	98US-0112851P.
PR	16-DEC-1998;	98US-0113145P.
PR	22-DEC-1998;	98US-0113511P.
PR	12-JAN-1999;	99US-0115585P.
PR	12-JAN-1999;	99US-0115565P.
PR	12-JAN-1999;	99US-0115733P.
PR	09-FEB-1999;	99US-0119341P.
PR	10-FEB-1999;	99US-0119537P.
PR	12-FEB-1999;	99US-0119965P.
PR	02-JUN-1999;	99WO-US012252.
PR	29-OCT-1999;	99US-0162506P.
PR	01-DEC-1999;	99WO-US028634.
PR	02-DEC-1999;	99WO-US02851P.
PR	09-DEC-1999;	99US-0170262P.
PR	11-FEB-2000;	2000WO-US003555.
PR	22-FEB-2000;	2000WO-US004414.
PR	03-MAR-2000;	2000WO-US005841.
PR	30-MAR-2000;	2000WO-US008439.
PR	30-MAY-2000;	2000WO-US014941.
PR	02-JUN-2000;	2000WO-US015264.

01-DEC-2000; 2000WO-US032678.
PR 25-MAY-2001; 2001US-00866034.
XX (GETH') 'GENENTECH INC.
XX Boetstein D, Deanoysers L, Ferrara N, Fong S, Gao W, Goddard A;
PI Gurney AL, Pan J, Roy MA, Stewart TA, Tumas D, Watanabe CK,
PI Wood WI;
XX WPI; 2002-673823/72.
DR N-PSDB; ABSS53479.
XX
PT Novel PRO polypeptides and nucleic acids encoding the polypeptides,
PT useful for preparing a medicament for the treatment of inflammatory and
PT immune related disorders.
XX
PS Claim 12; Fig 18; 125pp; English.
XX
CC The present invention relates to the isolation of novel human secreted
CC and transmembrane polypeptides, designated PRO polypeptides, and the
CC polynucleotide sequences encoding them. The PRO polypeptides of the
CC invention include PRO1800, PRO533, PRO982, PRO1434, PRO1863, PRO1917,
CC PRO1868, PRO3434 and PRO1927. The PRO polypeptides can inhibit the
CC stimulation of T-lymphocyte proliferation. The PRO polypeptides are
CC useful for the diagnosis and treatment of inflammatory diseases (e.g.
CC inflammatory bowel disease, rheumatoid arthritis, Sjogren's syndrome,
CC autoimmune haemolytic anaemia, thyroiditis, diabetes mellitus, multiple
CC sclerosis, hepatitis, contact dermatitis, allergic diseases and
CC psoriasis), immune related diseases, and kidney diseases in humans. The
XX present sequence represents human PRO1927 polypeptide
XX Sequence 548 AA;
XX

Query Match	Similarity	Score	DB 5:	Length	548:
Match	Local	Similarity	100.0%:	Pred. No. 1.le-270:	Mismatches
548:	Conservative	0:	Mismatches	0:	Indels
					Gaps
					0:
QY	1	MTLNGGFLTLTLFCLCAPLSLSWYALSGCKGVDVYQREFLALDRLLAAQESLKR	60		
Db	1	MTLNGGFLTLTLFCLCAPLSLSWYALSGCKGVDVYQREFLALDRLLAAQESLKR	60		
QY	61	SKEALNVLDLTKAVSRROALRQDGNRTWGRLTEDRLKPMNSHHVYHLPIVFFHLIP	120		
Db	61	SKEALNVLDLTKAVSRROALRQDGNRTWGRLTEDRLKPMNSHHVYHLPIVFFHLIP	120		
QY	121	HLAKESSLPQAVVGGQRTGVSVVMGIPSVRRRVSHVLTDTLHSLISLSLSPOKEBSVI	180		
Db	121	HLAKESSLPQAVVGGQRTGVSVVMGIPSVRRRVSHVLTDTLHSLISLSLSPOKEBSVI	180		
QY	181	VLLIAETDSQTSAVTENIKALPFTLEHSGLEAVISESPHEYPDPFSRLRESFGDPKEKVR	240		
Db	181	VLLIAETDSQTSAVTENIKALPFTLEHSGLEAVISESPHEYPDPFSRLRESFGDPKEKVR	240		
QY	241	WRTKONLDYCFLMWYASCKGIYYVQLEDLDIYAKPNVLSYTKMNFALQOPSEDMILLESQ	300		
Db	241	WRTKONLDYCFLMWYASCKGIYYVQLEDLDIYAKPNVLSYTKMNFALQOPSEDMILLESQ	300		
QY	301	GFIGKMKRSLDLSIYVFILMFTRDKRITDMLDHLIIWVKYCNPEKDKAGCDROKANIIR	360		
Db	301	GFIGKMKRSLDLSIYVFILMFTRDKRITDMLDHLIIWVKYCNPEKDKAGCDROKANIIR	360		
QY	361	FKPFLFOHVGTHSLAKIOKLDKDKGKQALRREHNPPEAVESTSLKTYOHTFLERAYL	420		
Db	361	FKPFLFOHVGTHSLAKIOKLDKDKGKQALRREHNPPEAVESTSLKTYOHTFLERAYL	420		
QY	421	REDFEFAFTPAAGDFIRFRFFQPLRLERFFFRSGNIEHPEDKLNTSVSVLPDNPOSDK	480		
Db	421	REDFEFAFTPAAGDFIRFRFFQPLRLERFFFRSGNIEHPEDKLNTSVSVLPDNPOSDK	480		
QY	481	EALQEGTATLRYRSPDGYLQIGSPFKGVAAEGVNDAPGELALRLSIQDSDSVWYILS	540		
Db	481	EALQEGTATLRYRSPDGYLQIGSPFKGVAAEGVNDAPGELALRLSIQDSDSVWYILS	540		


```

KW inflammatory bowel disease; ulcerative colitis; tumour; cancer;
KW colorectal cancer.
XX
OS Homo sapiens.
XX
PN US2002192668-A1.
XX
PD 19-DEC-2002.
XX
PF 27-DEC-2001; 2001US-00033244.
XX
PR 04-AUG-1998; 98US-0095325P.
PR 16-DEC-1998; 98US-0112851P.
PR 16-DEC-1998; 98US-0113145P.
PR 22-DEC-1998; 98US-0113511P.
PR 12-JAN-1999; 99US-0115558P.
PR 12-JAN-1999; 99US-0115565P.
PR 12-JAN-1999; 99US-0115733P.
PR 09-FEB-1999; 99US-0119341P.
PR 10-FEB-1999; 99US-0119537P.
PR 12-FEB-1999; 99US-011965P.
PR 02-JUN-1999; 99WO-US012252.
PR 29-OCT-1999; 99US-0162506P.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 09-DEC-1999; 99US-0170262P.
PR 11-FEB-2000; 2000WO-US003565.
PR 22-FEB-2000; 2000WO-US004414.
PR 02-MAR-2000; 2000WO-US005841.
PR 03-MAR-2000; 2000US-0187202P.
PR 30-MAR-2000; 2000WO-US008439.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 01-DEC-2000; 2000WO-US032678.
PR 23-MAY-2001; 2001US-00866034.
XX
XX (GERTH ) GENENTECH INC.
XX
PI Borstein D, Deenoyers L, Ferrara N, Fong S, Gao W, Goddard A;
PI Gunney AL, Pan J, Roy MA, Stewart TA, Tumas D, Watanabe CK;
PI Wood WI;
XX
XX WPI; 2003-328857/31.
XX
DR N-PSDB; ACA66979.
XX
PT New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammatory diseases, tumors or cancer.
XX
PS Claim 12; Fig 18; 119p; English.
XX
XX The invention relates to an isolated nucleic acid encoding a PRO
XX polypeptide. The nucleic acids and polypeptides are useful for treating
XX inflammatory diseases such as inflammatory bowel disease, ulcerative
XX colitis and Crohn's disease, tumors, or cancer such as colorectal
XX cancer. The nucleic acids are useful as hybridisation probes, in
XX chromosome and gene mapping and in generating antisense RNA or DNA. The
XX polypeptides are useful as pharmaceuticals, diagnostics, biosensors or
XX bioreactors. Both are useful in tissue typing. The present sequence
XX represents the amino acid sequence of a PRO polypeptide of the invention
XX
SQ Sequence 548 AA;

```

```

Query Match 100.0%; Score 2868; DB 6; Length 548;
Best Local Similarity 100.0%; Pred. NO. 1.1e-270;
Matches 548; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 1 MRLANGFTLLTLCCLAFSLISWYALSGKGVDVYQREPLARDRLHAQESIKR 60
XX |||||
DB 1 MRLANGFTLLTLCCLAFSLISWYALSGKGVDVYQREPLARDRLHAQESIKR 60
QY 61 SKEINLVDEIKRAVSEKQALRDGDGNTWRGLTEDPFLKRWNGSHRHVHLPTVFTHLP 120
XX |||||
DB 61 SKEINLVDEIKRAVSEKQALRDGDGNTWRGLTEDPFLKRWNGSHRHVHLPTVFTHLP 120

```

```

QY 121 HLLAKESSLQPAVRVGQRTGVSVMWGIPEVRREVHSYLTDTLHSLISELSPOKEKDSVI 180
XX |||||
DB 121 HLLAKESSLQPAVRVGQRTGVSVMWGIPEVRREVHSYLTDTLHSLISELSPOKEKDSVI 180
QY 181 VVLIAEFTDSQYTSAVTENIKALPPTETHSGLEIVISPSPHFYDPFSRLRESFGDPKERV 240
XX |||||
DB 181 VVLIAEFTDSQYTSAVTENIKALPPTETHSGLEIVISPSPHFYDPFSRLRESFGDPKERV 240
QY 241 WRTKQNLDYCEFLMWYAAQSKGIYYVQLDDIVAKPNYLSITMKNFALQOPSEDMMLLEFSOL 300
XX |||||
DB 241 WRTKQNLDYCEFLMWYAAQSKGIYYVQLDDIVAKPNYLSITMKNFALQOPSEDMMLLEFSOL 300
QY 301 GFIGKMFKSLDSLIVFIIMFYRDKPIDWLDHILMWKYCNPEKDAKHCDROKANTRIR 360
XX |||||
DB 301 GFIGKMFKSLDSLIVFIIMFYRDKPIDWLDHILMWKYCNPEKDAKHCDROKANTRIR 360
QY 361 FKPSLFGHVGTHSSLAGKIQKDKDKFGKQALRKEHVNPAEAVSTSLKTYQHFTLEKAYL 420
XX |||||
DB 361 FKPSLFGHVGTHSSLAGKIQKDKDKFGKQALRKEHVNPAEAVSTSLKTYQHFTLEKAYL 420
QY 421 REDFFMAFTPAAGDFIRFRFPQPLRERFFRSNGIEHPEDKLFNTSVEVLPFDPNPSDK 480
XX |||||
DB 421 REDFFMAFTPAAGDFIRFRFPQPLRERFFRSNGIEHPEDKLFNTSVEVLPFDPNPSDK 480
QY 481 EALOEGRTATLRYPSPDGYLQIGSFYKGYAEGEVDPAFPLKALRLSIOTDSFVWYILS 540
XX |||||
DB 481 EALOEGRTATLRYPSPDGYLQIGSFYKGYAEGEVDPAFPLKALRLSIOTDSFVWYILS 540
QY 541 EIFLKKAD 548
XX |||||
DB 541 EIFLKKAD 548

```

```

RESULT 8
ABG73316
ID ABG73316 standard; protein; 548 AA.
XX
XX ABG73316;

```

```

XX AC 30-APR-2003 (first entry)
XX
XX DE Human PRO1927 polypeptide.
XX
XX

```

```

KW Human; secreted and transmembrane polypeptide; PRO polypeptide;
KW inflammatory disease; immune-related disease; diabetes mellitus;
KW rheumatoid arthritis; glomerulonephritis; multiple sclerosis;
KW immune-mediated skin disease; contact dermatitis; graft rejection;
KW transplantation associated disease; graft-versus-host disease;
KW tumour diagnosis; tumour cell; antiinflammatory; immunosuppressive;
KW cytostatic; antianemic; antirheumatic; antiarthritic; antithyroid;
KW antidiabetic; nephrotoxic; antipsoriatic; dermatological; haemostatic;
KW hepatotropic; virucide; neuroprotective; PRO1927.

```

```

XX OS Homo sapiens.
XX
XX Key Location/Qualifiers
XX Peptide 1..23
XX FT /label= Signal_peptide
XX FT Protein 24..548
XX FT /label= Mature_PRO1927_polypeptide
XX
XX
XX US2002164646-A1.

```

```

XX PD 07-NOV-2002.
XX
XX PF 27-DEC-2001; 2001US-00033223.
XX
XX PR 04-AUG-1998; 98US-0095325P.
XX PR 16-DEC-1998; 98US-0112851P.
XX PR 16-DEC-1998; 98US-0113145P.
XX PR 22-DEC-1998; 98US-0113511P.
XX PR 12-JAN-1999; 99US-0115558P.

```

PR 12-JAN-1999; 99US-0115565P.
 PR 12-JAN-1999; 99US-0115733P.
 PR 09-FEB-1999; 99US-0119341P.
 PR 10-FEB-1999; 99US-0119537P.
 PR 12-FEB-1999; 99US-0119655P.
 PR 02-JUN-1999; 99WO-US012252.
 PR 29-OCT-1999; 99US-0162506P.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 09-DEC-1999; 99US-0170262P.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 12-FEB-2000; 2000WO-US004414.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 03-MAR-2000; 2000US-0187202P.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 25-MAY-2001; 2001US-00866034.
 XX (GENTH) GENENTECH INC.
 PA Borstein D, Desnoyers L, Ferrara N, Fong S, Gao W, Goddard A;
 PI Gurney AL, Pan J, Roy MA, Stewart TA, Tumas D, Wetanabe CK;
 PI Wood WL;
 XX WPI; 2003-238305/23.
 DR N-PSDB; ABX11175.
 XX
 PT New PRO polypeptides and nucleic acid molecules, useful in diagnosing or
 PT treating inflammatory diseases or immune-related diseases, e.g.
 PT inflammatory bowel disease, systemic lupus erythematosus or rheumatoid
 PT arthritis.
 PS
 PS Claim 12; Fig 18; 119pp; English.
 XX
 CC The present invention relates to the isolation of novel human secreted
 CC and transmembrane polypeptides designated PRO polypeptides (PRO1800,
 CC PRO539, PRO9824, PRO1434, PRO1863, PRO1917, PRO3434 and PRO1927),
 CC and the polynucleotide sequences encoding them. The PRO polypeptides and
 CC polynucleotide sequences of the invention are useful in diagnosing or
 CC treating inflammatory diseases or immune-related diseases (e.g.
 CC inflammatory bowel disease, systemic lupus erythematosus, rheumatoid
 CC arthritis, Sjogren's syndrome, autoimmune hemolytic anaemia, autoimmune
 CC thrombocytopenia, thyroiditis, diabetes mellitus, glomerulonephritis,
 CC multiple sclerosis, infectious hepatitis, immune-mediated skin diseases
 CC including psoriasis or contact dermatitis, and transplantation associated
 CC diseases including graft rejection or graft-versus-host disease). The PRO
 CC polypeptides are also useful for diagnosing tumours, and for inhibiting
 CC the growth of tumour cells. The PRO polynucleotide sequences may be used
 CC as hybridisation probes in chromosome and gene mapping, and in generating
 CC antisense RNA and DNA. They are also useful in preparing PRO
 CC polypeptides, in assays to identify other proteins or molecules involved
 CC in a binding reaction, to generate transgenic animals or knockout
 CC animals, which in turn are useful in the development and screening of
 CC therapeutically useful reagents, for chromosome identification, and
 CC tissue typing. The PRO polynucleotide sequences are also useful in gene
 CC therapy. Anti-PRO antibodies may be used in diagnostic assays for PRO
 CC polypeptides. The present sequence represents human PRO1927 polypeptide
 CC
 XX Sequence 548 AA;
 SQ
 Query Match 100.0%; Score 2868; DB 6; Length 548;
 Best Local Similarity 100.0%; Pred. No. 1.1e-270;
 Matches 548; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 121 HLAKESSLQPAVVGQRTGVSVVMGIPSYRRRVASHYLTDTLSLSISELSPQEKESVI 180
 DB 121 HLAKESSLQPAVVGQRTGVSVVMGIPSYRRRVASHYLTDTLSLSISELSPQEKESVI 180
 QY 181 VVLAETDSQVSAVTENIKALPTEIHSGLLEYISPPHPFPDSRLRESFGDPKERV 240
 DB 181 VVLAETDSQVSAVTENIKALPTEIHSGLLEYISPPHPFPDSRLRESFGDPKERV 240
 QY 241 WRTKONLDYCFILMYAOSKGIYYVQLEDIVAKENYLSYMKNFALQPSBDMILFEFSQL 300
 DB 241 WRTKONLDYCFILMYAOSKGIYYVQLEDIVAKENYLSYMKNFALQPSBDMILFEFSQL 300
 QY 301 GFITGMFKSLDLSILVEFILMFYDKPILDMILDIILWVKCNPEKDAKGCROKANIIR 360
 DB 301 GFITGMFKSLDLSILVEFILMFYDKPILDMILDIILWVKCNPEKDAKGCROKANIIR 360
 QY 361 FKPSLPQVGHSHSLAGKIQLKDKDQKQALREKHNVPFAEVSTSLKTYQHFLERAYL 420
 DB 361 FKPSLPQVGHSHSLAGKIQLKDKDQKQALREKHNVPFAEVSTSLKTYQHFLERAYL 420
 QY 421 REDEFMAFTPAAGDFIRRRFPQRLERFFRRSGNIEHPEDKLFNTSVYVLPFDNPOS DK 480
 DB 421 REDEFMAFTPAAGDFIRRRFPQRLERFFRRSGNIEHPEDKLFNTSVYVLPFDNPOS DK 480
 QY 481 EALQEGRTATIRYRSPDGYIQISFYKGVABGEVDPAFGLEALRLSIOTDSFWWYLS 540
 DB 481 EALQEGRTATIRYRSPDGYIQISFYKGVABGEVDPAFGLEALRLSIOTDSFWWYLS 540
 QY 541 EIFLKAD 548
 DB 541 EIFLKAD 548
 RESULT 9
 ID ABU60815 standard; protein, 548 AA.
 XX
 AC ABU60815;
 XX
 DT 06-MAY-2003 (first entry)
 XX
 DE Human secreted/transmembrane protein, #9.
 XX
 KW Human; PRO; secreted; transmembrane; pharmaceutical; diagnostic;
 KW biosensor; bioreactor; therapeutic; gene therapy; tumour;
 KW inflammatory disease; immune-related disease; inflammatory bowel disease;
 KW IBD; systemic lupus erythematosus; rheumatoid arthritis; thyroiditis;
 KW diabetes mellitus; glomerulonephritis; multiple sclerosis; cirrhosis;
 KW psoriasis; graft rejection; antiinflammatory; immunosuppressive;
 KW neuroprotective; hepatocytic.
 XX
 OS Homo sapiens.
 XX
 PN US2002160392-A1.
 XX
 PD 31-OCT-2002.
 XX
 PF 27-DEC-2001; 2001US-00033245.
 XX
 PR 04-AUG-1998; 98US-0095325P.
 PR 16-DEC-1998; 98US-0112851P.
 PR 16-DEC-1998; 98US-0113145P.
 PR 22-DEC-1998; 98US-0113511P.
 PR 12-JAN-1999; 99US-0115588P.
 PR 12-JAN-1999; 99US-0115565P.
 PR 12-JAN-1999; 99US-0115733P.
 PR 09-FEB-1999; 99US-0119341P.
 PR 10-FEB-1999; 99US-0119537P.
 PR 12-FEB-1999; 99US-0119655P.
 PR 02-JUN-1999; 99WO-US012252.
 PR 29-OCT-1999; 99US-0162506P.
 PR 01-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.
 PR 09-DEC-1999; 99US-0170262P.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 02-MAR-2000; 2000US-0187202P.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 25-MAY-2001; 2001US-00866034.

XX (GERTH) GENENTECH INC.

XX Boretstein D, Desnoyers L, Ferrara N, Fong S, Gao W, Goddard A;
 PI Gurney AL, Pan J, Roy MA, Stewart TA, Tumas D, Matanabe CK,
 PI Wood MI;

XX WPI; 2003-275292/27.
 DR N-PSDB; ABX90611.

PT New isolated PRO polypeptide, e.g. PRO1800 or PRO539, useful for
 PT diagnosing, preventing and treating tumors and inflammatory or immune-
 PT related diseases, e.g. systemic lupus erythematosus, thyroiditis,
 PT diabetes or psoriasis.

PS Claim 12; Fig 18; 11pp; English.

XX The invention discloses isolated PRO secreted/transmembrane polypeptides
 CC comprising a sequence without signal peptide and the nucleic acid
 CC encoding them. The polypeptides can be used to raise antibodies that
 CC specifically bind to the PRO polypeptide, for linking a bioactive
 CC molecule to a cell expressing a PRO protein and for modulating at least
 CC one biological activity of a cell. The PRO polypeptides and the antibody
 CC are useful for diagnosing, preventing and treating tumors and
 CC inflammatory or immune-related diseases, such as inflammatory bowel
 CC disease (IBD), systemic lupus erythematosus, rheumatoid arthritis,
 CC thyroiditis, diabetes mellitus, glomerulonephritis, multiple sclerosis,
 CC cirrhosis, psoriasis or graft rejection. The proteins and the antibody
 CC may also be used in preparing medicines and medicaments for treating the
 CC above-mentioned diseases. The polynucleotide is useful in molecular
 CC biology, including uses as hybridisation probes, in chromosome and gene
 CC mapping, in generating antisense RNA and DNA, and in gene therapy. The
 CC polynucleotide may also be used in preparing PRO polypeptides by
 CC recombinant techniques, and in generating either transgenic animals or
 CC knock-out animals which, in turn, are useful in the development and
 CC screening of therapeutically useful reagents. The sequences presented in
 CC ABU60807-ABU60815 are the human PRO polynucleotides of the invention
 CC
 XX

SQ Sequence 548 AA;

Query Match 100.0%; Score 2868; DB 6; Length 548;

Best Local Similarity 100.0%; Pred. No. 1,1e-270; Mismatches 0; Gaps 0;

Matches 548; Conservative 0; Indels 0; Gaps 0;

QY 1 MRLNGFTLTLFLCLCAFLSLSWAALSGQKGVVDVYQREFLALRDRLAAQESIKR 60
 DB 1 MRLNGFTLTLTLCLCAFLSLSWAALSGQKGVVDVYQREFLALRDRLAAQESIKR 60
 QY 61 SKEINLVDEIKRAVSEKRALRDGDNRTWGRLTEDPRLKFWNGSHRVHLPTVFNHLP 120
 DB 61 SKEINLVDEIKRAVSEKRALRDGDNRTWGRLTEDPRLKFWNGSHRVHLPTVFNHLP 120
 QY 121 HLAKESLSIOPAVVVGQRTGVSVVMGI PSVRRREVHSLVTTLTSLISELSPQEKDSVI 180
 DB 121 HLAKESLSIOPAVVVGQRTGVSVVMGI PSVRRREVHSLVTTLTSLISELSPQEKDSVI 180
 QY 181 VLLIAETDSQYTSAVTENIKALFPTIEHSGLEVISPSPHFYDPFSRLRESFGPKERV 240
 DB 181 VLLIAETDSQYTSAVTENIKALFPTIEHSGLEVISPSPHFYDPFSRLRESFGPKERV 240
 QY 241 WRTKQNLIDYCFLMVYASQSGIYYVLEDDIVAKENYLSLTKMNFALQPSSEDMILFESQL 300
 DB 241 WRTKQNLIDYCFLMVYASQSGIYYVLEDDIVAKENYLSLTKMNFALQPSSEDMILFESQL 300

DB 241 WRTKQNLIDYCFLMVYASQSGIYYVLEDDIVAKENYLSLTKMNFALQPSSEDMILFESQL 300
 QY 301 GFIGKMFKSLDSLIVEFILMFYRDKPIDMLDHLIMVAYCNPEKADAGCDROKANLIR 360
 DB 301 GFIGKMFKSLDSLIVEFILMFYRDKPIDMLDHLIMVAYCNPEKADAGCDROKANLIR 360
 QY 361 FKPSLFQVHGTHSLACKIQKLDKDKGKQALRKEHVNPPAEVSTSLKTYQHFTLEKAYL 420
 DB 361 FKPSLFQVHGTHSLACKIQKLDKDKGKQALRKEHVNPPAEVSTSLKTYQHFTLEKAYL 420
 QY 421 REDFFMAFTPAAGDFIFRRFPQPLRLERFFRRSGNIEHPEDKLFNTSVETLPPNPQSDK 480
 DB 421 REDFFMAFTPAAGDFIFRRFPQPLRLERFFRRSGNIEHPEDKLFNTSVETLPPNPQSDK 480
 QY 481 EALOEGRTATLRYPSPDGYLQIGSPFYKGAEGEVDPAPEPLLEALRLSIQDSEPVWYLS 540
 DB 481 EALOEGRTATLRYPSPDGYLQIGSPFYKGAEGEVDPAPEPLLEALRLSIQDSEPVWYLS 540
 QY 541 EIFLKKAD 548
 DB 541 EIFLKKAD 548

RESULT 10
 ID ABU81238 standard; protein; 548 AA.
 XX ABU81238;
 AC
 XX 23-JUN-2003 (first entry)
 DT
 XX Human PRO434 polypeptide.

XX Human: PRO polypeptide; secreted and transmembrane protein; antianaemic;
 KW inflammatory disease; immune related disease; rheumatoid arthritis;
 KW juvenile chronic arthritis; scleroderma; Sjogren's syndrome; sarcoidosis;
 KW autoimmune haemolytic anaemia; thyroiditis; psoriasis; Grave's disease;
 KW diabetes mellitus; immune-mediated renal disease; glomerulonephritis;
 KW demyelinating disease; nervous system; antithyroid;
 KW hepatobiliary disease; hepatitis; primary biliary cirrhosis;
 KW fibrotic lung disease; bullous skin disease; allergic disease;
 KW pulmonary fibrosis; transplantation associated disease; haemostatic;
 KW graft rejection; graft-versus host disease; cytostatic; dermatological;
 KW antidiabetic; antihemetic; antiarthritic; immunosuppressive;
 KW antiallergic; nephroprotective; neuroprotective; hepatotropic; antipsoriatic;
 KW
 XX
 OS Homo sapiens.
 XX
 XX US2003032060-A1.
 XX
 XX 13-FEB-2003.
 XX
 XX 27-DEC-2001; 2001US-00032990.

PR 04-AUG-1998; 98US-0095325P.
 PR 16-DEC-1998; 98US-0112851P.
 PR 16-DEC-1998; 98US-0113145P.
 PR 22-DEC-1998; 98US-0113511P.
 PR 12-JAN-1999; 99US-0115558P.
 PR 12-JAN-1999; 99US-0115558P.
 PR 12-JAN-1999; 99US-0115733P.
 PR 09-FEB-1999; 99US-0119341P.
 PR 10-FEB-1999; 99US-0119537P.
 PR 12-FEB-1999; 99US-0119655P.
 PR 02-JUN-1999; 99WO-US012252.
 PR 29-OCT-1999; 99WO-US0162506P.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028634.
 PR 09-DEC-1999; 99US-0170262P.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 02-MAR-2000; 2000WO-US005841.

PR 03-MAR-2000; 2000US-0187202P.
 PR 30-MAR-2000; 2000MO-US008439.
 PR 30-MAY-2000; 2000MO-US014941.
 PR 02-JUN-2000; 2000MO-US015264.
 PR 01-DEC-2000; 2000MO-US032678.
 PR 25-MAY-2001; 2001US-00866034.
 XX (GENTH) GENENTECH INC.
 PA Botstein D, Desnoyers L, Ferrara N, Fong S, Gao W, Goddard A;
 PI Gurey AL, Pan J, Roy MA, Stewart TA, Tumas D, Watanabe CK;
 PI Wood W;
 XX WPI; 2003-341961/32.
 DR N-PSDB; ACA67369.
 XX
 PT Novel isolated PRO polypeptides e.g. PRO1800, PRO539 and PRO892, of N-
 PT acetylglucosaminyltransferase protein family, useful for diagnosing,
 PT treating or preventing immune disorders and inflammatory disorders.
 PS Claim 12; Fig 18; 124pp; English.

CC The present invention relates to the isolation of novel human PRO
 CC polypeptides, and the polynucleotide sequences encoding them. The PRO
 CC polypeptides are secreted and transmembrane proteins. The PRO
 CC polypeptides and polynucleotides are useful for preparing a medicament
 CC useful in the treatment of inflammatory and immune related diseases such
 CC as inflammatory bowel disease, systemic lupus erythematosus (SLE),
 CC rheumatoid arthritis, juvenile chronic arthritis, spondyloarthritis,
 CC scleroderma, idiopathic inflammatory myopathies, Sjogren's syndrome,
 CC systemic vasculitis, sarcoidosis, autoimmune haemolytic anaemia,
 CC autoimmune thrombocytopenia, thyroiditis, Grave's disease, diabetes
 CC mellitus, immune-mediated renal disease, glomerulonephritis,
 CC demyelinating diseases of the central and peripheral nervous systems such
 CC as multiple sclerosis, idiopathic polyneuropathy, hepatobiliary diseases
 CC such as infectious hepatitis, autoimmune chronic active hepatitis,
 CC primary biliary cirrhosis, granulomatous hepatitis, sclerosing
 CC cholangitis, inflammatory and fibrotic lung diseases, gluten-sensitive
 CC enteropathy, Whipple's disease, autoimmune or immune-mediated skin
 CC diseases including bullous skin diseases, erythema multiforme and contact
 CC dermatitis, psoriasis, allergic diseases of the lung such as eosinophilic
 CC pneumonias, idiopathic pulmonary fibrosis and hypersensitivity
 CC pneumonitis, and transplantation associated diseases including graft
 CC rejection and graft-versus host disease. Anti-PRO antibodies are useful
 CC in diagnostic assays for PRO, in affinity purification of PRO, and for
 CC detection of PRO in biological samples. AB081230-AB081238 represent the
 CC human PRO polypeptides of the invention

XX Sequence 548 AA;

Query Match 100.0%; Score 2868; DB 6; Length 548;

Best Local Similarity 100.0%; Pred. No. 1,1e-270;

Matches 548; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MLRWGTFITLLFCLCAFLSLSWYAAISGQGDVVDVQREFLALRRLHAQESLKR 60
 DB 1 MLRWGTFITLLFCLCAFLSLSWYAAISGQGDVVDVQREFLALRRLHAQESLKR 60
 QY 61 SKELNLVDEIKRAVSERQALRDGQNRWGLTJEDPRKPNNGSHRHVLLPTVFHLLP 120
 DB 61 SKELNLVDEIKRAVSERQALRDGQNRWGLTJEDPRKPNNGSHRHVLLPTVFHLLP 120
 QY 121 HLAAESSIQPAVRVQGRGTGVVWGIPSVREHVSYLTDTLHSLISELSPQEKEDSVI 180
 DB 121 HLAAESSIQPAVRVQGRGTGVVWGIPSVREHVSYLTDTLHSLISELSPQEKEDSVI 180
 QY 121 HLAAESSIQPAVRVQGRGTGVVWGIPSVREHVSYLTDTLHSLISELSPQEKEDSVI 180
 DB 121 HLAAESSIQPAVRVQGRGTGVVWGIPSVREHVSYLTDTLHSLISELSPQEKEDSVI 180
 QY 161 VVLIAMTSQYTSATENIKALFPTIRHSGLLFVSPSHFPDPDSRLRESGDPKERYR 240
 DB 161 VVLIAMTSQYTSATENIKALFPTIRHSGLLFVSPSHFPDPDSRLRESGDPKERYR 240
 QY 241 WRTKONLDYCFILMAYAAQSGKIYVVOLEDDIVAKPNVYLSMKMKFALQOSEMDMLIFESOL 300
 DB 241 WRTKONLDYCFILMAYAAQSGKIYVVOLEDDIVAKPNVYLSMKMKFALQOSEMDMLIFESOL 300

QY 301 GFICKMFKSLDLSIVEFTIMFYDPKPIDWLLDHLVWKVCNPEKDAKCDROKANIIR 360
 DB 301 GFICKMFKSLDLSIVEFTIMFYDPKPIDWLLDHLVWKVCNPEKDAKCDROKANIIR 360
 QY 361 FKPSLFQVGTGTHSSLAGIQQLKDKDFGKALREKHNPAPAEVSTSLKTYOFTLEKAYL 420
 DB 361 FKPSLFQVGTGTHSSLAGIQQLKDKDFGKALREKHNPAPAEVSTSLKTYOFTLEKAYL 420
 QY 421 REDFFMAFTPAAGDFIRFRFPQPLRLRFPFRSGNIEHPEDKLENTSVYVLPFDNPOSDK 480
 DB 421 REDFFMAFTPAAGDFIRFRFPQPLRLRFPFRSGNIEHPEDKLENTSVYVLPFDNPOSDK 480
 QY 481 EALQGRATATRRSPDPGYQIGSPYKGVAKGEVDPAFGPLEALRLSIQDSVWWTLS 540
 DB 481 EALQGRATATRRSPDPGYQIGSPYKGVAKGEVDPAFGPLEALRLSIQDSVWWTLS 540
 QY 541 EIFLKAD 548
 DB 541 EIFLKAD 548

RESULT 11

ID AB062959 standard; protein; 548 AA.

XX AB062959;

DT 14-SEP-2003 (first entry)

XX Human PRO1927 protein.

XX Human; PRO1927; immunosuppressive; antiinflammatory; gene therapy;

KW immune disorder; inflammatory disorder; IBD; inflammatory bowel disease;

XX glycosyltransferase; enzyme.

OS Homo sapiens.

XX Key Location/Qualifiers

FT Peptide 1..23

FT Modified-site 5..9' /label= "Signal_peptide"

FT Modified-site /note= "N Glycosylation site"

FT Protein /label= "N_myristoylation_site"

FT Modified-site /label= Mature_protein

FT Modified-site /note= "N Glycosylation site"

FT Modified-site /note= "N Glycosylation site"

FT Modified-site /label= "N_myristoylation_site"

FT Modified-site /note= "N Glycosylation site"

FT Modified-site /label= "N_myristoylation_site"

PN US2003054447-A1.

PD 20-MAR-2003.

PF 27-DEC-2001; 2001US-00032996.

PR 04-AUG-1998; 98US-0095325P.
 PR 16-DEC-1998; 98US-0112851P.
 PR 16-DEC-1998; 98US-0113145P.
 PR 22-DEC-1998; 98US-0113511P.
 PR 12-JAN-1999; 99US-0115558P.
 PR 12-JAN-1999; 99US-0115565P.
 PR 12-JAN-1999; 99US-0115733P.

PR 09-FEB-1999; 99US-0119341P.
 PR 10-FEB-1999; 99US-0119537P.
 PR 12-FEB-1999; 99US-0119656P.
 PR 02-JUN-1999; 99WO-US012252.
 PR 29-OCT-1999; 99US-0162506P.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99US-0170262P.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 03-MAR-2000; 2000US-0187202P.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 25-MAY-2001; 2001US-00866034.
 XX
 PA (GENTH) GENENTECH INC.
 PI Borstein D, Deanoyers L, Ferrara N, Fong S, Gao W, Goddard A;
 PI Gunney AL, Pan J, Roy MA, Stewart TA, Tumas D, Watanabe CK;
 PI Wood WI;
 XX
 XX WPI; 2003-503626/47.
 DR N-PSDB; ACD26815.
 XX
 PT New secreted and transmembrane PRO polypeptides and nucleic acids
 PT encoding the polypeptides, useful in gene therapy, in diagnosing and/or
 PT treating immune-related and inflammatory diseases, or in identifying
 PT chromosomes.
 XX
 PS Claim 12; Fig 18; 118pp; English.

CC This invention relates to novel isolated nucleic acid sequences encoding
 CC secreted or transmembrane PRO polypeptides. Also disclosed is a method
 CC for producing a PRO polypeptide by culturing a host cell containing an
 CC expression vector comprising the full length nucleic acid sequence
 CC encoding the PRO protein. The protein and nucleic acid sequences of the
 CC invention may have immunosuppressive or antiinflammatory activities and
 CC may be used in gene therapy. Nucleic acids that encode PRO can be used to
 CC generate either transgenic animals or knock-out animals useful in
 CC developing and screening of therapeutically useful reagents. The nucleic
 CC acids may also be used in gene therapy for replacing a defective gene, in
 CC chromosome identification, as chromosome markers, or in generating probes
 CC to isolate full length PRO cDNA. The PRO polypeptides are useful as
 CC molecular markers for protein electrophoresis, and the isolated nucleic
 CC acids may be used for recombinantly expressing those markers. The PRO
 CC polypeptides and nucleic acids may also be used in tissue typing. Anti-
 CC PRO antibodies are useful in diagnostic assays for PRO, and in affinity
 CC purification of PRO from recombinant cell culture or natural sources. The
 CC proteins may also be used in the diagnosis and/or treatment of immune
 CC related diseases and inflammatory diseases (e.g. inflammatory bowel
 CC disease). The present sequence represents the human PRO1927 protein of
 CC the invention, this protein is a newly identified member of the
 CC glycosyltransferase family of proteins and may possess glycosylation
 CC activity
 CC
 XX

SQ Sequence 548 AA;

Query Match 100.0%; Score 2868; DB 6; Length 548;
 Best Local Similarity 100.0%; Pred. No. 1.1e-270; Indels 0; Gaps 0;
 Matches 548; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MRLNGFTLTLLTCLCAFLSLSWAALSGQKGDVVDVYQREFLALDRRLHAAGQESLKR 60
 DB 1 MRLNGFTLTLLTCLCAFLSLSWAALSGQKGDVVDVYQREFLALDRRLHAAGQESLKR 60
 QY 61 SKENLVVDDEIKRAVSEKQALRDGQNTKGRITLTPDLKRWNSGSHRVALLPTVFPHLLP 120
 DB 61 SKENLVVDDEIKRAVSEKQALRDGQNTKGRITLTPDLKRWNSGSHRVALLPTVFPHLLP 120
 QY 121 HILAKESSLQPAVRVGGQRTGVSVMGIPSVRREVHSYLTDTLHSLISELSPQEKEDSVI 180

DB 121 HILAKESSLQPAVRVGGQRTGVSVMGIPSVRREVHSYLTDTLHSLISELSPQEKEDSVI 180
 QY 181 VVLIATDSQYTAVENTENIKALPPTIHSGLLEVISPSPHFYDPFSRLRESFGDPKERYR 240
 DB 181 VVLIATDSQYTAVENTENIKALPPTIHSGLLEVISPSPHFYDPFSRLRESFGDPKERYR 240
 QY 241 WRTKONLDYCFLLMYAOSKGIYVVOLEDDI VAKPNYLSITMKNFALQPSSEDMWILEPSOL 300
 DB 241 WRTKONLDYCFLLMYAOSKGIYVVOLEDDI VAKPNYLSITMKNFALQPSSEDMWILEPSOL 300
 QY 301 GFIGKMFKSLDLSLYEFLIMFPRDKPIDMLDHLIMVVCNPEKAKCDROKAMLRIR 360
 DB 301 GFIGKMFKSLDLSLYEFLIMFPRDKPIDMLDHLIMVVCNPEKAKCDROKAMLRIR 360
 QY 361 FKPSLFOHVGTHSSLAGKI OKLKDQFGKQALKEHVNPPAEVSTSLKTYQHFTLEKAYL 420
 DB 361 FKPSLFOHVGTHSSLAGKI OKLKDQFGKQALKEHVNPPAEVSTSLKTYQHFTLEKAYL 420
 QY 421 REDFWAFTPAAGDFTFRFPOLRLERPFPSGNI EHPEDKLENTSVEVLPPDNQSDK 480
 DB 421 REDFWAFTPAAGDFTFRFPOLRLERPFPSGNI EHPEDKLENTSVEVLPPDNQSDK 480
 QY 481 EALQEGRTATLRYPRSPDGTLOIGSTYKGVABGEVDPAPGPLEBALSLIOTDSPVWVILS 540
 DB 481 EALQEGRTATLRYPRSPDGTLOIGSTYKGVABGEVDPAPGPLEBALSLIOTDSPVWVILS 540
 QY 541 EIFLKKAD 548
 DB 541 EIFLKKAD 548

RESULT 12

AB001896
 ID AB001896 standard; protein; 548 AA.

AC AB001896;

DT 07-AUG-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO1927.

XX Human; secreted and transmembrane protein; PRO; antiinflammatory;
 KW dermatological; immunosuppressive; antirheumatic; antiarthritic;
 KW antihypoid; antidiabetic; neuroprotective; hepatotrophic; vincide;
 KW cytostatic; gene therapy; antisense therapy; inflammatory bowel disease;
 KW systemic lupus erythematosus; rheumatoid arthritis; systemic sclerosis;
 KW Sjogren's syndrome; autoimmune thrombocytopenia; thyroiditis;
 KW diabetes mellitus; multiple sclerosis; hepatitis; erythema multiforme;
 KW contact dermatitis; graft-versus-host-disease; cancer.

OS Homo sapiens.

PN US2003027256-A1.

PD 06-FEB-2003.

PF 27-DEC-2001; 2001US-00033435.

XX 04-AUG-1998; 98US-0095325P.
 PR 16-DEC-1998; 98US-0112851P.
 PR 16-DEC-1998; 98US-0113145P.
 PR 22-DEC-1998; 98US-0113511P.
 PR 12-JAN-1999; 99US-0115558P.
 PR 12-JAN-1999; 99US-0115565P.
 PR 12-JAN-1999; 99US-0115565P.
 PR 09-FEB-1999; 99US-0115733P.
 PR 09-FEB-1999; 99US-0119341P.
 PR 10-FEB-1999; 99US-0119537P.
 PR 12-FEB-1999; 99US-0119656P.
 PR 02-JUN-1999; 99WO-US012252.
 PR 29-OCT-1999; 99WO-0162506P.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028651.

PR 09-DEC-1999; 99US-0170262P.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 03-MAR-2000; 2000US-0187202P.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 25-MAY-2001; 2001US-00866034.
 XX
 XX (GETH) GENENTECH INC.
 XX
 PI Botstein D, Deenoyers L, Ferrara N, Fong S, Gao W, Goddard A,
 PI Gurney AL, Pan J, Roy MA, Stewart TA, Tumas D, Watanabe CK,
 PI Wood WI;
 XX
 DR WPI; 2003-635077/60.
 DR N-PSDB; AAD58952.
 XX
 PT Isolated secreted and transmembrane PRO polypeptides e.g. PRO3434 and
 PT PRO1927, useful in the preparation of a medicament for treating a
 PT condition responsive to PRO polypeptide, and as therapeutic agents e.g.
 PT vaccines.
 PT
 PS
 PS Claim 12; Fig 18; 125pp; English.
 XX
 CC The invention relates to secreted and transmembrane polypeptides
 CC designated as PRO (e.g. PRO1800, PRO539, PRO982, PRO1434, PRO1863,
 CC PRO1917, PRO1868, PRO3434 and PRO1927) and nucleic acid molecules
 CC encoding such polypeptides. Sequences of the invention are useful in
 CC tissue typing, gene therapy and in the preparation of vaccines.
 CC Polypeptides of the invention are useful as molecular weight markers for
 CC protein electrophoresis, as therapeutic agent for in vivo therapeutic
 CC purposes and for screening compounds that modulate their activity. They
 CC are also useful in biotechnological, industrial and medical applications.
 CC Polynucleotides of the invention are used for constructing hybridisation
 CC probes for mapping the gene encoding PRO and for the genetic analysis of
 CC individuals with genetic disorders. They are also useful for generating
 CC transgenic animals or knockout animals for the development and screening
 CC of therapeutically useful reagents. The present sequence is human PRO
 CC protein
 CC
 SO Sequence 548 AA;
 Query Match 100.0%; Score 2868; DB 7; Length 548;
 Best Local Similarity 100.0%; Pred. No. 1.1e-270;
 Matches 548; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MRLNGTFLTLTCLCAFLSLSWYALSGQKGVVDVYQREPLALRDLHAQOESIKR 60
 DB 1 MRLNGTFLTLTCLCAFLSLSWYALSGQKGVVDVYQREPLALRDLHAQOESIKR 60
 QY 61 SKEINLVDEIKRAVSEKRALRDGDGNRTWGRLTEDPRKFWNGSHRHVHLPTVFHLLP 120
 DB 61 SKEINLVDEIKRAVSEKRALRDGDGNRTWGRLTEDPRKFWNGSHRHVHLPTVFHLLP 120
 QY 121 HILAKESLSQPAVVGQRTGVSVVMGIPSRREVHSLITTLTSLISELSPOKEKESVI 180
 DB 121 HILAKESLSQPAVVGQRTGVSVVMGIPSRREVHSLITTLTSLISELSPOKEKESVI 180
 QY 181 VLLIAEDSOYTSVAVTENIKALPTEIHSGLEVIYSPHPYPPSRRLRESFGPKERVR 240
 DB 181 VLLIAEDSOYTSVAVTENIKALPTEIHSGLEVIYSPHPYPPSRRLRESFGPKERVR 240
 QY 241 WRTKQNDLYCFLLMYAOSKGIYYVQLBEDDIYAKPNYLSITMKNPALQOPESEDMILLESQ 300
 DB 241 WRTKQNDLYCFLLMYAOSKGIYYVQLBEDDIYAKPNYLSITMKNPALQOPESEDMILLESQ 300
 QY 301 GFICKMKRSIDLSTLIVERFILMFYRDKPIDMLLDHILMWKVCNPKDAKHCROKANIRIR 360
 DB 301 GFICKMKRSIDLSTLIVERFILMFYRDKPIDMLLDHILMWKVCNPKDAKHCROKANIRIR 360

QY 361 FKPSLFQVGHSTSLACKIOKLDKDFGKALRKREHNPAAVSTSLKTYQHFTLEKAYL 420
 DB 361 FKPSLFQVGHSTSLACKIOKLDKDFGKALRKREHNPAAVSTSLKTYQHFTLEKAYL 420
 QY 421 REDDFMAFTPAAGRTIFRRFPQPLRLERFFRSNIEHPBDKLENTSVEVLPFNPOS DK 480
 DB 421 REDDFMAFTPAAGRTIFRRFPQPLRLERFFRSNIEHPBDKLENTSVEVLPFNPOS DK 480
 QY 481 EALOEGRTATLRYPSPDGLQIGSFYKGAEGEVDPAFGPLEALRLSIQDSPVWYILS 540
 DB 481 EALOEGRTATLRYPSPDGLQIGSFYKGAEGEVDPAFGPLEALRLSIQDSPVWYILS 540
 QY 541 EIFLKKAD 548
 DB 541 EIFLKKAD 548
 RESULT 14
 ID AAM63559 standard; protein; 548 AA.
 XX
 AC AAM63559;
 XX
 DT 24-NOV-1998 (first entry)
 XX
 DE Human beta(1 -> 4)-N-acetylglucosaminyl-transferase (Gnt-IV)b enzyme.
 XX
 KW Beta(1 -> 4)-N-acetylglucosaminyl-transferase; Gnt-IV; bovine; human;
 KW enzyme; sugar chain subunit; branched oligosaccharide; polysaccharide;
 KW drug; reagent; food; biopolymer; glycoprotein; erythropoietin.
 OS Homo sapiens.
 XX
 PN MO9826053-A1.
 XX
 PD 18-JUN-1998.
 XX
 PF 10-DEC-1997; 97MO-JP004546.
 XX
 PR 12-DEC-1996; 96JP-00332411.
 PR 18-JUN-1997; 97JP-00161462.
 XX
 PA (KIRI) KIRIN BEER KK.
 PI Oguri S, Minowa M, Yoshida A, Taniguchi N, Takeuchi M;
 DR WPI; 1998-348516/30.
 DR N-PSDB; AAV38385.
 XX
 PT Recombinant beta(1-4)-N-acetylglucosaminyl-transferase - allows
 PT production of difficultly accessible branched poly:saccharides for food
 PT and drug use.
 XX
 PS Claim 9; Page 70-74; 112pp; Japanese.
 XX
 CC This represents a human beta(1 -> 4)-N-acetylglucosaminyl-transferase
 CC (Gnt-IV)b enzyme. The invention provides bovine and human Gnt-IV enzymes
 CC that can be used for converting sugar chain subunits having one structure
 CC to another structure. Vectors containing the DNA sequences encoding these
 CC enzymes can be used to transform host cells for the production of the Gnt
 CC -IV enzymes. The enzymes are useful in the production of branched
 CC oligosaccharides and polysaccharides which are difficult of access by
 CC other methods. They are also useful in the production of drugs, reagents
 CC and foods and in modifying the properties of biopolymers containing sugar
 CC chains. The enzyme may also be used for the preparation of glycoproteins
 CC such as erythropoietin
 XX
 SO Sequence 548 AA;
 Query Match 99.9%; Score 2865; DB 2; Length 548;
 Best Local Similarity 99.8%; Pred. No. 2.2e-270;
 Matches 547; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MLNRGTETLTLLFCLCAFLSLSWYAAISGQGVVDVYQREFLALRDRHAAEBSLKR 60
DB 1 MLNRGTETLTLLFCLCAFLSLSWYAAISGQGVVDVYQREFLALRDRHAAEBSLKR 60
QY 61 SEENLVDEIKRAVSEKQALBDGDNRTWGRLTEDPRLKPNNGSHRYVHLPTVFHILP 120
DB 61 SEENLVDEIKRAVSEKQALBDGDNRTWGRLTEDPRLKPNNGSHRYVHLPTVFHILP 120
QY 121 HLLAKESSLOPAVRVQGRGVSVVMGIPSVREHVSYLTDTHLSLISELSPQEKEDSVI 180
DB 121 HLLAKESSLOPAVRVQGRGVSVVMGIPSVREHVSYLTDTHLSLISELSPQEKEDSVI 180
QY 181 VVLIAMTSQYTSANTENIKALFPTEIHSGLLSVSPSHFPDPSRLRESGDPKERYR 240
DB 181 VVLIAMTSQYTSANTENIKALFPTEIHSGLLSVSPSHFPDPSRLRESGDPKERYR 240
QY 241 WRTKONLDVCFLMWYAAOSKGIYVQLEDDIVAKPNVLSMKRFAALQPSSEDMWILDFEOL 300
DB 241 WRTKONLDVCFLMWYAAOSKGIYVQLEDDIVAKPNVLSMKRFAALQPSSEDMWILDFEOL 300
QY 301 GEIGMFKSLDSLIVEFLMFYRDKPIDMLDLHWKVCNPEKDAKHCROKANLRIR 360
DB 301 GEIGMFKSLDSLIVEFLMFYRDKPIDMLDLHWKVCNPEKDAKHCROKANLRIR 360
QY 361 FKPSLFOHVGTHSSLAGKIQKLDKXOFKQALRKHVNPAPAVSTSLKTYQHFTLEKAYL 420
DB 361 FKPSLFOHVGTHSSLAGKIQKLDKXOFKQALRKHVNPAPAVSTSLKTYQHFTLEKAYL 420
QY 421 REDFWAFTPAAGDPIRFPFQPLRLERFPFSGNIEHEDELFNTSYEVLPEFDPQSDK 480
DB 421 REDFWAFTPAAGDPIRFPFQPLRLERFPFSGNIEHEDELFNTSYEVLPEFDPQSDK 480
QY 481 BALQEGRTATLRRPPSPDGYLQIGSFYKGVAGEVDPAPAGPLEALRLSIQTDSPVWVLLS 540
DB 481 BALQEGRTATLRRPPSPDGYLQIGSFYKGVAGEVDPAPAGPLEALRLSIQTDSPVWVLLS 540
QY 541 EFLFKKAD 548
DB 541 EFLFKKAD 548

RESULT 15
AAB94456
ID AAB94456 standard; protein; 563 AA.
AC AAB94456;
XX
DT 26-JUN-2001 (first entry)
DE Human protein sequence SEQ ID NO:15104.
XX
KW Human; primer; detection; diagnosis; antisense therapy; gene therapy.
XX
OS Homo sapiens.
XX
EN EP1074617-A2.
XX
PD 07-FEB-2001.
XX
PF 28-JUL-2000; 2000EP-00116126.
XX
PR 29-JUL-1999; 99JP-00248036.
XX
PR 27-AUG-1999; 99JP-00300253.
XX
PR 11-JAN-2000; 2000JP-00118776.
XX
PR 02-MAY-2000; 2000JP-00183767.
XX
PR 09-JUN-2000; 2000JP-00241899.
XX
PA (HELI-) HELIX RES INST.
XX
PI Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;
XX
PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;
XX
DR WPI; 2001-318749/34.

XX
PT primer sets for synthesizing polynucleotides, particularly the 5602 full-length cDNAs defined in the specification, and for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs.
PT
PS Claim 8; SEQ ID NO 15104; 2537bp + Sequence listing; English.
XX
CC The present invention describes primer sets for synthesizing 5602 full-length cDNAs defined in the specification. Where a primer set comprises:
CC (a) an oligo-dT primer and an oligonucleotide complementary to the
CC complementary strand of a polynucleotide which comprises one of the 5602
CC nucleotide sequences defined in the specification, where the
CC oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC of an oligonucleotide comprising a sequence complementary to the
CC complementary strand of a polynucleotide which comprises a 5'-end
CC sequence and an oligonucleotide comprising a sequence complementary to a
CC polynucleotide which comprises a 3'-end sequence, where the
CC oligonucleotide comprises at least 15 nucleotides and the combination
CC of the 5'-end sequence/3'-end sequence is selected from those defined in the
CC specification. The primer sets can be used in antisense therapy and in
CC gene therapy. The primers are useful for synthesizing polynucleotides,
CC particularly full-length cDNAs. The primers are also useful for the
CC detection and/or diagnosis of the abnormality of the proteins encoded by
CC the full-length cDNAs. The primers allow obtaining of the full-length
CC cDNAs easily without any specialised methods. AAH03166 to AAH1628 and
CC AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to AAB95893
CC represent human amino acid sequences; and AAH13629 to AAH13632 represent
CC oligonucleotides, all of which are used in the exemplification of the
CC present invention
XX
SQ Sequence 563 AA;
Query Match 94.2%; Score 2701; DB 4; Length 563;
Best Local Similarity 100.0%; Pred. No. 2,4e-254;
Matches 516; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 33 GDVVDVYQREFLALRDRHAAEBSLKRKELNVLDIEIKRAVSEKQALRGGDNRTWGR 92
DB 48 GDVVDVYQREFLALRDRHAAEBSLKRKELNVLDIEIKRAVSEKQALRGGDNRTWGR 107
QY 93 LTEDPRLKPNNGSHRYVHLPTVFHILPHLLAKESSLOPAVRVQGRGVSVVMGIPSVR 152
DB 108 LTEDPRLKPNNGSHRYVHLPTVFHILPHLLAKESSLOPAVRVQGRGVSVVMGIPSVR 167
QY 153 REVHVSYLTDTHLSLISELSPQEKEDSVIVVLIAMTSQYTSANTENIKALFPTEIHSGLL 212
DB 168 REVHVSYLTDTHLSLISELSPQEKEDSVIVVLIAMTSQYTSANTENIKALFPTEIHSGLL 227
QY 213 EVISPSPHFYDPFSRLRESFGDPKERYVRWRTKONLDVCFLMWYAAOSKGIYVQLEDDIVA 272
DB 228 EVISPSPHFYDPFSRLRESFGDPKERYVRWRTKONLDVCFLMWYAAOSKGIYVQLEDDIVA 287
QY 273 KPNVLSMKRFAALQPSSEDMWILDFEOLGFIQKMKSLDSLIVEFLMFYRDKPIDML 332
DB 288 KPNVLSMKRFAALQPSSEDMWILDFEOLGFIQKMKSLDSLIVEFLMFYRDKPIDML 347
QY 333 DHILMWKVCNPEKDAKHCROKANLRIRFKPSLFOHVGTHSSLAGKIQKLDKXOFKQAL 392
DB 348 DHILMWKVCNPEKDAKHCROKANLRIRFKPSLFOHVGTHSSLAGKIQKLDKXOFKQAL 407
QY 393 RKEHVNPAPAVSTSLKTYQHFTLEKAYIRREDFPFAFTPAAGDPIRFPFQPLRLERPFER 452
DB 408 RKEHVNPAPAVSTSLKTYQHFTLEKAYIRREDFPFAFTPAAGDPIRFPFQPLRLERPFER 467
QY 453 SGNIEHEPEDKLFNTSYEVLPEFDPNPOSDKEALQEBRTATLRVRSPPDGYLQIGSFYKGVAB 512
DB 468 SGNIEHEPEDKLFNTSYEVLPEFDPNPOSDKEALQEBRTATLRVRSPPDGYLQIGSFYKGVAB 527
QY 513 GEVDPAPAGPLEALRLSIQTDSPVWVILSEITLKKAD 548
DB 528 GEVDPAPAGPLEALRLSIQTDSPVWVILSEITLKKAD 563

Wed Jul 21 07:55:17 2004

us-10-033-245-24.rag

Page 15

Search completed: July 20, 2004, 10:10:47
Job time : 57 secs

This Page Blank (uspto)